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ABSTRACT
ENGINEERING PROTEINS FOR SECRETION:
APPLICATION TO GENE TRANSFER AND DNA VACCINATION

by
Jingxue Liu

In recent years gene therapy has become a promising way of alleviating incurable
human ailments, its concept emerging as the ultimate therapy for many infectious and
genetic diseases. Two important aspects of the development of successful gene therapy
protocols are the ability to monitor gene transfer readily, and the establishment of new
protocols for treating specific diseases. In this work, Renilla luciferase and human
glutamic acid decarboxylase (GAD) 65 were engineered for secretion to address some
aspects of these issues.
Secreted reporter proteins are promising tools to study gene transfer and
expression in a non-destructive manner, and bioluminescent proteins are particularly
convenient to use for that purpose. To generate a secreted bioluminescent marker
protein, secreted Renilla luciferase (SRUC), was engineered by fusing the human
interleukin-2 signal peptide to Renilla luciferase. We further modified the Renilla
luciferase gene using site-directed-mutagenesis to obtain a mutant form of Renilla
luciferase, SRUC3, with dramatically improved stability. SRUC3 provides a rapid,

sensitive, and inexpensive assay that does not require disruption of transfected cells.
Data from animal experiments suggested that SRUC3 has the potential to be used as an in
vivo marker protein. Although SRUC3 activity was not detected from animal blood, data
indicated that improvement of the assay after further engineering of the sruc3 gene and
SRUC3 protein could allow detection of Renilla luciferase activity in the blood and
serum in the future.
To evaluate the potential of genes encoding engineered secreted autoantigens for
the treatment of autoimmune disease using gene vaccination, human GAD65 was
engineered to be secreted by mammalian cells. GAD65 is a major autoimmune antigen
involved in the development of type I diabetes in both non-obese diabetic (NOD) mice
and human patients. After the removal of the N-terminal end of GAD65, the truncated
GAD fragment was fused to the C-terminal of the human interleukin-2 leader peptide,
and a secreted form of GAD (SGAD55) was obtained. The intramuscular injection of
plasmid DNA encoding GAD65 and SGAD55 into three-week-old NOD mice showed a
dramatic reduction of development of insulitis, the first symptom of diabetes in NOD
mice.

2

CHAPTER ONE
INTRODUCTION

A. Naturally and artificially secreted proteins
Protein secretion is one of the most intricate cellular events in eukaryotic cells.
The internal membrane system provides a means whereby eukaryotic cells can regulate
the delivery of newly synthesised proteins to the outside of cells. The protein secretion
pathway includes several cellular compartments, such as the endoplasmic reticulum (ER)
and Golgi apparatus. Newly synthesised proteins enter the secretion pathway in the ER
by crossing the ER membrane from the cytosol, and are subsequently transported from
the ER to Golgi apparatus, and then to the cell surface. Transfer vesicles, which transfer
proteins from membrane to membrane or from lumen to lumen (or to extracellular space)
by cycles of vesicle budding and fusion, mediate the secretion process. The fusion of the
vesicles with the plasma membrane is called exocytosis, also known as constitutive
secretory pathway. However, specialized secretory cells have a second secretory
pathway in which soluble proteins and other substances are initially stored in secretory
vesicles for later release.

This is the regulated secretory pathway, which is found

mainly in cells that are specialized for secreting products rapidly on demand, such as
hormones, neurotransmitters, or digestive enzymes (Alberts et al, 1994).

3
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In the process of protein export, a central role is played by the signal peptide: an
N-terminal segment that somehow initiates export whereupon it is cleaved from the
mature protein. Three structurally dissimilar regions have been identified for signal
peptides: a positively charged N-terminal region, a central hydrophobic region, and a
more polar C-terminal region that seems to define the cleavage site (Heijine, 1985).
Generally, signal peptides are 15-30 residues long and highly hydrophobic. Many
features of the secretion pathway appear to be shared by all species, since most exported
proteins can be translocated and processed similarly by the export machinery from
several organisms. However, signal peptides display a remarkable lack of primary
sequence homology, even among closely related proteins (Gierasch, 1989).
In eukaryotes, the first interaction of the signal peptide appears to be with the
signal recognition particle (SRP). It ensures that the nascent protein chain will be
correctly targeted through subsequent specific binding between SRP and its receptor in
the ER membrane (Walter, 1994). This binding step occurs after the signal peptide
emerges from the ribosome when a chain of about 70-80 residues has been synthesized
(Heijine, 1985). It is believed that there is only one SRP in a particular organism
(Gierasch, 1989). In addition to directing the protein to the ER membrane, the signal
peptide also serves as a start-transfer signal, which remains bound to the translocation
apparatus while the rest of the protein is threaded continuously through the membrane as
a large loop. Once the C-terminal of the protein has passed through the membrane, the
signal peptide is released from the translocator pore, cleaved off by the signal peptidase,
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and rapidly degraded to amino acids by other proteases in the ER while the protein is
released into the ER lumen (Albert et al, 1994). A signal peptide from one
organism can target naturally non-secreted proteins from another organism into the
protein secretion pathway (Okano et al, 1990; Liu et al, 1997).

B. Application of bioluminescent gene expression markers and the secreted Renilla
Luciferase
Delivery of therapeutic genes to target cells and regulation of gene expression in
those cells are crucial to efficient gene therapy. Regulation of gene expression is
associated with an important question: how to monitor gene expression within an
experimental animal and perhaps the human body? Several marker genes have been
studied and well characterized for this purpose, p-galactosidase, chloramphenicol
acetyltransferase (CAT), and firefly luciferase genes have been widely used in gene
expression assays in both in vitro and in vivo experiments (Alam and Cook, 1990).
However, functional assays of these marker genes have the same shortcoming: the
removal of the transfected tissues is required to perform the assays and therefore limits
the assays for gene expression to a single point in time. It would be difficult to follow
gene activity once the continuity of experiment is stopped. Under certain circumstances,
it would be very difficult or impossible to obtain tissue samples during clinical trials.
The use of a secreted reporter protein is a logical alternative to intracellular
markers and their associated need for tissue removal. Secreted marker proteins would
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permit serial evaluation of in vivo gene transfection in the same subject and facilitate
efforts to study strategies designed to enhance the magnitude and duration of transfection
efficiency.
Light emission from bioluminescence or chemiluminescence has become a
powerful tool in molecular biology for detecting the presence of certain molecules as well
as for studying specific cellular events. Luciferase is especially useful because the light
emission assay is sensitive, simple, quick, easy to be quantified, cost effective, and
generally non-toxic (Alam and Cook, 1990; Kricka, 1991). The most widely used
luciferases for this purpose are from the bio luminescent Vibrio bacteria, from the jellyfish
Aequoria victoria, and from the firefly Photinus pyralis. Recently the use of a
fluorescent protein, the A. victoria green fluorescent protein (GFP), has permitted the
direct visualization of the location of various proteins within a living cell and of the
movement of living organisms within their environment (Kather et al., 1995 and 1997;
Presley et al., 1997; Wacker et al, 1997). The combination of secreted protein and
bioluminescence or chemiluminescence marker is extremely attractive because it will
provide a powerful tool to monitor gene transfection without destroying samples or
subjects. Several secreted bioluminescence or chemiluminescence marker proteins
including secreted alkaline phosphatase (SEAP) (Berger et al, 1988), Vargula
hilgendorfli luciferase (Thompson et al, 1990), apoaequorin (Inouye and Tsuji, 1992),
and GFP from Aequoria victoria (Kaether and Gerdes, 1995; Laukkanen et al, 1996),
have been developed. Of all these proteins only the Vargula luciferase is naturally
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secreted, however, its substrate is too expensive (about $2,000/mg), therefore restricting
its use as a reporter protein. Also restricted is the use of secreted GFP by mammalian
cells, due to the very low sensitivity of the GFP assay (Kaether and Gerdes, 1995). The
firefly luciferase is the most commonly used luciferase marker, but it was not functional
after being fused with signal peptide from insulin for secretion (Tyedmers et al, 1996).
Since it is unlikely there will be a “do it all” type reporter gene, it is necessary to develop
a new marker system for different purpose under defined conditions.
In recent years, Renilla luciferase has emerged as a useful reporter protein and has
been used as a marker of gene expression in bacteria (Lorenz et al, 1991), plants
(Mayerhofer et al, 1995), yeast (Srikanta et al, 1996), and mammalian cells
(Lorenz et al, 1996). The sea pansy Renilla reniformis (class Anthozoa), an anthozoan
coelenterate, is a bioluminescent soft coral living in shallow coastal waters of North
America. It displays blue-green bioluminescence upon mechanical stimulation
(Matthews, et al, 1977). The monomeric Renilla luciferase [Renilla-luciferin: oxygen 2oxidoreducatase (decarboxylating), EC 1.13.12.5] catalyzes a bioluminescent reaction by
oxidizing of coelenterazine in the presence of dissolved oxygen to yield oxy-luciferin,
C02 and blue light (lamda,™^ 480 nm) (Matthews, et al, 1977). In R. reniformis, the
energy of the reaction is transferred to the acceptor green fluorescent protein (GFP) which
emits green light as seen in the living coral (lambda max = 509 nm). When GFP is absent,
the reaction yields visible blue light (Matthews, et al, 1977). A cDNA encoding a
functional full-length Renilla luciferase protein was previously cloned and sequenced
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(Lorenz et al, 1991). Renilla luciferase is active as a nearly spherical single polypeptide
chain monomer of 35 kDa with a specific activity of 1.8 x 1015 hv s ’mg"1, and a turnover
number of 111 pmol min'1 pmol'1 of enzyme (Matthews, et al, 1977). The native Renilla,
luciferase contains three free SH groups but no disulfide bonds. The optimal temperature
for luciferase activity is 32°C, and the optimal pH is 7.4. Its activity is stimulated by the
presence of salts, such as NaCl and KC1, with optimal stimulation of 2.7-fold at 0.5 M,
and inhibited by many divalent cations, such as Zn2+, Cu2+, Fe2+, Mn2+. (Matthews, et al,
1977). The best substrates for Renilla. luciferase are e-coelenterazine and vcoelenterazine, which are significantly more efficient than native coelenterazine, but are
highly unstable at the same time (Inouye and Shimomure, 1997).
In this work, the Renilla reniformis luciferase gene product was chosen as a target
protein to be engineered for secretion by mammalian cells to develop a new secreted gene
expression marker for in vitro and in vivo studies. After being fused to the C-terminal
end of the human IL-2 signal peptide, Renilla luciferase was secreted into mammalian
cell culture media. Luciferase protein stability was further improved by substituting
cysteine residue 152 to alanine using site-directed mutagenesis. Secreted Renilla
luciferase activity was easily detected from mammalian cell culture media, but could not
be detected from animal blood samples. Further modifications are necessary before
secreted Renilla luciferase could be applied as an in vivo gene expression marker.

9
C. Gene therapy, DNA vaccination, and gene delivery systems
Gene therapy is defined as the treatment of diseases by transferring therapeutic
genes into target cells. The first gene therapy clinical trial was performed successfully in
1990 with two children suffering from adenosine deaminase (ADA) gene deficiency
syndrome (Bordignon et al, 1995; Blaese et al, 1995). Since then gene therapy has
become one of the most promising weapons in the battle against deadly diseases such as
cancer and AIDS (Anderson, 1998), as well as autoimmune and inflammatory diseases
(Seroogy e? a/., 1998).
Gene therapy may be a potentially revolutionary change to modem medicine.
Although tremendous progress has been achieved in the fields of anesthesia, vaccination,
transplantation, and radiotherapy, humans are still vulnerable to a wide variety of
inherited and acquired diseases. Newly emerging diseases, such as AIDS, make it
necessary to develop new forms of medical treatment. Compared to traditional
therapeutic approaches, gene therapy has several advantages. For example, when
compared to protein therapy, such as daily insulin injection, a gene therapy approach
would eliminate the possible endotoxin contamination present during protein purification.
It would also be more stable for storage and transport, and decrease the cost of
preparation. Unlike radiotherapy and chemotherapy, gene therapy seeks to target specific
cells or induce a specific immune response for therapeutic purposes. There are over one
hundred twenty-five clinical trials that have been approved since 1990 in the United
States alone, and 329 clinical studies with over 2500 patients have been initiated
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worldwide since 1989 (Gottschalk et al., 1998; Anderson, 1998). There is a wide variety
of human genetic diseases, acquired diseases, and infectious diseases that have been
selected for potential gene therapy treatment. The majority of gene therapy strategies
have fallen into one of the following three categories: (a) genetically modified tumour
vaccines, in which metastatic cancer cells from a patient are extracted, transfected ex vivo
with one of several functional cytokine genes, and reinfused into the patient following
irradiation to induce an enhanced target specific immune response to tumor sites
throughout the body, (b) direct local gene delivery, which is defined as direct injection of
gene vectors into target cells, (c) systemic directed gene therapy with subsequently
directed transfection of target tissues (Taneja et al, 1995). So far, however, no single
gene therapy approach has definitively improved the health of a single one of the more
than 2,500 patients who have enrolled in gene therapy trials worldwide (Anderson, 1998).
The majority of gene therapy trials are still in Phase I (evaluation of safety) or II
(preliminary evaluation of efficacy), and only one reached Phase III (evaluation of
efficacy). Although there are some promising results, the inconsistency of clinical trials,
limited knowledge of in vivo gene expression and host immune response, and lack of
ideal gene delivering system are among the main reasons for the relative failure of gene
therapy so far.
During recent years, another gene therapy strategy, DNA vaccination, also known
as genetic or polynucleotide immunization, has become a major focus of attention. DNA
vaccination is defined as the delivery of plasmid DNA encoding either individual or a
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collection of antigens specific to a particular pathogen to a host. The DNA is then taken
in by host cells and the gene(s) is expressed. The foreign protein is produced within the
host cells and then processed and presented appropriately to the immune system, inducing
a specific immune response (Cohen et al, 1998). The major difference between DNA
vaccination and traditional gene therapy approaches is that the goal of DNA vaccination
is to provoke a host immune response, not to alter or replace the function of certain genes.
Therefore, it may not be necessary to reach high gene expression/protein production
levels in DNA vaccination, because even small amount of antigen can theoretically
stimulate a protective immune response. Although traditional vaccination strategies,
such as live, attenuated or whole, inactivated agents, purified or recombinant subunit
proteins and synthetic peptides have been very successful in the past, they are often
hampered by toxicity, the presence of infectious agents, weak immune responses, and
prohibitive costs, especially in the developing world (Gregoriadis, 1998). Another major
disadvantage of traditional vaccines is time. The preparation of viral vectors, production
and purification of recombinant proteins from bacteria, yeast or stably transfected
mammalian cell lines can easily take months to develop, and even years in some cases
(Davis et al., 1995). In addition, DNA vaccination offers an extremely powerful tool for
molecular immunologists to study the immune system and with which to develop new
vaccines and other immunotherapeutic approaches. One can easily and rapidly clone and
modify genes in plasmid DNA expression vectors, allowing many new constructs to be
produced and tested in a short period of time which can be on the order of weeks. In
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animal model systems, DNA vaccines have proved to be as effective as traditional
vaccines, and in some cases, even better (Wahren et al, 1997; Davis et al., 1995).
Since DNA vaccines are taken by host cells, and antigens are synthesized inside
of cells, it is not surprising to find that DNA vaccination provokes strong and persistent
cell-mediated and humoral immune responses to the antigen encoded by the plasmid
(Davis et al, 1995). The endogenous synthesis of proteins leads to the induction of a
cytotoxic T lymphocyte (CTL) response via the major histocompatibility complex
(MHC) class-I-restricted pathway. Meanwhile, synthesised proteins are released
extracellularly through cell lysis. It is believed that the extracellular releasing of antigen
primes the induction of a humoral response, as well as a helper T lymphocyte (Th2)
response via MHC class-II- restricted antigen presentation by antigen-presenting cells
(APCs) that have taken up the foreign antigen (Cohen et al, 1998).
A variety of routes of administration and methods of DNA vaccination including
the use of the “gene gun”, aerosol delivery, and intramuscular DNA injection have been
developed (Lai et al, 1998). It is unlikely that there will ever be an universal method, but
rather there would be multiple approaches taken specifically for certain organ sites and
diseases (Wivel et al, 1998). Skeletal muscle has been the preferred target cell for DNA
vaccination because of its large mass, vascularity, and accessibility (Davis et al, 1995).
Since muscle fibers are nondividing, effective gene delivery could potentially result in
long-lived protein production (Kessler et al, 1996). Other organs, such as liver (Malone
et al, 1994), central nervous system (CNS), lung, kidney, and tongue (Prigozy
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et al, 1993), have also been selected as targets for DNA injection. Gene expression was
also reported in progeny after injection of plasmid DNA (Tsukamoto et al, 1995). DNA
vaccination has been applied to induce immune response against Influenza A
(Montgomery et al., 1993; Yankauckas et al, 1993), Hepatitis C (Geissler et al, 1997),
Hepatitis B (Mancini et al, 1995; Michel et al., 1995; Davis et al, 1995; Gramzinski et
al., 1998), HIV (Wang et al., 1993), malaria (Mor et al, 1995), rabies (Xiang et al..
1995), and most recently, Ebola (Xu et al, 1998). There are reports of DNA vaccination
being used for the treatment against tumor (Codon et al, 1996) and autoimmune diseases
(Youssef et al, 1998). Recent reports showed that delivering plasmid DNA encoding
cytokine (Nitta et al, 1998) or autoimmune antigen (Liu et al, 1998) through
intramuscular (IM) injection could prevent type I diabetes or reduce insulitis in nonobese-diabetic mice. Studies have shown that DNA injection is not likely to initiate or
accelerate the development of systemic autoimmunity (Wolff et al, 1993). DNA
vaccination protocols have recently entered the clinic for initial safety and
immunogenicity testing in humans against colon cancer (carcinoembryonic antigen) and
cutaneous T cell lymphoma (T cell receptor V(3) (Horn et al, 1995; Cohen et al, 1998).
A major technical obstacle for gene therapy/genetic vaccination is to find an ideal
delivery system. Many different gene-delivering systems have been applied in gene
therapy, and they can be divided into two groups: viral and nonviral vectors. Each type
of vector system has its own advantages and disadvantages. Among viral vectors,
retroviral vectors were the first ones to be applied in gene therapy trial and are the most
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extensively studied vectors (Mavilio et al, 1994; Miller et al, 1992). Retroviral vectors
can integrate into host genomes and offer possible long-term gene expression. However,
retroviral vectors are unable to infect postmitotic cells, such as mature myofiber, and are
limited to carrying relatively small segments of DNA (no bigger than 7 kb). In addition,
retroviral vectors present general disadvantages, such as the possibilities of carrying over
of adventitious microorganisms, insertional mutagenesis and/or disruption of host
genome, and replication-competent (helper) retroviral production. Adenoviral vector is
another commonly used viral vector, and currently is the primary candidate for direct in
vivo gene delivery, but also is limited by size of DNA is can carry. Compared to the
retroviral vector, adenoviral vectors are considered safer, have a larger capacity for
foreign genes (up to 40 kb), and will not integrate into host genome. Adenovirus is also
able to infect nonreplicating cells, including skeletal muscle in vivo (Quantin et al..
1992). The drawbacks are that genes may have transient function due to lack of
integration, and there is a strong host immune response against the viral proteins (Miller
et al., 1992). Several other viral vectors are being explored: adeno-associated viruses,
herpesviruses, alphavirus, lentiviruses, and poxviruses. None of these viral vectors is
perfect, and each is likely to have its own therapeutic advantages.
The known and unknown side effects of viral systems have encouraged the
development of nonviral delivery system (Gao et al, 1995). Compared to viral vectors,
nonviral vectors usually do not integrate into the host genome, and gene transfer
efficiency is, in general, lower when compared with viral vectors. Liposomes, which are
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small spheres composed of lipid bilayers, were the first nonviral delivering vehicle, but
are considered too inefficient for gene therapy (Feigner, 1997). The DNA-lipid complex
eliminates the introduction of virus particles but demands large amount of DNA and
transfection efficiency is lower compared to virus vectors. Another shortcoming of
liposomes is that because of mismatch between liposome and plasmid (0.025-0.1 micron
versus 2 microns), only a small portion of plasmid (less than 1%) can be encapsulated
when liposomes are synthesized in the presence of plasmids. Cationic lipids have been
applied to replace simple lipids for packaging of plasmid DNA. These new lipids, named
lipoplexes, are more variable and complicated then simple liposomes and lead to higher
gene expression level (Feigner, 1997). Combined with the use of gene gun, the gene
delivering efficiency of lipoplexes can be greatly increased (Feigner, 1997). However,
the liposomes/lipoplexes systems are generally considered much less efficient compared
to viral vector (Crystal, 1995). As the initial route of administration for DNA
vaccination, intramuscular (IM) injection of naked DNA started to be developed as a
simple and safe way to deliver foreign genes around the late 1980’s. IM injection was
first reported for transferring genes into skeletal muscle in vivo by direct injection of
plasmid DNA without any delivery vehicle, such as a lipid shell (Wolff et al, 1990).
Intramuscular DNA delivery has been used to express reporter genes in animal models.
Several reporter genes, such as Firefly luciferase (Wolff et al, 1990; Levy et al., 1996;
Perez et al., 1996; Prigozy et al., 1993), chloramphenicol acetyltransferase (Wolff et al.,
1990; Wells, 1993; Prigozy et al., 1993), p-galactosidase (Wolff et al., 1990; Nishi et al..
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1996; Prigozy et ai, 1993), and human placental alkaline phosphatase (Perez et al., 1996)
have been expressed in adult and neonatal rat (Wolf et al., 1991), primate skeletal muscle
(Jiao, et al., 1992), cardiac muscle (Lin et al, 1990) and even in progeny (Tsukampoto et
al, 1995).
Compared with viral vectors, “naked” gene transfer offers several advantages
{Levy et al, 1996; Davis et al, 1993). “Naked” DNA gene transfer strategies do not
require dividing cells, has virtually no size limitation, and should be less likely to create
immunological problems, since plasmid DNA can be purified to homogeneity. Despite
evidence that most of the DNA remains in an unintegrated circular form, which
minimizes the risk of genomic insertional mutagenesis, expression has been shown to
persist for up to 19 months (Wolff et al, 1992). Studies have shown that in mouse
skeletal muscle, plasmid DNA transfer is more efficient than that of adenovirus and
retrovirus (Davis et al, 1993).
There are several factors affecting the efficiency of “naked” DNA transfer and the
stability of its expression should be considered during DNA injection. Degeneration of
muscle, preinjection of sucrose (Davis et al, 1993; Wells and Goldspink, 1992), and
preinjection of dexamethazone (Malone et al, 1994) have been found to be able to
improve the distribution of injected DNA and gene expression, although the mechanism
behind the effects remain unclear. It is believed that DNA expression in muscle is dosedependent, volume-dependent (larger volume gives better expression and less variation),
and that muscle cells can be saturated by DNA injection (Davis et al, 1993). Direct gene
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transfer into mouse muscle in vivo was also shown to be affected by age and gender. It is
believed that 5-6 weeks old male mice are optimal for “naked” DNA injection (Wells and
Goldspink, 1992).

D. Application of engineered secreted proteins in gene therapy and DNA
vaccination
Most current gene therapy protocols require genetic modification of autologous
cell (Hughes et al, 1994). Unfortunately, not all kinds of autologous cells are suitable to
be genetically modified and most of these modification procedures are labor intensive,
time consuming and costly (Hughes et al, 1994). Although injection of therapeutic
protein has been successful in several cases, for example, daily injection of insulin in
treatment of diabetes type I, it is not a viable option to cure disease, considering the cost
of preparation, and the side-effects such as hypoglycemia and dawn phenomenon
(Fenjves et al, 1994). Another approach, cell therapy, has been hampered by the
difficulty to maintain therapeutic cells in the recipient due to host immune rejection.
Even without host rejection, the availability of donors for therapeutic cells remains as a
significant concern for cell therapy (Gottschalk et al, 1998).
Alternatively, genes may be delivered to tissues which serve as sites for the
synthesis and secretion of proteins that have effects elsewhere in the body. Secreted
protein should be exposed throughout the body following the bloodstream, rasing the
possibility to genetically modify certain autologous cells, release therapeutic protein, and
reach certain cells or organ, which otherwise would be difficult to be modified. For
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instance, this would be helpful for cancer patient at metastatic stage. If an organ or
tissue-specific-targeting-signal can be added to therapeutic secreted protein, it will make
gene therapy of secreted protein even more attractive. Although the duration of gene
expression and protein circulation may vary in different cases, it was reported that
secreted human erythropoietin (Epo) protein could be detected in circulation for at least
10 weeks after single intramuscular DNA injection (Kessler et al., 1996). The long-term
secretion of (3-glucuronidase, a therapeutic protein for the treatment of human
mucopolysaccharifosis (MPS) type VII, was also achieved in mice skeletal muscles cells
(Naffakh et al, 1996).
Many naturally secreted proteins have been applied in gene therapy and gene
vaccination to treat a wide variety of diseases. For example, human erythropoietin (Epo)
(Kessler et al, 1996; Tripathy et al, 1994), human a 1-antitypsin (Mastrangeli et al.
1994), human apolipoprotein E (Fenjves et al, 1994), human IL-10 (Nitta et al, 1998),
human IL-12 (Tahara and Lotze, 1995), human growth hormone (hGH) (Anwer et al.
1998), hepatitis B surface antigen (Davis et al, 1993), hookworm larval antigen
ancylostoma secreted protein (ASP) (Hotez et al, 1996), and human vascular endothelial
growth factor (VEGF) 165 (Muhlhauser et al, 1995) have been secreted into the
circulation of experimental animals and induced corresponding biological responses.
However, there are many proteins with therapeutic potential that are not naturally
secreted. For example, the retinoblastoma (RB) protein, a tumor suppressor implicated
as a regulator of several cellular processes, was injected into the blood stream causing
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tumor regression in humans (Welch and Wang, 1995). The autoimmune antigen glutamic
acid decarboxylase (GAD) 65 is another example. It was reported that intrathymic and
intravenous injection of the purified GAD65 protein into non-obese mice (NOD) could
protect NOD mice from the development of insulin-dependent diabetes mellitus (IDDM)
(Kaufman et al, 1993; Tisch et al, 1993). Both retinoblastoma and GAD65 are not
naturally secreted, and it may open new directions in cancer therapy and autoimmune
research if retinoblastoma and GAD65 can be engineered to become secreted proteins,
and mimic the result from that of protein injection. Engineering the in vivo secretion of
protein may provide more stable and longer-lasting therapeutic protein levels than that
from the injection of purified proteins, and should be economically more advantageous
and less painful physically and psychologically to the patients compared to protein
injection.
In general, a leader sequence encoding a hydrophobic signal peptide is used to
generate secreted protein. The signal peptide will redirect naturally non-secreted protein
to the protein secretion pathway, eventually causing it to be secreted by the host cell.
Several therapeutic proteins, including human adenosine deaminase (ADA) (Hughes
et al, 1994), acidic fibroblast growth factor (aFGF) (Tabata et al, 1997), human
thyrotropin receptor (Chazenbalk et al, 1997), and human leukocyte elastase (HLE)
(Okano et al, 1990), have been engineered to become secreted proteins for therapeutic
purposes. It was reported that artificially secreted proteins are immunologically and
often catalytically similar to their intracellular forms (Hughe et al, 1994).
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E. Insulin-dependent type I diabetes: Glutamic Acid Decarboxylase (GAD65) as an
autoantigen, and the NOD mouse as an animal model
Diabetes is the seventh leading cause of death by disease in the United States
(Stryer, 1988). There are two types of diabetes: Type 1 is an autoimmune disease where
the body does not produce any insulin; Type 2 is a metabolic disorder resulting from the
body’s inability to make enough, or properly use, insulin. It has been reported that the
incidence of diabetes mellitus in industrialized countries is about 1%, and there are 15.7
million people or 5.9% of the population in the United States who have diabetes (Stryer,
1988). While an estimated 10.3 million have been diagnosed, unfortunately, 5.4 million
people are not aware that they have the disease, and approximately 2,200 people are
diagnosed with diabetes every day. Based on death certificate data, diabetes contributed
to more than 187,000 deaths in 1995. A total of 75,000 workers were reported to be
permanently disabled because of diabetes in 1997. The total annual economic cost of
diabetes in 1997 was estimated to be $98 billion dollars, including $44.1 billion in direct
medical and treatment costs, and $54 billion for indirect costs attributed to disability and
mortality. Although diabetes studies and medical research have made tremendous
progress during the last decade, diabetes still remains a chronic disease with no cure.
Diabetic patients require daily insulin injections to stay alive.
The mechanism behind diabetes is not clear. Diabetes Type I is considered as an
organ-specific autoimmune disease, resulting from a failure to develop or maintain
immune tolerance to self-antigens expressed in the islets of Langerhans (Winter et al,
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1997; Andrea et al, 1992). Although both T cells and B cells are involved, the
destruction of pancreatic p cells is mediated predominantly by the activity of CD4+ and
CD8+ T cells (Lemmark et al, 1994). During the normal development of T cells in the
thymus, self-antigen-reactive T cells undergo clonal deletion or clonal anergy, which
effectively removes these cells from the pool of mature antigen reactive T cells (Alberts
et al, 1994). In general, T-cell reactivity against self- antigen expressed on P cells does
not occur because of the failure to activate T cells reactive with the antigen, termed clonal
ignorance. This may be broken with viral infection or cytokines. In one transgenic
model, dendritic cells surrounding the islets of Langerhans have been shown to be
responsible for presentation of islet antigens to the immune system. B-cell tolerance can
also involve mechanisms of clonal deletion or clonal anergy similar to that of T cells.
In the case of Diabetes Mellitus Type I, the failure of immune tolerance leads to
total destruction of pancreatic p cells, and insulin production is subsequently stopped.
The development of diabetes can be divided into three stages. First, immune ignorance
against autoimmune antigens (GAD65, insulin etc.) presented by pancreatic p-cells is
suppressed, and self-reactive T and B lymphocytes recognize these antigens. Second, the
activation of the Thl cell population leads to the infiltration of pancreatic p-cells by
macrophage, CTL, and autoantibody-producing B-cells resulting in insulitis. Third,
insulin production is stopped due to extensive pancreatic tissue damage. It is believed
that both cellular and humoral type of host immunity are involved in the development of
diabetes, and balance shifting between Thl/Th2 cell population plays an important role in
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diabetes (Parish et al, 1995). Insulitis is a crucial stage during the development of
diabetes, and protection of pancreatic tissue from insulitis is a good indication for the
protection of diabetes (Herold et al, 1992; Andrea et al, 1996).
The clinical syndrome of human diabetic patients starts with increased urinary
glucose level (glucosuria > 10.0 mM throughout the day and night). As the disease
progresses, hyperglycemia, visual blurring, and weight loss are the first symptoms found
in diabetic patients. The symptoms of diabetes complication include: diabetic retinopathy
(retinal micro angiopathy), diabetic nephropathy (microangiopathy involving the kidney, a
major cause of morbidity and mortality), diabetic neuropathy (disordered function of
somatic or autonomic nerves), coronary artery disease, peripheral vascular disease
(diabetic foot, skin damage, etc), and diabetic ketoacidosis (Felig et al, 1987). Several
clinical treatments have been established for diabetes with daily injection of insulin as the
main treatment. Insulin is injected twice a day or administered with a portable pump.
However, there are several complications with insulin treatment that can cause severe
side effects in patients: hypoglycemia, Somogyi phenomenon (rebound or reactive
hyperglycemia and ketinuria after excessive insulin administration), dawn phenomenon
(early-morning rise in blood glucose concentration), insulin lipodystrophy (poor insulin
absorption of subcutaneous tissues), insulin allergy, resistance to insulin, and insulininduced edema. The quality of human insulin products also presents a problem for
insulin treatment. Dietary management is another form of treatment for diabetic patients,
but successful implementation of diet is only achieved occasionally (Felig et al, 1987).
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Besides daily insulin injection, transplantation of islet cells or pancreas tissue into
diabetic patients has also shown some encouraging results since 1986. However,
extremely high cost (up to $100,000/ patient) and strong host immune rejection, have to
be overcome before cell/tissue transplantation can be widely applied to diabetic patients.
Gene therapy would be an attractive approach to prevent or treat diabetes if it
could restore host immune tolerance through genetic vaccination or provide physiological
levels of insulin. Up to now, most studies were conducted in NOD mice, an animal model
for IDDM. Several genes have been selected for genetic vaccination of diabetes: insulin
(Kolodka et al, 1995), glutamic acid decarboxylase (GAD) 65 (Kaufman et al, 1993;
Tisch et al, 1993), and GAD67 (Elliott et al, 1993). Among these autoantigens, GAD65
protein is one of the earliest recognized by autoimmune antibodies in IDDM (Peterson et
al, 1994). The recognition of GAD65 is believed to be the trigger of other autoimmune
reactions (Kaufman D. L. et al, 1993. Tisch R. et al, 1993; Aizpurua et al, 1994).
Therefore if immune tolerance against GAD65 can be restored, there is a possibility of
delaying the development of diabetes.
GAD is the biosynthetic enzyme for y-aminobutyric acid (GABA), an inhibitory
neurotransmitter in the central nervous system (Erlander and Tobin, 1991). GABA is
also found outside of the central nervous system, in the liver, oviduct, adrenal,
sympathetic ganglia, gastrointestinal tract, circulating erythrocytes, testis, ovary, kidney
and pancreatic islets (Tillakaratne-NJ et al, 1995). GAD exists in two isoforms: GAD67
and GAD65, encoded by two different genes on different alleles. GAD67 is a 67
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kilodalton (KDa) protein found in the cytosol (Erlander and Tobin, 1991). The gad67
gene is located on human chromosome 2, contains 16 exons and covers a 45 kb region.
GAD65 is an amphiphilic and membrane-anchored protein with a molecular weight of 65
kDa. The gad65 gene is located on human chromosome 10 with 16 exons and covers a
79 kb region (Bu and Tobin, 1994). There is 65% amino acid sequence homology
between GAD67 and GAD65, with low-homology at the N-terminus (Li, et al., 1995).
The cDNA encoding the GAD65 protein has been cloned, and both DNA and
protein have been thoroughly studied. The majority of epitopes associated with IDDM
have been located at the C-terminal and the middle region of the protein (Richter et al.
1993; Ujihara et al, 1993). No epitope is found at the N-terminal region (Richter et al.
1993). After being synthesized, the GAD65 protein goes to the endoplasmic reticulum
and Golgi apparatus, and undergoes a postranslational modification step called
palmitoylation (Christgau et al, 1992). The palmitoylation modification adds a
16-carbon saturated fatty acid to the N-terminus of GAD65 protein. GAD65 then
becomes an N-terminal membrane-anchored protein found on the surface of
microvesicles (Christgau et al, 1992). It has also been shown that amino acid residues
24-31 and a signal located within amino acid 1-27 of GAD65 are crucial for GAD65
membrane anchoring (Shi et al, 1994; Solimena et al, 1994).
In addition to IDDM, another human disease, stiff-man syndrome (SMS), is also
associated with autoimmunity to GAD (Erlander and Tobin, 1991; Solimena et al, 1991).
The GAD65 antigen is the most often targeted isoform for IDDM and SMS, even though
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different GAD65 epitopes are recognized in the two diseases (Hagopian et al., 1993).
Injections of GAD65 purified protein in NOD mice, which is the established animal
model to study human diabetes, have been shown to delay the development of insulitis
and diabetes (Kaufman et al, 1993; Tisch et al, 1993). Because of the high cost with
protein isolation, and of the impossibility to thoroughly eliminate endotoxin
contamination during protein purification, the vaccination against injection of GAD65
protein does not appear to be the most practical solution for the treatment of diabetes.
The non-obese diabetic (NOD) mouse is an important animal model for human
IDDM. The NOD mouse was first established as an inbred strain in 1974 at the Shionogi
Research Laboratories in Osaka, Japan (Hanafusa et al, 1994). It was derived from a
subline of the CTS strain on a JCL-ICR background, during selective breeding searching
for a new animal model of diabetes. Interestingly, the NOD was derived from a normal
glycemic subline instead of a hyperglycemic one (Hanafusa et al, 1994).
The NOD mouse is an excellent animal model for human IDDM because it can
spontaneously develop IDDM with a similar immunopathological profile to the human
disease (Jaramillo et al, 1994; Shieh et al, 1993; Hanafusa et al, 1994). It has been
shown that the development of IDDM in NOD mice is under polygenic control and is
influenced by many environmental factors (Bowman et al, 1994). Generally 60-80% of
females and 20% of males show accumulative diabetes incidence by 30 weeks of age
(Hanafusa et al, 1994. Aizpurua et al, 1994. Baxter et al, 1991). Although promising
data were obtained through experiments conducted on NOD mice (French et al, 1998;
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Kolodka et al., 1995), we are still far away from controlling the disease in either mice or
humans.
Many key features of human insulin-dependent diabetes (IDD) are observed in the
NOD mouse: the development of insulitis, whereby pancreatic islets of Langerhans are
infiltrated by lymphocytes that are selectively cytotoxic to the insulin-producing p cells,
the inheritance of particular major histocompatibility complex (MHC) class II alleles,
representing the major component of genetic susceptibility, the transmission of IDDM by
hematopoietic cells in bone marrow, and the T cells dependence of disease pathogenesis
(Bowman et al., 1994). There are also some minor differences between human and
mouse disease. The presence of a high percentage of T cells in NOD lymphoid tissues
and peripheral blood distinguishes NOD mice from human with IDDM. NOD mice do
not display the severe diabetic ketoacidosis character as do untreated human patients with
IDDM, perhaps due to an enhanced ability of mice to metabolize blood ketones to lactate.
In addition, NOD mice exhibit a pronounced female gender bias for disease
susceptibility that is not seen in humans (female: male ratio is about 4:1 in NOD mice
and 1.7:1 in human patients). While the specific reasons for this difference are unclear,
female mice are known to show stronger immunological responses to exogenous stimuli
than males and it has been demonstrated that the lower incidence of IDDM in NOD males
is partially regulated by gonadal sex steroids. Finally, the pathogenesis of IDDM in NOD
mice is associated with expression of endogenous defective retrovirus in p cells, a feature
not seen in human (Bergman et al, 1994).
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A major difference must be considered when comparing IDDM in human and
NOD mice (Bowman et al, 1994). Given the genetic heterogeneity within the human
population, the development of IDDM in NOD mice is likely to reflect heterogenous
mixtures of susceptibility genes whose penetrance are responsive to different NOD mice
that inherit the same gender-specific set of susceptibility genes, a consequences of over
50 generations of sibling matings. The penetrance of these genes can be analyzed under
constant, well-defined environment conditions of diet, temperature and exposure to
pathogenic agents. Consequently, the natural history of IDDM development in a wellmaintained NOD colony is quite predictable. Indeed, an intervention study in NOD mice
can be designed in such way that the treatment is initiated at a presymptomatic stage prior
to the occurrence of insulitis (up to 3 weeks postpartum), or before the onset of diabetes
(4 to 8 weeks postpartum), or before the onset of disease, at a time when considerable
numbers of p Langerhans cells are still intact. By contrast, the genetic and environmental
heterogeneity associated with the natural history of IDDM in humans is such that the age
of disease onset is extremely broad and may occur beyond 50 years of age. Given these
complexities, it has been difficult for clinical investigators to develop simple diagnostic
tools for the early identification of humans destined to develop IDDM. For these reasons,
studies to prevent IDDM in NOD mice must be carefully analyzed for their applicability
to the therapeutic intervention in human disease (Bowman et al, 1994).
The NOD mice used in this project, NOD/MrkTacBR, were purchased from the
Taconic Lab. This strain was derived by Taconic ini985, and an inbred foundation
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colony has since been maintained in genotobiotic isolators. The NOD mouse was
developed from non-inbred ICR mice and subsequently inbred by Makino for over
20 generations. Diabetes development in NOD/MrkTacBR mice is characterized by
insulitis, defined as leukocytic infiltration of the pancreatic islets. Marked decreases in
pancreatic insulin content occur in females at about 12 weeks of age (Gaskins, et al.
1992) and several weeks later in males. Onset of diabetes is marked by moderate
glycosuria (1+ reading on Lily Tes-Tape™) and the non-fasting plasma glucose higher
than 250 mg/dl. It is best to begin monitoring for development of glycosuria at weekly
intervals starting at 10 weeks of age. The incidence of diabetes in NOD/MrkTacBR
females and males are currently at 85% and 50% respectively at 39 weeks of age.
In this work, a secreted form of GAD was engineered to evaluate its biological
effect on diabetes in NOD mice. Intramuscular DNA injection was conducted to inhibit
the development of diabetes in NOD mice. Results showed that IM injection of both
intracellular and secreted forms of GAD dramatically reduced the development of
insulitis compared to control groups.

CHAPTER TWO
MATERIALS AND METHODS
A. Reagents
Double-distilled water (Nanopure II System, Bamsted/Thermolyne Corp.,
Dubuque, Iowa) and commercially available chemicals were used to make all solutions.
Solutions and glassware were autoclaved (AMSCO Eagle Series, Steris Corporation,
Eire, PA, USA) if necessary. All reagents for mammalian cell culture are purchased from
Sigma Chemical Co. (St. Louis, MO), ICN Biomedical Inc. (Aurora, Ohio), and Life
Technologies Inc. (Grand Island, NY). Culture media were kept at +4 ° C, and -20 ° C for
long time storage.

B. Gene expression vectors used in this project
Two retroviral vectors, pLNCX and pLXSN, were kindly presented by Dr. Miller
from the University of Washington. The retrovirus vector pLNCX (Figure 1 A) is a
double stranded (ds) DNA cloning vector that can transfer and express foreign genes in
dividing mammalian cells (Miller et al., 1989). The sources of pLNCX vector include
moloney murine leukemia virus DNA, moloney murine sarcoma virus DNA, human
cytomegalovirus DNA, and transposon Tn5 DNA. The full length of pLNCX vector is
6620 bp. A neomycin gene is transcriptionally controlled by the 5' moloney murine
sarcoma virus (Mo-Musv) long terminal repeat (LTR) promoter and will be used as a
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positive selectable marker for transfection of mammalian cells. A multiple cloning site is
available for cloning of foreign DNA and the cloned foreign DNAs will be under the
transcriptional control of cytomegalovirus (CMV) promoter. There is a poly A signal in
the 3' LTR (Miller et al., 1989).
Retrovirus vector pLXSN (Figure IB) is a 5874 bp double strand DNA cloning
vector for gene transfer and gene expression (Miller et al., 1989). Its structure is very
similar to that of vector pLNCX except that the cloned foreign DNA in pLXSN vector is
transcriptionally controlled by the 5' LTR instead of a CMV promoter.
Another mammalian cell expression vector, pND2 (Figure 1C), was chosen as a
gene delivery vector for animal studies. pND2 was developed by Dr. Rhodes at
University of California at Davis and Dr. Malone at University of Maryland at Baltimore.
The foreign genes cloned into pND2 vector are under transcriptional control of CMV
promoter. A CMV promoter enhancer and an intron in pND2 can increase the gene
expression level. An Ampicillin gene is used as selection marker for DNA
transformation in E.coli. pND2 vector has been applied for in vitro and in vivo studies
previously and high levels of gene expression have been reached (Dr. Malone, personal
communication).
Preliminary data showed that the CMV promoter is much stronger than LTR
promoter in LMTK( ) and COS cells. Compared to pLNCX vector, the result of in vitro
studies showed that PND2 vector has 15 to 50 times higher gene expression level than that
from pLNCX (Liu et al, unpublished data). Therefore the pLNCX vector was selected as

31
gene transfer vector for in vitro study, and pND2 was used for in vivo study. All
published results and data are based on the studies conducted on pLNCX retroviral vector
and pND2 vector.
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Figure 1. Partial structures of gene transfer vectors used in this study. Ampicillin
resistance gene and bacterial origin of replication are not shown. LTR, long terminal
repeat; neo, neomycin resistance gene; pA, polyadenylation site; MCS, multiple cloning
site (5 ’ to 3 ’: Sail - BgH - Nar\ - Nhel - Clal - Smal - BamHT)‘, SV, simian virus 40
promoter; HCMV IE1, the CMV immediate early promoter.
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C. DNA sequence analysis and oligonucleotide synthesis
DNA sequencing and oligonucleotides synthesis were performed using a 3 73A
DNA Sequencer (Applied Biosystems, Inc.) and a 394 DNA/RNA Synthesizer (Applied
Biosystems, Inc.) respectively, at the Center for Molecular Biology and Gene Therapy,
Loma Linda University.
The PRISM Ready Reaction DeDeoxy Terminator Cycle Sequencing Kit
(Applied Biosystems, Inc.) was used for DNA sequencing. DNA templates
(OD 260/280 > 1.8) were prepared with double-distilled water at a concentration of 200 pg/pl.
Reaction solution was prepared by mixing 9.5 pi terminator mix, 5.0 ul DNA template,
and 3.2 pmol DNA primer in 600 pi centrifuge tube. The final volume was adjusted to
20 pi with water. The reaction was set up as follows: preheating to 96° C, 96° C for
10 seconds, 50° C for 5 s, 60° C for 4 minutes, and total for 25 cycles. Samples were
purified with Centri-Sep columns as follows: columns were hydrated with 800 pi of
double-distilled water for 30 minutes, centrifuged at 750 x g for 2 minutes, and samples
were then loaded to the center of the column. Samples were collected from columns after
being centrifuged at 750 x g for 2 minutes, air dried, and resuspended with 4 pi of loading
buffer (5 pi deionized formamide, 1 pi 50 mM EDTA, pH 8.0). Samples were placed on
ice after being denatured at 90° C for 2 minutes, and were loaded on a 373A DNA
Sequencer.
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D. Restriction enzyme analysis of DNA
Restriction endonucleases from Boehringer Mannheim Corporation (Indianapolis,
IN) were used to digest plasmid or genomic DNA, according to the manufacturer’s
instruction. Generally, 500 ng of DNA were digested by 1 unit of enzyme for 2 hours at
final volume of 30 pi. DNA samples were analyzed by 0.8% agarose gel electrophoresis.

E. DNA ligation
T4 DNA ligase (Boehringer Mannheim Corporation, Indianapolis, IN) was used
for ligation of DNA fragments, according to the manufacturer’s instruction. For DNA
ligation between cohesive ends, 500 ng of total DNA was used in a final volume at 20 pi,
with a vector-to-insert ratio of 1:3. For DNA ligation between blunt ends, 1 ng of total
DNA was used in a final volume at 20 pi with a vector-to-insert ratio of 1:5. Ligation
reactions were incubated at 17 °C overnight, and 10 pi aliquots of ligation mixture were
used to transform E. coli competent cells.

F. Gel electrophoresis of DNA
To analyze DNA samples after restriction enzyme digestion, 1% agarose (wt/vol)
dissolved in TAB buffer (50mM Tris base, 50 mM boric acid, ImM disodium EDTA,
pH 8.0) was used. The samples were mixed with 1/10 volume of 5x loading buffer
(30% glycerol, 1.8x TBE, pH 8.0, 0.06% bromophenol blue, 60 mM disodium EDTA,
0.12% mg/ml DNAase-free Rnase), loaded in wells, and were subjected to a 90 V current
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for 45 minutes. Gels were stained with ethidium bromide (0.5% fig/ml, final) for
5 minutes before being visualized under ultraviolet (UV) light.
To detect small DNA fragments (< 250 bp), SDS-polyacrylamide gel was used.
To make 5 ml 12% resolving gel, 1.6 ml of H20, 2 ml of 30% acrylamide mix (29 g
acrylamide and 1 g N, A’-methylenebisacrylamide in 100 ml H20), 1.3 ml of 1.5 M Tris
(pH 8.8), 50 pi of 10% SDS, 50 pi of 10% ammonium persulfate, and 2 pi of TEMED
were mixed. To make 2 ml 5% stacking gel, 1.4 ml of H20, 330 pi of 30% acrylamide
mix, 250 pi of 1.0 M Tris (pH 6.8), 20 pi of 10% SDS, 20 pi of 10% ammonium
persulfate, and 2 pi of TEMED were mixed. The samples were mixed with 1/10 volume
of 5x loading buffer, loaded in wells, and were subjected to a 125 V current for
60 minutes. Gels were stained with ethidium bromide (0.5% pg/ml, final) for 5 minutes
before being visualized under ultraviolet (UV) light.

G. Mini-prep of plasmid DNA by boiling method
Bacterial cells were seeded into 2 ml LB medium with 100 pg/ml ampicillin and
grown at a 37°C shaker overnight. The 2 ml cultures were then transferred into 2 ml
Eppendorf tubes and spun down at 10,000 x g for 5 minutes. The pelleted cells were
suspended in 200 pi of double distilled water (ddH20) and 200 pi of 2 x lysis solution
(16% sucrose, 1% Triton X-100, 100 mM EDTA, and 20 mM Tris-HCl, pH 8.0).
Twenty-five microliters of lysozyme solution (10 mg/ml in H20) were added to each
tube. Tubes were vortexed well and boiled in a water bath for 40 seconds, then spun
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down at 12,000 x g for 10 minutes at room temperature. The debris at the bottom of each
tube was removed with a toothpick. DNA was precipitated with 40 pi 3M NaAC and
400 pi of isopropanol. DNA was resuspended in H20 and loaded on gel directly to
determine the MW. Samples were then taken for restriction enzyme analysis.

H. Maxi-prep of plasmid DNA using alkali lysis method
Thirty milliliters of bacteria culture carrying a plasmid of interest were grown to
late log phase, and 25 ml of culture were inoculated into 500 ml of LB medium
containing the appropriate antibiotic in a 2-liter flask. The culture was grown for about
12-16 hours at 37°C with vigorous shaking (300 cycles/minutes on a rotary shaker).
Bacterial cells were harvested from 500 ml culture by centrifugation at 6000 rpm for
15 minutes at 4°C in a Sorvall GS3 rotor (Beckman, Palo Alto, CA). The supernatant
was discarded, and the bottle was kept in an inverted position to allow all of the
supernatant to drain.
The cell pellet was resuspended in 10 ml of Solution I (50 mM glucose, 25 mM
Tris-HCl, pH 8.0; 10 mM EDTA. pH 8.0). One milliliter of freshly prepared solution of
lysozyme (10 mg/ml in lOmM Tris-HCl, pH 8.0) and 20 ml of freshly prepared Solution
II were added into cell suspension, thoroughly mixed, and stored at room temperature for
10 minutes. Fifteen milliliters ice-cold Solution III (60 ml of sodium acetate, 11.5 ml
acetic acid and 28.5 ml H20 mixed together) were added and mixed well, stored on ice
for 10 minutes.
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Bacterial lysates were spun down at 8000 rpm for 15 minutes at 4°C in a Sorvall
GS3 rotor. The supernatant was filtered through four layers of cheesecloth in a 250 ml
centrifuge bottle. Isopropanol was added to solution of 0.6 volume ratio, mixed well and
stored at room temperature for 10 minutes. The nucleic acids were recovered by
centrifugation at 8000 rpm for 15 minutes at 4°C in a Sorvall GS3 rotor. The
supernatant was removed carefully and the open bottles were inverted to allow the last
drops of supernatant to drain. Five ml 70% ethanol were used to wash the pellet twice
before the pellet was dried in open air for 5 minutes. DNA pellet was then dissolved in
2 ml TE (pH8.0) and stored at -20°C.

I. Purification of closed circular DNA by equilibrium centrifugation in CsClEthidium gradients
E.coli cells transformed with DNA constructs of interest were grown in two-liter
culture LB medium with antibiotics overnight. Cells were spun down and DNA was
extracted using standard alkaline-lysis method. DNA was dissolved in double distilled
water and Cesium chloride (CsCl) was added at a 1 g/1 ml ratio. The solution was
warmed up to 30°C to facilitate the dissolution of the salt. Eight milliliters of a solution
of ethidium bromide (10 mg/ml in water) were added to every 100 ml of the DNA/CsCl
salutation. The ethidium bromide solution was immediately mixed with the denser
DNA/CsCl solution. The final density of the solution should be 1.55 g/ml, and the
concentration of ethidium bromide should be approximately 740 pg/ml.
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DNA/CsCl solution was added into 15 ml high-speed Quick-Seal tubes
(16 x 76 mm, Beckman, Palo Alto, CA) and centrifuged at 75,000 rpm for 16 hours at
20°C in a XL-90 Ultracentrifuge (Beckman, Palo Alto, CA) rotor. Three layers were
formed and the clear, red one in the middle contained the DNA. An 18-gauge needle was
used to transfer the clear red solution into another 15 ml tube, and CsCl was added again
and DNA-CsCl solution was centrifuged again to obtain purified plasmid DNA. The
plasmid DNA band was removed and transferred into a 50 ml plastic tube. Aluminum
foil was used during the whole procedure to avoid DNA degradation by light.
Isobutanol saturated with water was then used to remove the ethidium bromide
from the DNA solution. An equal volume of isobutanol was added to the DNA solution
and mixed well by vortexing. The upper layer of solution containing ethidium bromide
was removed. The procedure was repeated at least 10 times until all the pink color
disappeared from both the aqueous phase and the organic phase.
CsCl was removed from DNA solution by dialysis through Slide-A- Lyzer 2KTM
dialysis Cassettes (Pierce, Rockford, IL, USA). The solution was dialysed twice in two
liters TE buffer for 24 hours at 4°C. DNA was finally precipitated with 10% Ammonium
Acetate and 3 volumes of 100% ethanol for five hours at -20°C followed by
centrifugation at 10,000 x g for 30 minutes at 4°C. DNA was resuspended in double
distilled water at a concentration of 4 pg/pl.
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I. Preparation of E.coli competent cells
Media (SOB, SOC, and LB) were prepared as described by Hanahna (Hanahan,
et al, 1983). SOC medium is the same as SOB medium (2% tryptone, 0.5% yeast
extract, 10 mM NaCl, 2.5 mM KCL, 10 mM MgCl2, and 10 mM MgS04) except for the
adding of 20 mM glucose. For selection of transformed E.coli, LB plates containing
100 pg/ml ampicillin were used. To make Transfer Buffer (TB) (10 mM Pipes, 55 mM
MnCl2, 15 mM CaCl2, and 250 mM KC1), all the components except for MnCl2 were
mixed and the pH was adjusted to 6.7 with KOH. Then MnCl2 was dissolved, the
solution was sterilized by filtration through a 0.45 pm filter unit and stored at 4°C. All
salts were added as solids.
Frozen stock of DH5a cells were thawed, streaked on to an ampicillin/LB agar
plate, and cultured overnight at 37°C. Ten to twelve large (2-3 nm in diameter) colonies
were isolated with a plastic loop, inoculated into 250 ml of SOB medium in a 2-liter
flask, and grown to an OD 600 of 0.6 at 18°C with vigorous shaking (200-250 rpm). The
flask was removed from the incubator and placed on ice for 10 minutes. The culture was
transferred to a 500 ml centrifuge bottle and spun at 2500 x g for 10 minutes at 4°C. The
pellet was resuspended in 80 ml of ice-cold TB, incubated in an ice bath for 10 minutes,
and spun down as described above. The cell pellet was gently resuspended in 10 ml of
TB, and DMSO was added with gentle swirling to a final concentration of 7%. After
incubating in an ice bath for one minute, the cell suspension was dispensed by 1-2 ml into
tissue-culture cell-freezing tubes and immediately chilled by immersion in liquid
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nitrogen. The frozen competent cells were stored at - 70°C for at least 4 months without a
detectable loss of competence.

J. Polymerase Chain Reaction (PCR)
The PCR reaction was conducted as previously described (Sambrook et al, 1989).
The PCR amplification mixture was prepared by adding reagents to a sterile micro
centrifuge tube in the following order: 10 pi of 10 x Reaction Buffer (250 mM MgCl2,
100 mM Tris, 500 mM KC1, pH8.3), 2 pi of 10 mM PCR nucleotide Mix, 5 pi of 20 pM
upstream and downstream primers (1 pM final concentration), 1 pi of template DNA
(50 pg/pl), 1 pi of DNA polymerase (5 U/pl), and H20 were added to bring final volume
to 100 pi.
The condition of PCR for amplification of normal length DNA fragments (from
200 bp to 2.5 kb), PCR was performed usingpwo polymerase (Boehringer Mannheim)
under the following conditions: 94°C for 2 min for one cycle, followed by 94°C for
30 sec, + 55°C for 30 sec, + 65 °C for 60 sec for 25 cycles.
The condition of PCR for IL-2 leader sequence was as described previously: PCR
was performed using pwo polymerase (Boehringer Mannheim) under the following
conditions: 94°C for 2 min for one cycle, followed by 94°C for 15 sec + 50°C for 30 sec
for 30 cycles.
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K. Site-directed mutagenesis
The Quick Change™ Site-Directed Mutagenesis Kit from Stratagene was used to
introduce mutation in the Renilla luciferase gene. Plasmid pND2-SRUC was used as a
template and two primers were designed for one amino acid substitution. Sample
reactions were prepared as described: 5 pi of 10 x reaction buffer, 25 ng of ds DNA
template, 125 ng of oligonucleotide A, 125 ng of oligonucleotide B, 1 pi of dNTP mix,
and H20 was used to bring a final volume to 50 pi. One pi of Pfu polymerase (2.5 U/pl,
Stratagene, San Diego, CA) was added right before the cycling reaction.
Cycling reactions were performed using Pfu DNA polymerase under the
following condition: 95°C for 30 seconds for one cycle, followed by 95°C for 30 sec,
55°C for one min, 68°C for 10 min, 30 sec for 16 cycles. Following temperature cycling,
the reactions were cooled on ice for 2 minutes. Ten Units of Dpn I restriction enzyme
were directly added into each amplification reaction to digest parental DNA template at
37°C for one hour. The amplified DNA was then used to transform E.coli XLl-Blue
competent cells. Three colonies were randomly selected for DNA sequencing analysis.
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L. Western blotting analysis
Western blotting analysis was conducted as previously described (Sambrook
et al, 1989). Transfected mammalian cells were harvested 48 hours after transfection by
scraping with a rubber policeman 100 pi 2 x gel-loading buffer (0.1% Bromophenol Blue,
1M sodium phosphate, pH7.4, 4% SDS, 20% glycerol) and transferred into a 1.7 ml
eppendorf tube. Cells were lysed by sonication for 3x 10 sec, boiled for 10 minutes, and
the supernatants were transferred into another tube. Twenty microliters of sample was
loaded on SDS-polyacrylamide mini-gel. Proteins were separated by electrophoresis at
165 volts for 1.5 hours. Protein bands were electrotransfered to PVDF membrane for
2 hours by a LABCONCO semi-dry blotter.
The membrane was then washed with 1 x TBST (20 mM Tris-HCl; 137 mM
Sodium Chloride; 3.8 mM Hydrochloric acid; 0.1% Tween-20), and then was blocked
with 1% Gelatin/ TBST at room temperature overnight. The membrane was washed three
times (1x15 min, and 2x5 min) with TBST, and incubated with antibodies
(1:10,000 dilution in TBST) raised against the protein of interest for two hours at room
temperature on a shaker. After being washed three times, the membrane was incubated
with anti-mouse IgG2a conjugated to Peroxidase (Amersham) diluted 1:15,000 in TBST
for one hour at room temperature before being washed with TBST buffer. The blotted
membrane was incubated with SuperSignal Substrate Working Solution (Pierce,
Rockford, IL, U.S.A.) for 5 minutes. The working solution was removed and blot was
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wrapped in plastic warp. A Kodak X-ray film was exposed to the blot for
chemiluminescent detection and the film was developed.

M. Protein labeling with 35S-methionine
To detect secreted GAD proteins in cell culture media, 35S-methionine (specific
activity>1000 Ci/mmol, from DuPont NEN, Boston, MA) was used to label total cell
protein from COS-7 cells. Media was removed after incubation with the DNA-calcium
phosphate complex, and cells were rinsed twice with 1 x PBS and once with medium
without methionine and serum. Cells were then incubated in 3 mL DMEM medium
without methionine + 1% dialyzed FBS for 20 min to deplete intracellular pools of
endogenous methionine. One hundred microcuries of35S-methionine were then added
directly into media for protein labeling. Cells were incubated for 24 hours before being
harvested.

N. Immunoprecipitation of secreted proteins
The Immunoprecipitation Kit (Protein A) from Boehringer Mannheim was used in
the experiment. Thirty-six hours after transfection, cells were washed with lx PBS twice.
One hundred microliters of cooled lysed buffer (50 mM Tris-HCL; 150 mM NaCl;
1% Nonidet P40, 0.5% sodium deoxycholate; 1 Complete™ protease inhibitor cocktail
tablets, pH 7.5) were added into plates and cells were scraped into an Eppendorf tube

45
with a rubber policeman. Cells were lysed by sonicating 3x10 seconds. Homogenized
suspension was centrifuged at 12,000 x g 10 minutes at 4°C to remove cell debris.
To immunoprecipitate secreted protein from cell culture medium, medium was
collected 36 hours after transfection, centrifuged at 800x g at 4°C to remove dead cells
and cell debris, and Centriprep-10 concentrators (Amicon, CA) were used to concentrate
medium from 2.5 ml to 0.5 ml. 2 x lysis buffer (100 mM Tris-HCl; 300 mM NaCl;
2% Nonidet P40, 1% sodium deoxycholate, pH 7.5); 2 Complete™ protease inhibitor
cocktail tablets was mixed with concentrated medium at 1:1 ratio.
To reduce background caused by nonspecific binding of irrelevant cellular
proteins to protein A/G-agarose, a precleaning step was performed: 50 pi of the
homogeneous protein A/G-agarose suspension (25 pi bed volume) was added to the
sample and incubated for at least 3 hours at 4°C on a rocking platform. Beads were then
pelleted by centrifuged at 12,000x g for 20 seconds, and the supernatant was transferred
to fresh tubes.
To immunoprecipitate the target proteins, the appropriate amount of the specific
monoclonal antibody (5 pi) was added to samples and gently shaken for 2 hours at 4°C.
Fifty microliters of the homogeneous protein A/G-agarose suspension (25 microliters bed
volume) were added into the mixture and incubated at 4°C overnight. Complexes were
collected by centrifugation at 12,000 x g for 20 s. The supernatant was removed and
beads were resuspended in 1ml lysis buffer and incubated at 4°C for another 20 minutes
on a rocking platform. The beads were washed with 1 ml lysis buffer one more time.
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Beads were collected and washed with 1 ml wash buffer 2 (50 mM Tris-HCl;
500 mM NaCl; 1% Nonidet P40, 0.05% sodium deoxycholate, pH 7.5) twice before being
washed with wash buffer 3 (50 mM Tris-HCl; 1% Nonidet P40, 0.05% sodium
deoxycholate, pH 7.5). Beads were then centrifuged at 12,000 x g at 4°C and the
supernatant was removed.
Fifty microliters of gel-loading buffer were added to the agarose pellet. Proteins
were denatured by heating in boiling water for 3 min. The protein A/G- agarose was
removed by centrifuged at 12,000 x g for 20 seconds at room temperature, and the
supernatant was transferred to fresh tubes. The immunoprecipitates were fractionated by
SDS-polyacrylamide gel electrophoresis.

O. Chemiluminescent SEAP assay
The secreted form of human placental alkaline phosphatase (SEAP) has been used
as a reporter molecule to monitor the activity of promoters and enhancers. The
chemiluminescent SEAP assay was performed following the User Manual from Clontech,
Palo Alto, CA.
Great EscAPe SEAP™ Assay Kit was purchased from Clontech and performed as
described. One ml IX lysis buffer (10 mM Tris-HCl, pH 7.5, 0.5 mM MgCl2, and
0.1% Triton X-100) was used to homogenize muscle samples. Fifty microliters
homogenized tissue and 50 pi serum samples were used in each assay. Tissue and serum
samples were mixed with 75 pi 1 x dilution buffer and incubated at 65°C for 30 minutes.
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Samples were cooled to room temperature by being placed on ice for 2-3 minutes, and
then being equilibrated to room temperature. 100 pi of assay buffer was added to each
sample and incubated for 5 minutes at room temperature. One hundred pi of 1.25 mM
chemiluminescent substrate CSPD (CSPD: chemiluminescent =1:19) was added to each
sample and incubated for 30 minutes at room temperature before light production was
measured in TURNER TD-20e luminometer.

P. Intramuscular DNA injection
The protocols for animal experiments were approved by the animal care
committee at Loma Linda University. Seven-week-old BALB/c mice (about 25 gm body
weight, Jaskson Lab) and three-week-old NOD (about 15 gm body weight, Laconic Lab)
were maintained in Loma Linda University animal care facility during the experiment.
Mice were anesthetized by i.p. injection with Ketamine (66 mg/Kg body weight, Phoenix
Pharmaceutical, St. Joseph, M), xylazine (7.5 mg/Kg body weight, LLOYD Laboratories,
Shenandoah, Iowa), and Acepromazine Maleate (1.5 mg/Kg body weight, Fermenta,
Kansas City, MO. Plasmid DNA (200 pg/leg) was injected into mice quadriceps muscle
with a 1-cc sterile 27G1/2 syringe (Becton Dickinson Company, Franklin Lakes, NJ).
One hundred microliter (200 pg) of DNA were injected into each leg. NOD mice
received a second injection five days after the first one in a similar fashion.
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Q. Mitogen stimulation assay for GAD65
About 5 x 106 spleen cells were isolated from NOD mice. Isolated lymphocytes
were cultured with GAD65 purified protein for 72 hours, at which time the maximal
effect of DNA synthesis should be seen. The measurement of this DNA synthesis was
accomplished by pulsing the cultures with tritiated thymidine, a nucleotide precursor that
is incorporated into DNA. The lymphocytes are then harvested and later counted on a
scintillation counter. The counts obtained quantitate DNA synthesis, and represent
lymphocyte responsiveness to the nonspecific antigens. The data are expressed as counts
from the stimulated cultures divided by counts from unstimulated cultures, which yields a
ratio, called the Stimulation Index.

R. Histopathological analysis of insulitis
Ten-week-old NOD mice were killed and the pancreatic islets were removed for
insulitis scoring. The pancreas were placed into Bouin’ fixative (75 ml picric acid, 25 ml
formalin, 5 ml glacial acetic acid) for two days. Pancreas samples were dehydrated after
being placed into an increasing concentration of alcohol (30, 50, 70,80, 95% and
100% alcohol) until disappearance of yellow color. Each stain required two to three
hours. Pancreas were incubated in 100% alcohol one more time to remove water
completely.
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Paraffin was melted at 56 to 58 °C. Tissues were placed in small container filled
with melted Paraffin and were cooled in water. The microtome was used for slide
preparation. The average thickness of each section was 5 microns. The slides were
stained with hematoxylin, and then counterstained with eosin.
Average of fifteen islets per mouse were scored. A 7-level semi-quantitative
scoring scale (Zhang et ah, 1991) was used for insulitis scoring: 0: normal islet tissue
without any detectable lymphocytes infiltration; 1: focal peri-islet T cell infiltration with
less than one-third of the peri-islet area; 2: more extensive peri-islet T cell infiltration
with less than two-thirds of the peri-islet area; 3: peri-islet T cell infiltration with more
than two-thirds of the peri-islet area; 4: intra-islet T cell infiltration with less than onethird of the islet area; 5: intra-islet T cell infiltration with less than two-thirds of the islet
area; 6: severe intra-islet T cell infiltration with more than two-thirds of the islet area.
Scoring of 1-3 indicated peri-insulitis, and scoring of 4-6 indicated intra-insulitis.
Scoring was performed using the double-blind method by two different scorers.
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1. ABSTRACT
The soft coral Renilla reniformis luciferase enzyme (RUC) is a monomeric
soluble intracellular protein that is increasingly being used as a marker of gene
expression. Here the rue gene was engineered to encode a protein product secreted by
mammalian cells. The 5' end of the rue gene was fused in frame with the 3' end of a short
DNA sequence encoding the signal peptide from human interleukin-2 (IL-2) protein.
This construct was cloned under the transcriptional control of the cytomegalovirus
(CMV) promoter into a mammalian expression vector. Simian COS-7 cells were
transiently transfected with the construct, and light emission was measured both from cell
lysates and from cell culture media. Results indicated that RUC was secreted as a
functional protein by mammalian cells. The advantages and disadvantages of secreted
RUC as a marker of gene expression when compared to other secreted protein markers
are discussed.
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2. INTRODUCTION
Light emission from bioluminescence or chemiluminescence has become a
powerful tool in molecular biology for detecting the presence of certain molecules as well
as for studying specific cellular events. Marker genes encoding luciferases provide rapid
and sensitive means of detecting gene expression in a quantitative manner both in vitro
and in vivo. The most widely used luciferases for this purpose are from the
bioluminescent Vibrio bacteria, from the jellyfish Aequoria victoria, and from the firefly
Photinus pyralis. Recently the use of the A. victoria green fluorescent protein (GFP), a
photonprotein, has permitted the direct visualization of the location of various proteins
within a living cell, and of the movement of living organisms within their environment.
However none of the above reporter proteins is considered universal in its application,
and the use of other less well known luciferases or GFPs could be better suited for
particular experimental conditions. The luciferase from Renilla reniformis is an example
of such a reporter protein.
The sea pansy Renilla reniformis is an anthozoan coelenterate living in shallow
coastal waters of North America, and can display blue-green bioluminescence (Matthews,
et al., 1977). The light emission activity is catalyzed by a luciferase enzyme. The
monomeric RUC protein (Mr: 36 kDa) catalyzes the oxidative decarboxylation of the
complex organic molecule coelenterazine (the luciferin) in the presence of dissolved
oxygen to yield oxyluciferin, C02, and blue light (lambdamax=480nm) in vitro. In
R. reniformis, energy transfer from the luciferase-bound oxyluciferin excited state donor
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to a green fluorescent protein acceptor results in blue-green light emission
(lambdamax = 509 nm). A cDNA encoding a functional full-length RUC protein was
previously cloned and sequenced (Lorenz et al., 1991). This cDNA has been used as a
marker of gene expression in bacterial (Lorenz et al., 1991), plant (Mayerhofer et al.,
1995), yeast (Shrikanta et al., 1996), and mammalian cells (Lorenz et al., 1996).
The firefly luciferase gene is the most often used luciferase marker gene in
eukaryotic cells. When compared in vitro, the specific quantum yield of RUC is
approximately one order of magnitude less than that of firefly luciferase (Sherf et al..
1996). However in some cases in vivo, cells expressing the rue gene show much higher
levels of light emission than the same cells expressing the firefly luciferase gene. For
instance in the case of the yeast Candida albicans, cells expressing the firefly luciferase
gene show little bioluminescence activity (Shrikanta et al., 1995). This absence of
activity is probably due to the synthesis of a non-functional firefly luciferase enzyme,
since the firefly luciferase gene contains nine CUG codons which are translated to serine
in C. albicans, instead of the conventional leucine (Santos et al., 1993). Because the rue
gene does not contain any CUG codons, it encodes a fully functional protein in this
organism (Shrikanta et al., 1996). Plants are another example of the occasional
superiority of the rue gene as a marker over other luciferase genes: light emission
obtained from electroplated alfalfa protoplasts and transgenic tobacco, tomato, and potato
plants is much higher when the rue gene is used instead of the bacterial or firefly
luciferase genes (Mayerhofer et al., 1995).
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In the work presented here, the range of application of the rue gene as a marker of
gene expression has been extended by fusing it in frame with a DNA fragment encoding
the human IL-2 signal peptide (IL2SP). When expressed in mammalian cells this
construct encodes a product that is secreted as a functional RUC enzyme. This new
reporter gene could be best suited for the monitoring of gene expression in animal
models.

3. MATERIALS AND METHODS
3.1 Plasmids construction
pLNCX-RUC: plasmid pLNCX-RUC was constructed by ligating the rue gene as
a 975 bp EcoRV-Smal DNA fragment from plasmid pBluescript II KS(+) carrying the
rue gene (Mayerhofer et ah, 1995) into the Hpal site of plasmid pLNCX (Miller and
Rosman,1989), generating plasmid pLNCX-RUC (Fig.lA).
pLNCX-ILRUC: an 87 bp DNA fragment encoding the first 23 amino acid
residues of IL-2 protein that contain IL2SP was amplified from human embryonic kidney
cell line A293 genomic DNA using the polymerase chain reaction (PCR) with primers
IL-01 (5'TTTGAATTCATGTACAGGATGCAACTCCT3') and IL-02
(5'TTTGAATTCAGTAGGTGCACTGTTTGTGAC3'). PCR was performed using Pwo
polymerase (Boehringer Mannheim) under the following conditions: 94°C for 2 min for
one cycle, followed by 94°C for 15 sec + 50°C for 30 sec for 30 cycles. The PCR
fragment was cloned directly into vector pGEMT (Promega), excised using the EcoRl
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sites introduced by both primers, and ligated 9 bp upstream of the rue gene in plasmid
pLXSN-RUC (the construction of pLXSN-RUC will be described elsewhere). The
correct sequences of the PCR product and of the in-frame fusion of this product with the
rue gene were confirmed by automated DNA sequencing. The DNA sequence encoding
the IL2SP-RUC protein fusion was amplified using primers IL-01 and RUC-1
(5'TTTCCCGGGAAAAATGTAAATAAAAAACCA3') and cloned into plasmid
pGEMT. The PCR product was then subcloned as a Kspl-Smal fragment into the Hpal
site of plasmid vector pLNCX, generating plasmid pLNCX-ILRUC (Fig. IB).

3.2 Cell culture and transfection
Simian COS-7 cells were grown in 60 mm tissue culture dishes containing 3 ml
DMEM medium supplemented with 10% fetal bovine serum (FBS). Medium was
changed 3 hrs prior to transfection when cells were 75% confluent. Cell transfection was
performed according to the ProFection calcium phosphate system (Promega) using 25 pg
plasmid DNAs per plate. Cells were washed twice with PBS buffer 6 hrs after
transfection, and 3 ml DMEM+10 % FBS was added to each plate.

3.3 RUC assay
Cells were harvested by trypsinization 48 hrs after transfection, washed once with
RUC assay buffer (0.5 M NaCl, ImM EDTA, lOOmM potassium phosphate, pH 7.4),
resuspended in 1 ml of the same buffer, and sonicated on ice twice for 10 sec. Five
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hundred microliters of cell lysates was assayed in each case for bioluminescence in a
luminometer (Turner TD-20e) after rapid injection of 500 pi 1 pM coelenterazine hep
(Molecular Probes Inc.). Media from transfected cells were saved at harvesting and
centrifuged at 800g to remove cell debris. Two hundred microliters aliquots of media
were assayed for bioluminescence as described above.

3.4 Time-course assay ofsecreted RUC
The RUC assay was performed every 12 hrs with 200 ul of media taken from
dishes containing growing cells transiently transfected with plasmids pLNCX, pLNCXRUC, or pLNCX-ILRUC. Two hundred microliters of fresh media was added each time
to the plates as replacement for the taken aliquot. With one plate the medium was
changed after 24 hrs to serum-free medium (QBSF 51 from Sigma) supplemented with
1% FBS to investigate the effects of medium composition on accumulation of functional
secreted RUC.

3.5 Measurement ofRUC stability in cell culture media and in blood
Three nanograms of purified RUC isolated from an overexpressing Escherichia
coli strain was added to a 10 cm plate containing COS-7 cells growing at 70% confluence
in 10 ml DMEM +10% FBS, or in 10 ml QBSF 51+1% FBS. The plates were incubated
at 37°C in 5% C02, and a 200 pi aliquot of medium was taken every two hours for
bioluminescence assay. To measure stability of RUC in blood, 3 ng of isolated RUC was
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added to 700 (4,1 of complete hamster blood containing 50 ul of a heparin solution (1000
units/ml, from Elkins-Sinn) and placed at 37°C. A twenty microliters aliquot was taken at
regular time intervals and diluted into 200 pi RUC assay buffer for bioluminescence
assay.

3.6 Immunoblot analysis ofRUC
For immunoblot analysis of intracellular RUC, COS-7 cells were washed twice
with cold phosphate buffer saline (PBS) buffer 48 hrs after transfection, and harvested by
scrapping in 200 pi PBS buffer using a rubber policeman. Cells were pelleted at 10,000g,
resuspended into 100 ul 2x gel-loading buffer (100 mM Tric.HCl, 4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, 0.01% bromophenol blue), and lysed by sonication.
Samples were placed in boiling water for 3 min, centrifuged at 10,000g for 10 min to
pellet debris, and 30 pi of each sample was loaded on a 12% SDS-polyacrylamide gel.
Fractionated proteins were then transferred onto a nylon membrane, reacted with a
polyclonal antibody raised against RUC as previously described (Mayerhofer et al..
1995), and detected using chemiluminescence.
For immunoblot analysis of secreted RUC, 1.5 ml aliquots of cell culture media
(QBSF 51 + 1% FBS) were taken 48 hrs after transfection of COS-7 cells and centrifuged
at 10,000g to pellet cell debris. The aliquots were concentrated down to 0.5 ml using a
centriprep concentrator (Amicon) with a molecular weight cut-off of 15 kDa. RUC
present in the concentrates was immunoprecipitated using the Protein A
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Immunoprecipitation Kit (Boehringer Mannheim) and polyclonal antibodies raised
against RUC, and immunoanalyzed after SDS-PAGE using the same antibodies as
described above.

4. RESULTS
4.1 Construction ofpLNCX-ILRUC
The signal peptide of human IL-2 protein was previously used to cause secretion
by mammalian cells of human leukocyte elastase (Mr: 27 kDa) when fused to its amino
terminal domain (Okano et al., 1990). In the present work, the DNA sequence isolated by
PCR using primers 11-01 and IL-02 encodes the first 23 amino acid residues from human
IL-2, with the putative site of cleavage of the signal peptidase situated between residues
20 and 21 (Taniguchi et al., 1983). The Ilruc gene encodes the 23 aa IL-2 signal
sequence fused to the RUC protein by an additional 5 aa as a result of the cloning
procedure (Fig. IB). The Ilruc gene was cloned under the transcriptional control of the
CMV promoter into retroviral vector pLXSN for expression studies, and for future
packaging into retroviral particles and introduction into animal models.

4.2 Expression of the rue and Ilruc genes in mammalian cells
Plasmids pLNCX, pLNCX-RUC, and pLNCX-ILRUC were introduced into
simian COS-7 cells using the calcium phosphate transfection method. No differences in
cell morphology or cell growth were observed between cells expressing the rue gene and
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cells expressing the Ilruc gene fusion (data not shown). After 48 hrs, RUC activity was
measured both from cell lysates and from the medium (Fig.2). Luciferase activity
measured from lysates of cells expressing the wild type rue gene was approximately
15 times higher than that measured from lysates of cells expressing the Ilruc gene fusion
(Fig.2A). In contrast, RUC activity could be measured from cell culture medium only in
the case of cells expressing the Ilruc gene (Fig. 2B).

4.3 Time course of appearance ofRUC activity in cell culture media
RUC activity could be detected in cell culture medium (DMEM+10% FBS) less
than 10 hrs after cell transfection, but only with cells transfected with plasmid pLNCXILRUC. In contrast, medium taken from plates containing cells transfected with plasmid
pLNCX-RUC did not show detectable RUC activity (Fig.3). In the case of cells
transfected with pLNCX-ILRUC, luciferase activity increased over time until it reached a
plateau 48 hrs after transfection. Significantly, when cell growth was slowed down by
replacing the medium with QBSF 51 medium+1% FBS, RUC activity was still increasing
80 hrs after transfection (Fig.3).

4.4 Stability ofRUC in cell culture media and in blood
Isolated RUC was added to plates containing COS-7 cells growing in DMEM
medium +10% FBS or in QBSF 51 medium +1% FBS, and bioluminescence activity was
measured over time from the media. The half-life of RUC was similar in both media at
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37°C (Fig.4), with calculated values of 50 min and 57 min, respectively. The half-life of
isolated RUC in undiluted complete blood at 37°C was calculated to be 36 min.

4.5 Immunodetection of RUC
Presence of RUC both in cell lysates and in cell culture media was investigated
using immunoblot analysis after protein fractionation with SDS-PAGE. A protein band
corresponding to the RUC protein was found in lysates of COS-7 cells transfected with
plasmids pLNCX-RUC and in lysates of cells transfected with pLNCX-ILRUC (Fig. 5A).
When cell culture media were analyzed, RUC was found only in the case of cells
transfected with pLNCX-ILRUC (Fig5.B).

5. DISCUSSION
Several secreted proteins have been used as markers of gene expression in recent
years. The main advantage of using a secreted reporter protein versus an intracellular
reporter protein is the ability to measure gene expression without destroying the cells or
tissues containing the marker gene. This ability is particularly useful when doing timecourse studies of transcriptional activity, for instance in cell cultures (Cullen and Mallim,
1992), during embryo development (Thompson et al, 1995), or when monitoring gene
expression in situ after introduction of naked DNA or genetically engineered cells in
animal models (Naffakh et al., 1996).
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The most sensitive secreted reporter proteins are light-catalyzing and lightemitting proteins such as alkaline phosphatase (AP) (Berger et al., 1988), Vargula
hilgendorfii luciferase (Thompson et al., 1990), apoaequorin (Inouye and Tsuji, 1992),
and GFP from Aequoria victoria (Kaether and Gerdes, 1995; Laukkanen et al., 1996).
Of all these proteins only the Vargula luciferase is naturally secreted. However, its
substrate is not commercially available, therefore restricting its use as a reporter protein.
Also restricted is the use of secreted GFP by mammalian cells, due to a requirement for
temporary arrest of protein transport in order to allow formation of the GFP chromophore
within the cell (Kaether and Gerdes, 1995). To our knowledge there has been no report
of secretion by living cells of active bacterial luciferase or of active firefly luciferase,
although both enzymes can recover their function after translocation into microsomes in
vitro (Brunke et al., 1996; Tyedmers et al., 1996).
In the work presented here, a DNA sequence encoding the signal peptide of the
human IL-2 protein was fused in frame with the open reading frame encoding the RUC
protein, generating the Ilruc gene construct. Light emission measured from cell culture
media showed that media in which cells expressing the Ilruc gene were growing (ILRUC
medium) contained significant levels of RUC activity (Fig.2B, lane3). This result was
unlike the result obtained with medium in which cells expressing the rue gene encoding
wild type RUC were growing (RUC medium), which did not contain detectable luciferase
activity (Fig.2B, lane2). In addition, immunoblot analysis of ILRUC medium showed the
presence of a protein band with a molecular weight corresponding to that of RUC,
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together with another protein band of lower molecular weight, likely the result of RUC
protein degradation (Fig.SB, lane 2). Immunoblot analysis of RUC medium showed the
presence of a faint protein band corresponding to the putative RUC degradation product
(Fig. 5B, lane 3). These results indicated that mammalian cells expressing the Ilruc gene
construct secreted a functional Renilla luciferase protein. The luciferase activity
measured in the ILRUC medium was not a result of cell lysis, since 3 ml of ILRUC
medium (DMEM+10% FBS) from a 100% confluent 60 mm culture dish contained on
average 375 relative light units (RLU) 48 hrs after transfection, while cell lysates from
the same plate contained on average only 60 RLU. Furthermore, when cell growth was
slowed down by changing medium to QBSF 51 + 1% FBS, a medium where RUC
stability does not change significantly when compared to DMEM+ 10% FBS (Fig.4), the
time of accumulation of RUC in the medium could be extended by at least 30 hrs (Fig.3),
another indication that RUC protein was secreted.
Light emission measured from cell lysates showed that cells expressing the rue
gene contained approximately 15 times more RUC activity than cells expressing the Ilruc
gene construct (Fig.2A). However, immunoblot analysis of cell lysates revealed that this
increase in activity could not be explained by an identical increase in RUC protein
amounts (Fig.5A), indicating that intracellular RUC in cells expressing the Ilruc gene had
a lower activity than intracellular RUC in cells expressing the rue gene. The reason for
this reduced activity is not clear, but since the RUC protein contains three predicted
cysteine residues, it is possible that the reduced activity was due to formation of various
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illegitimate disulfide bonds in the endoplasmic reticulum. If this were the case, it could
be possible to improve the sensitivity of secreted RUC as a reporter protein by replacing
these cysteine residues with other amino acids. The fact that cells expressing the Ilruc
gene contained less RUC protein than cells expressing the rue gene was another
indication that Ilruc encoded a secreted product, presumably because the RUC protein
fused to IL2SP did not accumulate in the cytosol.
To be advantageous a secreted protein marker should allow for a sensitive and
rapid assay, and should have a short half-life. The assay for secreted RUC is not as
sensitive as the assay for secreted AP, itself 10-fold more sensitive than firefly luciferase
in mammalian cells, but it is comparable to the assay for secreted apoaequorin (Inouye
and Tsuji, 1992). However, the rapidity of the RUC assay (<1 min) is a significant
advantage when compared to the secreted AP assay which requires at least 45 min
(Berger et al., 1988), and when compared to the secreted apoaequorin assay which
requires at least 2 hrs (Inouye and Tsuji, 1992). Although a short half-life is not
absolutely required when previously secreted protein can be removed before the
beginning of a time-course study, it becomes an important factor if the study is to be
performed in a closed system, such as within an animal. RUC had a half life of 50 min in
DMEM + 10 % FBS, 57 min in QBSF 51 + 1% FBS, and 36 min in blood, which should
allow monitoring of gene expression in closed systems.
Secreted RUC could be best applied for the monitoring of gene expression in
animal models. Measuring activity of a secreted protein marker in mammals permits the

65
monitoring of gene expression directly in situ without killing the animal. The naturally
secreted human growth hormone protein has been used for this purpose (Selden et ai.
1986). However, ideally a secreted marker of gene expression in mammals should be
“neutral”, i.e., it should not have a biological function having an effect on the metabolism
and/or the development of the animal, as human growth hormone can have (Hackett and
Gitlin, 1992). Thus, although AP seems to be a more sensitive reporter protein than
RUC, it might not be the best choice for synthesis in animals because high levels of AP in
blood may cause unwanted physiological side-effects, and because of possible elevated
background readings due to alkaline phosphatases already present in sera. Secreted RUC
could be a good candidate as a marker of gene expression in this case, since RUC
bioluminescence activity can be quickly measured from blood, and because we do not
foresee a physiological effect of secreted RUC in animals. In addition, background
bioluminescence upon injection of coelenterazine in blood was not significant (data not
shown), and although undiluted complete blood quenched RUC activity by a factor of
ten, this activity could be completely recovered after a ten fold dilution into RUC assay
buffer (data not shown).
In summary, secreted RUC is a bioluminescent reporter protein that offers a
sensitive, rapid assay, whose substrate is commercially available, and whose activity is
unaffected by a variety of media and sera (Ogbonna and O’Kane, 1994). We are
presently investigating the use of secreted RUC for monitoring gene transfer and
expression in animal models.
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Figure 1. Partial structures of the plasmids used in this study. Ampicillin resistance
gene and bacterial origin of replication are not shown. A. Plasmid pLNCX-RUC carries a
cDNA encoding the wild-type RUC protein. B. Plasmid pLNCX-ILRUC carries the Ilruc
gene encoding IL2SP fused to the wild type RUC protein; the aa sequence of the protein
fusion junction is shown: aal4-23, C-end of IL2SP; aa24-28, linker aa; aa29, N-end of
RUC; the arrow indicates the putative cleavage site for signal peptidase. LTR, long
terminal repeat; neo, neomycin resistance gene; pA, polyadenylation site.
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Figure 2. Renilla luciferase activity in cell lysates (A) and in cell culture medium (B).
Light emission was measured with COS-7 cells transfected with 1, pLNCX; 2, pLNCXRUC; and 3, pLNCX-ILRUC. Results obtained from six individual transfection are
shown. Relative light units (RLU) are shown as per second, per 50ug total protein in (A),
and as per second, per 200 ul medium in (B).
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Figure 3. Time-course of Renilla luciferase activity appearance in cell culture media.
Simian COS-7 cells were transfected with plasmid pLNCX-ILRUC and grown in DMEM
medium + 10% FBS ( • ); transfected with plasmid pLNCX-ILRUC and grown in
DMEM medium + 10% FBS for the first 42 hours, and then grown in QBSF 51 medium
+ 1% FBS ( A ); transfected with plasmid pLNCX-RUC and grown in DMEM medium
+ 10% FBS ( ♦ ); and transfected with plasmid pLNCX and grown in DMEM medium +
10% FBS ( ■ ). Relative light units (RLU) are shown as per second, per 200 ul medium
in (B).
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Figure 5. Immunoblot analysis of cell lysates (A) and immunoprecipitated cell culture
media (B) using Renilla luciferase mAb. Simian COS-7 cells were transfected with
plasmid pLNCX-ILRUC (lane 2), plasmid pLNCX-RUC (lane 3), and vector only (lane
4). Lane 1 contains 10 ng isolated Renilla luciferase as control. For total cell lysates (A),
protein amounts were determined by densitometry after comparison with isolated Renilla
luciferase protein (lane 1), and calculated to be 0.9 ng for the luciferase encoded by Ilruc
(lane 2), and 1.7 ng for the luciferase encoded by the Renilla luciferase cDNA (lane 3).
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Abstract
We have previously reported the construction of a functional Renilla luciferase
enzyme secreted by mammalian cells when fused to the leader peptide of human
interleukin-2. The presence of three predicted cysteine residues in the amino acid
sequence of Renilla luciferase suggested that its secreted form(s) contained an oxidized
sulfhydryl group, which might impair enzyme activity and/or stability. Four secreted
Renilla luciferases were constructed to investigate this possibility: three luciferases where
in which a different cysteine residue was replaced by an alanine residue, and one
luciferase mutant which all three cysteine residues was replaced by alanine residues.
Simian cells were transfected with the genes encoding these mutant luciferases, as well as
with the original gene construct, and cell culture media were assayed for bioluminescence
activity. Only media containing a mutated luciferase with a cysteine to alanine
substitution at position 152 in the preprotein showed a marked increase in
bioluminescence activity when compared to media containing the original secreted
Renilla luciferase. This increase in light emission was due mostly to enhanced stability of
the mutant enzyme. This new enzyme represents a significant improvement in the
sensitivity of the secreted Renilla luciferase assay.
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1. Introduction
Secreted reporter proteins offer the distinct advantage of permitting the
monitoring of gene expression over time, without cell or tissue destruction. Examples of
proteins used for this purpose are human growth hormone (Selden et al., 1986), and
secreted alkaline phosphatase (SEAP) (Berger et al., 1988). Light-emitting reporter
proteins such as SEAP are particularly convenient, because their assays offer great
sensitivity, and permit easy quantification of the reporter protein (Yang et al., 1997).
We have already described the construction and use of a secreted form of the
Renilla luciferase by mammalian cells (Liu et al., 1997). The wild type luciferase enzyme
of the sea pansy Renilla reniformis is a monomeric protein with molecular weight 36
kDa, and is normally found intracellularly. This enzyme catalyzes the emission of visible
light in presence of oxygen and the luciferin coelenterazine, or one of its analogues
(Inouye and Shimomura, 1997), yielding oxyluciferin and carbon dioxide. A cDNA
encoding Renilla luciferase has been used to monitor gene expression in bacterial (Jubin
and Murray, 1998), yeast (Srikantha et al., 1996), plant (Mayerhofer et al., 1995), and
mammalian (Lorenz et al., 1996) cells.
Secreted Renilla luciferase catalyzes a “glow type” of light emission; moreover,
its assay can be performed quickly after obtaining samples, and its luciferin is
commercially available. Altogether, these properties make secreted Renilla luciferase a
potentially attractive marker protein for studying gene expression, or for experimental
control in conjunction with other secreted marker proteins. Although naturally secreted
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luciferases do exist, for example, the luciferase from the marine ostracod Vargula
hilgendorfii (Thompson et al., 1989), or from the decapod shrimp Oplophorus
(Shimomura et al., 1978), their use as practical reporter proteins is still hampered by the
fact that either the luciferin is not commercially available, or the encoding gene has not
been isolated.
During our studies of secreted Renilla luciferase, we have sometimes observed its
intracellular aggregation in transfected mammalian cells, depending on undefined cell
growth conditions (J.L. and A.E., unpublished data). Because the wild-type Renilla
luciferase protein sequence contains three predicted cysteine residues (Lorenz et al.,
1991), this phenomenon suggested a conformational instability of the secreted Renilla
luciferase, possibly due to the odd number of cysteine residues present in Renilla
luciferase. Cysteine residues in a naturally secreted protein are generally found as cystine
or buried within the protein, because of the highly reactive nature of the oxidized
sulfhydryl group found on unpaired cysteines. Because secreted Renilla luciferase
presumably folds in the endoplasmic reticulum where sulfhydryl groups are oxidized, the
third predicted cysteine residue in its sequence might have interfered with productive
protein folding or stability. Therefore, we investigated whether a secreted Renilla
luciferase with improved bioluminescence activity could be obtained by substituting each
of its cysteine residues with alanine, an amino acid considered to be one of the most
“neutral” when used for this purpose (Cunningham and Wells, 1989).
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In this work, we report the construction and in vivo activity of four new secreted
Renilla luciferases obtained after site-specific mutagenesis of the original secreted Renilla
luciferase gene construct. One of the mutant luciferases displayed a significant increase
in stability, which resulted into up to a 100-fold increase in light emission 48 h after cell
transfection when compared to the original secreted Renilla luciferase.

2. Materials and Methods
2.1. Plasmid construction and site-specific mutagenesis
The gene encoding secreted Renilla luciferase (previously named Il-ruc and
renamed sruc in this report) was excised from plasmid pLNCX-ILRUC (Liu et al., 1997)
as a 1.1 kb HindUl-Clal DNA fragment with the Clal site blunt-ended with Klenow
enzyme, and was ligated into the Hindlll-Smal sites of plasmid pBluescript II KS(+)
(Stratagene, San Diego, CA). This gene was then subcloned as a SaFL-Xbal DNA
fragment into plasmid vector pND2 (Gary Rhodes and Robert Malone, unpublished data),
under the transcriptional control of the cytomegalovirus promoter, generating plasmid
pND2-SRUC.
Plasmid pND2-SRUC then served as a template for site-directed mutagenesis.
The Quick Change Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA) was used
to introduce three individual cysteine to alanine substitutions at positions 52, 101, and
152 in the preprotein form of secreted Renilla luciferase, generating mutant proteins
SRUC1, 2, and 3, respectively (Fig.l).
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Mutagenesis was performed according to the manufacturer’s protocol, using the
following DNA oligomers: SDMRUCA1
(5'CCGCAGTGGTGGGCCAGAGCTAAACAAATGAATGTTCTT3') and
SDMRUCA2 (5GAAGAACATTCATTTGTTTAGCTCTGGCCCACCACTGCG3') for
mutagenesis at position 52; SDMRUCB1
(5'GAGCCAGTAGCGCGGGCTATTATACCAGATCTTATTGG3') and SDMRUCB2
(5'CCAATAAGATCTGGTATAATAGCCCGCGCTACTGGCTC3') for mutagenesis at
position 101; and SDMRUCC1
(5' GGCC AT GATT GGGGT GCTGCTTT GGC ATTT C ATTATAGC 3') and SDMRUCC2
(5'GCTATAATGAAATGCCAAAGCAGCACCCCAATCATGGCC3') for mutagenesis
at position 152. In addition, oligomer pairs SDMRUCB1 and B2, and Cl and C2, were
used in succession on plasmid pND2-SRUCl to generate plasmid pND2-SRUC4. This
plasmid carries a gene encoding a mutant secreted Renilla luciferase where all predicted
cysteine residues in the luciferase were replaced by the amino acid alanine (Fig.l). For
mutagenesis, the amplification reaction was performed using a Perkin-Elmer Gene-Amp
2400 using the following program: 95°C for 30 s for one cycle, followed by 95°C for 30 s
+ 55°C for 1 min + 68°C for 10.5 min for 16 cycles. All mutants were identified by DNA
sequencing at the site of mutation. In each case, at least two independent mutants were
used for mammalian cell transfection to determine whether additional mutation(s) had
been introduced that could affect bioluminescence activity.
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2.2 Cell culture and DNA transfection
Simian COS-7 cells were grown in 100 mm tissue culture plates containing 10 ml
DMEM medium (Sigma Chemical, St. Louis, MO) +10% fetal bovine serum (FBS,
Biowhittaker, Walkersville, MD), or in Cellgro complete serum free medium (Mediatech,
Herndon, VA) + 1% FBS. Cell transfection was performed using the ProFection Calcium
Phosphate System (Promega, Madison, WI), according to the manufacturer’s protocol,
using a total of 30 pg of plasmid DNA per plate (25 pg of Renilla luciferase plasmid for
experimental purpose, and 5 pg of firefly luciferase plasmid for normalization between
experiments). Cells were washed twice with phosphate-buffered saline (PBS) 15 h after
transfection, and 10 ml of DMEM medium + 10% FBS or Cellgro complete serum free
medium + 1% FBS was added.

2.3. Luciferase assay
The Renilla luciferase assay was performed as previously described (Liu et al,
1997) with a Turner TD-20e luminometer. Unmodified coelenterazine was used as a
substrate (Molecular Probes, Eugene, OR, catalog # C-2944). The firefly luciferase assay
was performed according to a protocol from the manufacturer of the assay system
(Promega, Madison WI). For time course measurement of secreted Renilla luciferase
activities, simian COS-7 cells were transiently transfected with the different plasmid
constructs encoding the secreted Renilla luciferases shown in figure 1. Cells were then
grown in Cellgro complete serum free medium + 1% FBS for 90 h, and the Renilla
luciferase assay was performed at regular time intervals with media aliquots.
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2.4. Measurement of secreted Renilla luciferase stability in cell culture medium
Stability of the secreted Renilla luciferases showing highest light emission
(example, SRUC and SRUC3) was measured in cell culture medium. COS-7 cells grown
in 100 mm tissue culture dishes were transiently transfected with 30 pg DNA of plasmid
pND2-SRUC and pND2-SRUC3. Thirty-six hours after transfection, 10 ml medium from
a dish containing cells transfected with pND2-SRUC, and 200 pi of medium from a dish
containing cells transfected with pND2-SRUC3 were taken, centrifuged briefly at 800 x g
to remove cells and debris, and added into a 100 mm plate containing untransfected COS7 cells. The final volume of medium in the plate containing SRUC3 was brought up to
10 ml with cell culture medium. Cells were then incubated at 37°C, and 200 pi aliquots
of media were taken at intervals for Renilla luciferase assay.

2.5. Immunoblot analysis ofRenilla luciferase
To confirm synthesis of full-length mutant luciferases, immunoblot analysis of
secreted Renilla luciferases was performed after fractionation of total COS-7 cell lysates
using SDS-PAGE as previously described (Liu et al., 1997). To investigate whether the
introduced mutations affected disulfide bond formation, lysates were fractionated under
oxidizing conditions in the absence of 2-mercaptoethanol in the loading buffer.
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3. Results
3.1. Construction and expression of mutant secreted Renilla luciferase genes in
mammalian cells
Four new secreted Renilla luciferases were obtained after site-specific
mutagenesis (Fig.l): SRUC1 (cysteine 52 to alanine), SRUC2 (cysteine 101 to alanine),
SRUC3 (cysteine 152 to alanine), and SRUC4 (cysteines 52, 101 and 152 to alanine).
Immunoblot analysis of lysates of COS-7 cells expressing the mutant luciferase genes
and fractionated under reducing conditions indicated that all mutant proteins appeared to
be full-length, and synthesized at similar levels (Fig. 2A). Under oxidizing conditions,
immunoblot analysis indicated that substitution from cysteine to alanine in SRUC1, 2,
and 3 had an effect on disulfide bond formation, as suggested by the presence of higher
molecular weight forms of these luciferases (Fig. 2B, lanes 4, 5, and 6).

3.2. Bioluminescence activity of cell lysates and culture media containing secreted
Renilla luciferases
Renilla luciferase activity present in lysates and culture media (serum free
medium +1% FBS) of COS-7 cells synthesizing the SRUC1, 2, 3, 4 and SRUC
luciferases was measured 48 h after transfection (Fig. 3). Measurements of Renilla
luciferase activity in cell lysates revealed that only two of the four luciferase mutants,
SRUC1 and SRUC3, exhibited significant intracellular bioluminescence activities
(Fig. 3 A). While SRUC1 exhibited only half the activity of the original SRUC luciferase,
SRUC3 exhibited approximately three times the activity of SRUC luciferase.
Measurements of Renilla luciferase activity in culture media revealed that medium
containing SRUC3 luciferase had a bioluminescence activity up to 100-fold higher than
medium containing the SRUC luciferase (Fig. 3 B). Time course measurements of
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Renilla luciferase activity in culture media confirmed this finding (Fig. 4). Thirty hours
after transfection, bioluminescence activity of media containing SRUC luciferase
decreased, while bioluminescence activity of media containing SRUC3 luciferase
remained at a similar level for at least 50 h.

3.3. Stability of secreted Renilla luciferases in culture medium
To determine whether the increased bioluminescence activity of SRUC3 in culture
medium was a result of increased stability, the activities of secreted SRUC and SRUC3
luciferases were measured over time at 37°C in serum free medium + 1% FBS. From the
data obtained (Fig. 5), the half-lives of SRUC and SRUC3 were calculated to be 14 and
82 h, respectively.

3.4. Cell culture medium dependency ofsecreted Renilla luciferase activity
We had previously observed that the activity of SRUC luciferase was dependent
on the type of culture medium in which cells were growing (Liu et al. 1997). To
determine whether this was also the case for SRUC3 luciferase, COS-7 cells were
transfected with plasmid pND2-SRUC3, grown either in DMEM medium +10% FBS or
serum-free medium + 1% FBS for 48 h, and Renilla luciferase activity was measured in
both cell lysates and culture media. Lysates and culture media of cells grown in DMEM
+ 10% FBS showed a two fold and a more than five fold reduction in light emission,
respectively, when compared to lysates and culture medium of cells grown serum free
medium + 1% FBS (Fig. 6).
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Discussion
The work presented here provides further evidence that Renilla luciferase is
remarkably well-suited to be engineered for secretion by mammalian cells as a functional
enzyme. This property is probably the result of its low molecular weight and the small
number of cysteine residues it contains. The importance of protein size for the functional
secretion of a normally intracellular protein is suggested by the examples of firefly
luciferase and the photonprotein apoaequorin. Although firefly luciferase (MWr: 65 kDa)
appears to be secreted by mammalian cells when fused to preproinsulin, it does not give a
bioluminescence activity in cell culture media which is higher than that resulting from the
release of intracellular Renilla luciferase synthesized by the same cells, indicating low
activity of the secreted insulin-firefly luciferase fusion protein (Pouli et al., 1998). In
contrast, the apoaequorin protein (MWr: 21 kDa) from the jellyfish Aequorea victoria,
retains full function even when secreted as part of a fusion with an immunoglobulin
heavy chain polypeptide (Casadei et al., 1990).
In addition to protein size, the number of cysteine residues present in an
intracellular protein which is to be engineered for secretion should also be an important
factor. Disulfide bond formation plays a determining role during folding of secreted
proteins (Clarke and Fersht, 1993), and can increase protein stability (Thornton, 1981).
Disulfide bond engineering for increased protein stability is an often-used approach,
which can be met with more or less success (Wells and Powers, 1986; Matsumura et al,
1989; Van den Burg et al., 1994; Mansfeld et al., 1997). Loss of protein function after
introduction of a disulfide bond has been attributed to side effects of the substitution of an
amino acid by cysteine per se (Wells and Powers, 1986; Mitchinson and Wells, 1989;
Matsumura et al., 1989; Van den Burg, 1994), as well as to conformational constraints
imposed by the introduced disulfide bond (Katz and Kossiakov, 1986; Villafranca et al..

89
1987). It seems therefore likely that the larger and the more cysteine residues an
intracellular protein has, the less probable it will be for that protein to retain its function
when secreted.
Wild-type Renilla luciferase protein contains three predicted cysteine residues in
its amino acid sequence (Lorenz et al., 1991). For comparison, apoaequorin, another
example of an intracellular protein that was successfully modified for functional
secretion, also contains three cysteine residues. When secreted, apoaequorin has several
apparent molecular weights in a non-reducing polyacrylamide gel, presumably because of
the presence of different disulfide bonds within different conformations (Inouye and
Tsuji, 1992). Together with our unpublished observation that secreted Renilla luciferase
could sometimes form large aggregates in mammalian cells, this result suggested that the
odd number of cysteine residues in secreted Renilla luciferase could affect its
bioluminescence activity. Each cysteine residue in Renilla luciferase was therefore
replaced individually by alanine, to obtain three different secreted Renilla luciferases with
a single disulfide bond. In addition, a luciferase with all three cysteines replaced by
alanine was also generated.
Immunoblot analysis of lysates of COS-7 cells synthesizing these proteins and
fractionated under oxidizing conditions revealed that substitution of the various cysteines
by alanine had an effect on disulfide bond formation (Fig. 2B). Surprisingly, SRUC
luciferase, presumed to contain three cysteine residues, was detected as a single species
(Fig. 2B, lane 3) with the same apparent molecular weight as cytosolic Renilla luciferase
(lane 2). In contrast, SRUC1, 2, and 3, which are presumed to contain two cysteine
residues, were present in addition as higher molecular weight species (lanes 4, 5, and 6,
respectively), likely corresponding to multimers of Renilla luciferase. We can only
speculate that removal of a cysteine residue may have affected the folding of secreted

90
Renilla luciferase and/or its interaction with folding machinery (eg., protein disulfide
isomerases, molecular chaperones) in a way that prevented efficient folding of the mutant
luciferases. Higher molecular weight forms of secreted mutant Renilla luciferases might
also be explained by the presence of undetected additional cysteine residue(s) that would
be available for intermolecular cross-linking. However this seems less likely in view of
the fact that luciferase SRUC4, which contains all three substitutions, did not form
similar complexes (lane 7).
Measurements of Renilla luciferase activity from lysates of simian cells
expressing the different gene constructs revealed that two out of the four mutant
luciferases, SRUC1 and SRUC3, had significant bioluminescence activity (Fig. 3A). In
contrast, SRUC2 and SRUC4 showed levels of light emission merely above background.
In the absence of a known three dimensional structure of Renilla luciferase, it is difficult
to speculate on the reason causing this loss of activity. However, since SRUC2 and
SRUC4 luciferases are the only two mutants containing a cysteine to alanine substitution
at position 101 (Fig. 1), it is possible that the loss of activity was due to a side effect of
this particular mutation.
Between the two functional mutants, SRUC3 was the only luciferase to show a
higher bioluminescence activity in cell lysates when compared to the original construct
SRUC. When Renilla luciferase activity was measured in culture media of the same
cells, this difference in light emission was even more pronounced (Fig. 3 B). Increased
bioluminescence activity of media containing the SRUC3 luciferase when compared to
media containing the SRUC luciferase could be observed shortly after transfection
(Fig.4). In both cases, light emission reached a plateau approximately 30 h after
transfection. However, while light emission from SRUC-containing medium started to
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decline after that time, light emission from SRUC3-containing medium remained
relatively constant.
Altogether, these data suggested that the increased bioluminescence activity of
SRUC3 when compared to SRUC was due mostly to increased stability of the SRUC3
luciferase. Stability measurements of both luciferases confirmed that this was the case
(Fig. 5). The half-life of SRUC and SRUC3 luciferases secreted by simian cells at 37°C
into serum free medium +1% FBS was calculated to be 14 and 82 h, respectively. We
cannot exclude the possibility that part of the light emission measured with media
containing SRUC3 resulted from increased specific activity of SRUC3, and /or increased
rate of secretion of that protein, as it was shown that removal of cysteine residues from a
secreted protein could result in the latter (Omura et al., 1992).
We had previously detected higher light emission from serum-free medium + 1%
FBS where SRUC-secreting simian cells were growing than from DMEM medium + 10%
FBS containing similar cells (Liu et al, 1997). In addition, aggregation of SRUC in
mammalian cells had been observed after one rare instance when no light emission could
be detected from transfected cells grown in DMEM medium +10% FBS. Aggregation
could be observed only when using non-reducing SDS-PAGE, suggesting that it was the
result of intermolecular disulfide bonds (data not shown). We had not seen this
occasional loss of activity with cells grown in DMEM+ 10% FBS and synthesizing
SRUC3 luciferase. However, we did detect a medium-dependency of the SRUC3
luciferase activity (Fig. 6). The decrease in light emission observed when SRUC3 is
secreted into DMEM medium +10% FBS when compared to SRUC3 secretion into serum
free medium + 1% FBS is not entirely due to a difference in stability of the luciferase in
the two different media, as it was shown that stability of wild type Renilla luciferase does
not vary drastically in these two media (Liu et al, 1997). Preliminary data suggest that it
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is the presence of FBS which is responsible for this variation, as removal of FBS from
DMEM resulted in increased light emission in the culture medium (data not shown). This
effect appears to be specific to secreted Renilla luciferase, because it was not observed
with SEAP.
Our results show that removal of a single cysteine residue from the original
secreted Renilla luciferase construct (SRUC) resulted in a dramatic increase in stability of
the mutated enzyme. This increase in stability could be the result of the formation of a
unique disulfide bond within secreted Renilla luciferase. Although possible, it seems
unlikely that this increase in stability is a direct effect of the single cysteine to alanine
substitution at position 152. This is suggested by the example of a thermolysin-like
protease from Bacillus thermoproteolyticus, where increase in stability obtained after the
engineering of a single disulfide bond (Mansfeld et al., 1997) was found to be equivalent
to the introduction of a total of five amino acid substitutions (Eijsink et al., 1995).
From a practical standpoint, the increased light emission associated with
increased stability of SRUC3 makes this luciferase a much improved marker protein.
Secreted Renilla luciferase appears to be a good candidate to be used in conjunction with
SEAP in a dual assay system of gene expression, where one marker protein is used for
studying the activity of a promoter of interest, and the other marker protein is used for
normalization between experiments. The “dual-luciferase assay system,” which
integrates the intracellular firefly and Renilla luciferases, illustrates the advantages that a
dual assay system using light emission-catalyzing proteins has to offer, i.e., simplicity of
use and sensitivity (Sherf et al., 1996). A similar dual assay system based on secreted
reporter proteins could make this kind of assay even more simple to perform.

93
Acknowledgment
We would like to thank Gary Rhodes and Robert Malone for the gift of plasmid
vector pND2, and Sandra Hilliker for helpful comments during the preparation of the
manuscript. This work was supported in part by a grant from the National Medical
Technology TestBed and by funds from Loma Linda University awarded to AE.

94
References
Casadei, J., Powell, M.J., Kenten, J.H., 1990. Expression and secretion of
aequorin as a chimeric antibody by means of a mammalian expression vector. Proc. Natl.
Acad. Sci. USA 87, 2047-2051.

Clarke, J., Fersht, A.R., 1993. Engineered disulfide bonds as probes of the
folding pathway of bamase: increasing the stability of proteins against the rate of
denaturation. Biochemistry 32, 4322-4329.

Cunningham, B.C., Wells, J.A., 1989. High-resolution epitope mapping of
hGH-receptor interactions by alanine-scanning mutagenesis. Science 244, 1081-1085.

Eijsink, V.G., Veltman, O.R., Aukema, W., Vriend, G., Venema, G., 1995.
Structural determinants of the stability of thermolysin-like proteinases. Nat. Struct. Biol.
2, 374-379.

Inouye, S., Tsuji, F.I., 1992. Monitoring gene expression in Chinese hamster
ovary cells using secreted apoaequorin. Anal. Biochem. 201, 114-118.

95
Inouye, S., Shimomura, O., 1997. The use of Renilla luciferase, Oplophorus
luciferase, and apoaequorin as bioluminescent reporter protein in the presence of
coelenterazine analogues as substrate. Biochem. Biophys. Res. Commun. 233, 349-353.

Jubin, R., Murray, M.G., 1998. Activity screening of bacteria containing Renilla
luciferase plasmids. Biotechniques 24, 185-188.

Katz, B.A., Kossiakoff, A., 1986. The crystallographically determined structures
of atypical strained disulfides engineered into subtilisin. J. Biol. Chem. 261,
15480-15485.

Liu, J., O'Kane, D.J., Escher, A., 1997. Secretion of functional Renilla reniformis
luciferase by mammalian cells. Gene 203, 141-148.

Lorenz, W.W., McCann, R.O., Longiaru, M., Cormier, M.J., 1991. Isolation and
expression of a cDNA encoding Renilla reniformis luciferase. Proc. Natl. Acad. Sci.
USA 88, 4438-4442.

Lorenz, W.W., Cormier, M.J., O'Kane, D.J., Hua, D., Escher, A., Szalay, A.A.,
1996. Expression of the Renilla reniformis luciferase gene in mammalian cells. J.
Biolumin. Chemilumin. 11, 31-37.

96
Mansfeld, J., Vriend, G., Dijkstra, B.W., Veltman, O.R., Van den Burg, B.,
Venema, G., Ulbrich-Hofmann, R., Eijsink, V.G., 1997. Extreme stabilization of a
thermolysin-like protease by an engineered disulfide bond. J. Biol. Chem. 272,
11152-11156.

Matsumura, M., Signor, G., Matthews, B.W., 1989. Substantial increase of
protein stability by multiple disulphide bonds. Nature 342, 291-293.

Mitchinson, C., Wells, J.A., 1989. Protein engineering of disulfide bonds in
subtilisin BPN'. Biochemistry 28, 4807-4815.

Omura, F., Otsu, M., Kikuchi, M., 1992. Accelerated secretion of human
lysozyme with a disulfide bond mutation. Eur. J. Biochem. 15, 551-559.

Pouli, A.E., Kennedy, H.J., Schofield, J.G., Rutter, G.A., 1998. Insulin targeting
to the regulated secretory pathway after fusion with green fluorescent protein and firefly
luciferase. Biochem. J. 331, 669-675.

Selden, R.F., Howie, K.B., Rowe, M.E., Goodman, H.M., Moore, D.D., 1986.
Human growth hormone as a reporter gene in regulation studies employing transient gene
expression. Mol. Cell. Biol. 6, 3173-3179.

97
Sherf, B.A., Navarro, S.L., Hannah, R.R., Wood, K.V., 1996. Dual luciferase
reporter assay: an

advanced co-reporter technology integrating firefly and Renilla

luciferase assays. Promega Notes 57, 2-9.

Thornton, J.M., 1981. Disulphide bridges in globular proteins. J. Mol. Biol. 151,
261-287.

Van den Burg, B., Dijkstra, B.W., Vriend, G., Van der Vinne, B., Venema, G.,
Eijsink, V.G., 1994. Protein stabilization by hydrophobic interactions at the surface. Eur.
J. Biochem. 220, 981-985.

Villafranca, J.E., Howell, E.E., Oatley, S.J., Xuong, N.H., Kraut, J. 1987. An
engineered disulfide bond in dihydro folate reductase. Biochemistry 26, 2182-2189.

Wells, J.A., Powers, D.B., 1986. In vivo formation and stability of engineered
disulfide bonds in subtilisin. J. Biol. Chem. 261, 6564-6570.

Wet, J.R., Wood, K.V., DeLuca, M., Helinski, D.R. and Subramani,S., 1987.
Firefly luciferase gene: Structure and expression in mammalian cells. Mol. Cell. Biol. 7,
725-737.

98
Yang, T.T., Sinai, P., Kitts, P.A., Kain, S.R., 1997. Quantification of gene
expression with a secreted alkaline phosphatase reporter system. Biotechniques 23,
1110-1114.

99

Cys52 O/slOl Cysl52
342

SRUC

N

c

EL
Ma52 CyslOl Cysl52
342

SRUC1

IL

N

C
Cys52 MalOl Cysl52
342

SRUC2

N

IL

C
Cys52 CyslOl Mal52
342

SRUC3

N

IL

C
Ma52 MalOl Mal52

1
SRUC4

N

342

IL

C

Figure 1. Secreted Renilla luciferases used in this study. The SRUC preprotein (342 aa)
is a fusion of the human interleukin-2 leader peptide (IL, aa 1 to aa 23) to wild type
Renilla luciferase (Liu et al., 1997), which contains three predicted cysteine residues.
SRUC1, 2, and 3 are mutants of SRUC where in each case a cysteine residue was
replaced by alanine. In the case of SRUC4, all three cysteines were replaced by alanine.
N: amino terminus; C: carboxyl terminus.
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Figure 2. Immunoblot analysis of lysates of COS-7 cells transiently expressing genes
encoding secreted Renilla luciferases. Total protein from cell lysates were fractionated
under reducing (A), or oxidizing (B) conditions using 12% SDS-PAGE, transferred to a
membrane, and reacted with rabbit polyclonal antibodies raised against wild-type Renilla
luciferase. Cells were transfected with the plasmid vector only (lane 1), PND2-RUC
encoding wild-type intracellular Renilla luciferase, (lane 2), PND2-SRUC (lane 3),
PND2-SRUC1 (lane 4), PND2-SRUC2 (lane 5), PND2-SRUC3 (lane 6), and PND2SRUC4 (lane 7); lane 8 contains wild type Renilla luciferase isolated from Escherichia
coli as control.
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Figure 3. Renilla luciferase activity in mammalian cell lysates (A) and culture media
(B). Light emission was measured 48h after transfection, with COS-7 cells synthesizing
SRUC (1), SRUC1 (2), SRUC2 (3), SRUC3 (4) and SRUC4 (5). In A, cells were lysed
in 1 ml buffer, and 3 jul lysate aliquots were taken for analysis. In B, 200 \i\ aliquots of
cell culture media from the same plates were taken for the assay, with the exception of
cells transfected with plasmid PND2-SRUC3, where only 2 pi aliquots of media were
taken and diluted into 198 pi of culture medium for measurement of light emission, to
keep readings within the scale of the luminometer. The number of relative light units
(RLU) obtained in that case was multiplied by 100 before being used as data. In all
cases, measurements were normalized using intracellular firefly luciferase activity. Data
represent the average of five different experiments.
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Figure 4. Time-course measurement of secreted Renilla luciferase activity in cell culture
medium. Simian COS-7 cells were transfected with plasmid pND2-SRUCl ( ■ ), SRUC2
( ♦ ), SRUC3 ( A ), SRUC4 ( x ), and SRUC ( • ).

104

2*

▲ ■
A

aSRUC

A

■ SRUC3

A

>
A

o

CT5
P

o
O)

A

o

A

0

o

50

100

150

200

250

300

350

Time (hours)

Figure 5. Stability of secreted luciferases in cell culture medium. Already secreted
SRUC (A) and SRUC3 ( ■ ) luciferases were incubated at 37°C in culture dishes
containing COS-7 cells growing in serum free medium + 1% FBS, and Renilla luciferase
activity was measured over time.
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Figure 6. Dependence of SRUC3 bioluminescence activity on cell growth condition.
COS-7 cells were transiently transfected with plasmid pND2-SRUC3, grown in DMEM
medium +10 FBS (DMEM) or serum free medium + 1% FBS (SFM), and Renilla
luciferase activity was measured in cell lysates and cell culture media 48 h after
transfection.
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Abstract
The luciferase enzyme from Renilla reniformis and the green fluorescent protein
from Aequorea victoria (GFP) have been used to monitor gene expression and protein
translocation in a variety of cell types. We have previously shown that an engineered
form of Renilla luciferase (SRUC) is secreted as a functional enzyme by mammalian
cells, and that fusing non-secreted Renilla luciferase with GFP yields a chimeric protein
retaining light-emission properties similar to that of unfused Renilla luciferase and GFP.
In the work presented here, the SRUC protein was fused with GFP to determine whether
it could be used to both visualize and quantify protein secretion in mammalian cells.
Simian COS-7 and Chinese hamster ovary (CHO) cells were transiently transfected with
DNA constructs encoding a secreted or an intracellular version of a Renilla luciferaseGFP fusion protein. Renilla luciferase activity was measured from COS-7 cell lysates
and culture media, and GFP activity was detected in CHO cells using fluorescence
microscopy. Data indicated that the SRUC-GFP fusion protein was secreted as a
chimeric protein that had both Renilla luciferase and GFP activity. Secreted Renilla
luciferase-GFP fusion protein has the potential of being a powerful marker for the study
of protein secretion in mammalian cells.
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Introduction
Protein secretion by eukaryotic cells is a complex cellular event which is still not
fully understood. Several methods and marker proteins have been used to study many
aspects of the protein secretion pathway. In recent years, the use of the green fluorescent
protein from Aequorea victoria (GFP) has permitted direct visualization of protein
secretion within a living cell. GFP (Mr: 27 kDa) is a soluble cytosolic protein that
fluoresces (lambda max=480) when exposed to U.V. light, and does not require any
substrate or cofactor to be functional (Nishiuchi et al, 1999). The only requirement for
GFP fluorescence is atmospheric oxygen (Heim et al, 1994), which is necessary for
formation of the GFP chromophore. GFP has been fused with several naturally secreted
peptides and proteins, including human chromogranin B (Kather and Gerdes, 1995;
Wacker et al., 1997; Lang et al, 1997), trans-Golgi network 38 protein (Girotti et al..
1996), vesicular stomatitis virus glycoprotein (Presley et al, 1997), neuropeptide Y
(Lang et al., 1997), and insulin (Pouli et al., 1998). Fusion of GFP with these proteins
has permitted scientists to follow their translocation within mammalian cells in real time,
and has yielded valuable information on the kinetics and mechanisms of protein
secretion.
However, it is difficult to quantify the amounts of these secreted protein fusions
when using GFP activity due to the poor sensitivity of its assay, combined with
background fluorescence in cell culture media. Fusing a secretory signal peptide with a
luciferase fused to GFP could allow one to follow visually the fate of the secreted fusion
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protein by observing GFP fluorescence within a cell, and at the same time to quantify
secretion by measuring luciferase activity in the cell culture medium.
The Renilla luciferase enzyme (Mr: 36 kDa) is a monomeric intracellular protein
which has been used as a marker of gene expression in cells of various origins (Lorenz et
al, 1991; Mayerhofer

<2/., 1995; Srikantha ^ a/., 1996; Lorenz

<2/., 1996). This

luciferase catalyzes emission of visible light (lambda max= 509 nm) in presence of
oxygen and coelenterazine (Matthews et al, 1977). Fusion of a human interleukin-2
(IL-2) signal peptide with Renilla luciferase was shown to cause its secretion by
mammalian cells as a functional enzyme (Liu et al., 1997). In addition, Renilla
luciferase-GFP and GFR-Renilla luciferase fusion proteins are known to retain both
luciferase and GFP activity (Wang et al, 1997). Altogether, these results suggested that
Renilla luciferase was a good candidate for the construction of a secreted luciferase-GFP
fusion.
In this work, we present evidence that an IL-2 signal peptide-Ztem7/<2 luciferaseGFP fusion protein can be secreted by mammalian cells while retaining luciferase and
GFP activities, based on measurements of Renilla luciferase activity and visualization of
GFP fluorescence. These results indicate that secreted Renilla luciferase-GFP fusion
protein could be used as both a quantitative and qualitative marker of protein trafficking
in mammalian cells, and that active Renilla luciferase can be secreted as part of a
chimeric protein.

Ill
Materials and Methods
1. Plasmid construction
Plasmid pND2-RUC/GFP was constructed by ligating a Renilla luciferase-GFP
gene fusion as a 1690 bp BamHl-Apal DNA fragment from plasmid pGEM-5zf (+)-RG2
into the BamHl-Apal sites of plasmid PND2-RUC (the constructions of pGEM-5zf (+)RG2 and pND2-RUC will be described elsewhere), generating plasmid PND2-RUC/GFP
(Figure 1 A). Plasmid pND2-SRUC/GFP was constructed by ligating a Renilla luciferaseGFP gene fusion as a 1690 bp. BamHl-Apal DNA fragment from plasmid pGEM-5zf
(+)- RG2 into the BamHl-Apal sites of plasmid pND2-SRUC (construction pND2-SRUC
will be described elsewhere), generating plasmid pND2-SRUC/GFP (Figure IB).

2. Cell culture and transfection
COS-7 and CHO cells were grown in 60 mm tissue culture plates containing 3 ml
DMEM medium with 10 % Fetal Bovine Serum (FBS). Cells were subcultured 24 hours
before transfection and grown until they reached 60% confluence. The ProFection
calcium phosphate system (Promega, Madison WI) was used for transfection, with 30 pg
of plasmid DNA per plate. Cells were washed with cold phosphate-buffered saline (PBS)
8 hours after transfection, 3 ml serum free medium (Sigma) +1% FBS was added to each
plate, which were then incubated at 37°C in a humidified 5% C02 incubator.
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3. Immunoblot analysis
COS-7 cells grown in 60 mm plates were washed twice with cold PBS 48 hours
after transfection, and harvested by scraping into 100 pi 2x gel-loading buffer
(0.1% Bromophenol Blue, 1M sodium phosphate, pH7.4, 4% SDS, 20% glycerol). Cells
were then lysed by sonication on ice (2x 10 seconds), samples were placed in boiling
water for 3 min, and centrifuged at 10,000 x g at room temperature for 10 min to pellet
cell debris. For each sample, 25 pg total protein was loaded on a 12%
SDS-polyacrylamide gel for electrophoresis. Fractionated proteins were then transferred
by electroblotting onto a nylon membrane, reacted with a monoclonal antibody (mAb)
raised against Renilla luciferase, and detected on an x-ray film using chemiluminescence.

4. Renilla luciferase assay and GFP visualization
The Renilla luciferase assay was performed as previously described (Liu et al.
1997). Five microliters total protein of cell lysate and 200 pi of culture medium were
used per assay. For GFP visualization, CHO culture medium was changed to FX12
medium 34 hours after transfection, and GFP fluorescent signal was detected using an
inverted fluorescent microscope (Zeiss, Oberkochen, Germany).
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Results
1. Construction of the SRUC-GFP fusion protein and immunoblot analysis
DNA sequences encoding the interleukin-2 signal peptide (23 aa), Renilla
luciferase (320 aa), and GFP (242 aa) were ligated to generate a 1.7 Kb DNA fragment
carrying the sruc-gfp gene, encoding a 583 aa fusion protein. The sruc-gfp gene construct
was then expressed in simian COS-7 cells together with a Renilla luciferase-GFP gene
fusion lacking the IL-2 sequence (Wang et al., 1997, named ruc-gfp in this article), and
immunoblot analysis of total cell lysates was performed using a mAh raised against
Renilla luciferase protein. Results indicated that cells expressing ruc-gfp (Fig.2 lane 2)
and sruc-gfp (Fig.2 lane 3) gene constructs synthesized proteins with a molecular weight
corresponding to that of the RUC-GFP fusion protein, and that cells expressing sruc-gfp
contained lower amounts of luciferase-gfp fusion protein than cells expressing ruc-gfp.
Altogether, these data suggested that SRUC-GFP fusion protein was synthesized in fulllength, properly processed, and secreted.

2. Renilla luciferase assay
Renilla luciferase activity was measured with lysates and culture media of cells
transfected with plasmids pND2, pND2-RUC/GFP, and pND2-SRUC/GFP. Luciferase
activity measured from lysates of cells expressing the ruc-gfp gene was approximately
12 times higher than that of cells expressing the sruc-gfp gene (Fig.3 A, 2 and 3,
respectively). In contrast, luciferase activity measured from culture media of cells
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expressing the sruc-gfp gene was about 800 fold higher compared to that of cells
expressing the ruc-gfp gene (Figure 3 B, 3 and 2, respectively). These results were
similar to those obtained with COS-7 cells expressing the sruc gene alone (Liu et al,
1997), and a further indication that the SRUC-GFP protein fusion was actively secreted
by mammalian cells.

3. Visualization of intracellular GFP fluorescence
GFP fluorescence was detected in CHO cells expressing the ruc-gfp and sruc-gfp
gene constructs using fluorescence microscopy. Cells transfected with vector pND-2
only showed low levels of background fluorescence (data not shown), while cells
expressing the gene fusion constructs showed strong fluorescent signals with distinct
intracellular distribution. Cells expressing the ruc-gfp gene displayed a diffuse GFP
signal in both the cytosol and the nucleus (Fig. 4 A). In contrast, cells expressing the
sruc-gfp gene displayed a reticular and punctuate pattern of GFP fluorescence throughout
the cell (Fig. 4 B). These patterns are characteristic of wild type GFP and secreted GFP
fluorescence, respectively, in mammalian cells (see discussion), and indicated secretion
of the SRUC-GFP fusion protein by CHO cells.
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Discussion
Reporter genes have been widely used to understand many aspects of gene
expression in mammalian cells. Genes encoding bioluminescent marker proteins have
been particularly useful, because they provide a very sensitive means to detect
transcriptional and translational activity of a specific gene, or to localize the presence of a
particular gene product within a single cell or multicellular organism. In most cases,
intracellular marker proteins are sufficient for a given purpose. However, there are times
when a secreted bioluminescent marker protein becomes a primary choice. In recent
years, research focusing on intracellular eukaryotic protein trafficking has made
increasing use of bioluminescent proteins as new tools to study protein secretion. The
green fluorescent protein from Aequorea victoria (GFP) has been the light-emitting
marker protein of choice for studying protein secretion. Because GFP only requires
atmospheric oxygen and U.V. light to be functional, differential uptake of substrate by
various membrane-bound structures containing GFP is not a factor affecting fluorescence.
More importantly, this feature allows the investigation of protein translocation within a
single living cell, and in real time. In combination with photobleaching, which permits
measurement of secretory granule mobility (i.e., rate and trajectory) after fluorescence
recovery, these properties of GFP have helped to gather new data on protein secretion
which were previously difficult to obtain (Levitan, 1998).
For all the advantages that GFP has to offer as a marker of intracellular protein
trafficking, there is still a limitation to its use for studies of protein secretion. Measuring
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levels of protein secreted into cell culture media based on GFP fluorescence can be
difficult, due to the inherent low sensitivity of its assay. It is possible to detect presence
of GFP secreted by mammalian cells after blocking its secretion, releasing the blockage,
and measuring a peak of GFP fluorescence when GFP accumulated intracellularly is
released into the medium (Wacker et al, 1997). However, little or no GFP activity can
be detected at steady state levels (Wacker et al, 1997; Pouli et al., 1998). Nevertheless,
some luciferases and other light-catalyzing proteins with higher assay sensitivity than
GFP can be used to measure secretion in cell culture media readily, such as Vargula
hilgendorfii luciferase (Thompson et al, 1990), secreted Renilla luciferase (Liu et al..
1997), secreted apoaequorin (Inouye and Tsuji, 1992), and secreted alkaline phosphatase
(Berger et al., 1988). Thus, fusing a secreted luciferase enzyme with GFP appears to be
an attractive way of combining the sensitivity of a luciferase assay for measuring protein
secretion in a quantitative manner easily, with the ability to directly localize the same
secreted protein using GFP fluorescence in situ.
In this work, we have constructed such a chimeric marker protein by fusing
secreted Renilla luciferase with GFP. Secreted Renilla luciferase was a candidate of
choice for this purpose, because we were aware that a fusion of intracellular Renilla
luciferase with GFP (RUC-GFP) was functional in mammalian cells (Wang et al, 1997).
The secreted Renilla -luciferase GFP fusion protein, SRUC-GFP, appeared to be
synthesized full-length and properly processed in mammalian cells, as determined by
SDS-PAGE and comparison with RUC-GFP (Fig. 2). Two lines of evidence indicated
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that the secreted Renilla luciferase-GFP fusion protein was secreted, and moreover
retained the light-emitting functions of Renilla luciferase and GFP. First, significant
Renilla luciferase activity could be detected in cell culture medium only when the
interleukin-2 signal peptide was fused to the Renilla luciferase-GFP fusion; in its
absence, luciferase activity was merely above background (Fig. 3 B). Second,
visualization of intracellular GFP activity in mammalian cells synthesizing RUC-GFP
and SRUC-GFP fusion proteins showed that while RUC-GFP was present diffusely
throughout the cell, SRUC-GFP had a distinct subcellular localization (Fig. 4). The
observed distributions observed in each case corresponded to the abundantly documented
patterns of fluorescence seen in mammalian cells with unfused intracellular GFP, and
secreted GFP in mammalian cells, respectively. The fusion protein RUC-GFP, with a
molecular weight of 64 kDa, could freely diffuse into the nucleus without the need for
active transport and a nuclear localization signal (Fig. 4 A). In contrast, SRUC-GFP,
which has a similar molecular weight, was found in entirely different sites within the cell
(Fig. 4 B). Fluorescence from the presumably processed SRUC-GFP was seen in
structures most likely corresponding to the Golgi apparatus and secretory vesicles.
Future studies using confocal microscopy should reveal the precise nature of these
intracellular organelles.
The secreted Renilla luciferase-GFP fusion protein represents a significant
advance in the development of marker proteins for the study of protein secretion. Using
this protein in living cells, one could alter mammalian protein secretion (eg., using

118
antisense oligonucleotides to modify expression of a gene suspected to be involved in
protein secretion, or inhibitory peptides, Ca++, etc.) and follow changes in protein
secretion in qualitatively in situ using GFP fluorescence at the single cell level, as well as
quantitatively by measuring Renilla luciferase activity in the culture medium at the
population level. Because luciferase and GFP activities would come from the same
protein, one would be able to compare directly the data obtained for each assay. This is
contrast with the use of secreted luciferase and secreted GFP used as separate markers,
where such comparison would be difficult to make as a result of differential rate of gene
expression, protein secretion or degradation
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A. pND2-RUC-GFP
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ruc-gfp

B. pND2-SRUC-GFP
CMV
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Figure 1. Partial structures of the plasmids used in this study. Ampicillin resistance
gene and bacterial origin of replication are not shown. (A) Plasmid pND2-RUC/GFP
carries a cDNA encoding the wild type Renilla luciferase-GFP fusion protein. (B)
Plasmid pND2-SRUC-GFP carries the SRUC-GFP gene, which encodes IL2SP fused to
the wild type RUC/GFP fusion protein.
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Figure 2. Immunoblot analysis of total cell lysates using Renilla luciferase mAb.
Simian COS-7 cells were transfected with plasmid pND2-RUC/GFP (lane 2), plasmid
pND2-SRUC/GFP (lane 3), and vector pND2 only (lane 1). Lane 4 contains 10 ng
isolated Renilla luciferase as control. Totally 25 ug of cell lysates were loaded on each
well.
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Figure 3. Renilla luciferase activity from RUC-GFP fusion protein in cell lysate (A) and
in cell culture (B). Light emission was measured with simian COS-7 cells transfected
with: 1. pND2 vector only; 2, pND2-RUC-GFP; 3, pND2-SRUC-GFP. Results obtained
from three individual transfections are shown. Relative light units (RLU) are shown as
per second, per 5 pg total protein in (A), and as per second, per 200 pi medium in (B).
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Figure 4. Directly visualization of protein secretion pathway through GFP fluorescence.
CHO cells were transfected with plasmid pND2-RUC-GFP (A), and plasmid pND2SRUC-GFP (B). Thirty-four hours after transfection, CHO cells were visualized under
uv microscope.
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Abstract
Four reporter genes encoding secreted alkaline phosphatase, secreted Renilla
luciferase, and Firefly luciferase, were transferred into BALB/c mice after intramuscular
“naked” DNA injection. Enzymatic assays were performed on muscle and serum
samples. Results showed that Renilla luciferase could be used as a reporter protein in
mice. Result from organ culture showed that secreted Renilla luciferase were secreted by
muscle cells, although there was no signal of secreted Renilla luciferase can be detected
from whole blood or serum. Possible strategies to improve secreted Renilla luciferase as
an in vivo marker are discussed.
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1. Introduction
Bioluminescent reporter genes have emerged as powerful tools to study gene
delivering efficiency and promoter regulation. Light-emission from bioluminescent
reaction provides a rapid and sensitive assay to quantitatively monitor gene expression.
Among several bioluminescent markers, Firefly luciferase and green fluorescent protein
(GFP) are the most commonly used ones. Because none of these markers protein can be
applied universally under different conditions in different biological systems, it is
necessary to develop new bioluminescent markers. During the past few years, Renilla
luciferase has been developed as a new member of luciferase family. Isolated from sea
pansy R.reniformis, an anthozoan coelenterate living in shallow coastal waters of North
America (Matthews et al, 1997), Renilla luciferase catalyzes a blue-green light emitting
bioluminescent reaction. As a gene expression maker, Renilla luciferase has been applied
in bacterial (Lorenz et al, 1991), plant (Mayerhofer et al, 1995), yeast (Srikantha et al,
1996), and mammalian cells (Lorenz et al, 1996).
However, most gene expression markers mentioned above are intracellular
proteins. Host cells carrying these marker genes have to be destroyed before analysis can
be conducted. Cell lysis means disruption of experimental continuity, and makes certain
experiments, such as time-course experiments, more unreliable. The requirement of cell
lysis becomes more unacceptable when gene activity is monitored in an isolated system,
such as animal model or human body in gene therapy trials, because it is not practical to
repeatedly remove tissue or organ samples for analysis from an animal or human body.

130
Unlike intracellular marker proteins, secreted markers allow continuous gene expression
monitoring on the same group of cells or tissues without cell lysis since signals for
marker proteins could be picked up from cell culture medium {in vitro), or body fluid
{in vivo). There are several secreted reporter proteins that have been developed, such as
secreted alkaline phosphatase (SEAP) (Berger et al, 1990), secreted Renilla luciferase
(SRUC) (Liu et al, 1997), Vargula hilgendorfii luciferase (Thompson et al, 1990),
apoaequorin (Inouye and Tsuji, 1992), and GFP from Aequoria victoria (Kaether and
Gerdes, 1995; Laukkanen et al, 1996). The application of Vargula hilgendorfii
luciferase is limited because its substrate is too expensive (about $2,000/g). Requirement
for temporary arrest of protein transport and difficulty to quantitatively monitoring gene
expression restricted the use of secreted of GFP. SEAP and SRUC are good candidates
as secreted reporter protein to quantitatively monitor gene expression. SEAP has been
applied as a regular secreted protein for in vitro studies, but to our knowledge there is no
report on SEAP for in vivo studies. This in vivo study was conducted to detect secreted
Renilla luciferase (SRUC) in BALB/c mice, but no signal of SRUC could be detected
from blood/serum samples. To optimize SRUC as a marker protein, SRUC3 has been
developed as a mutant form of SRUC with dramatically improved protein stability
(Liu et al, unpublished data). Although it may affect SRUC3 to dynamically reflect the
change of gene activity, increased stability should allow secreted protein to accumulate to
a certain level to be detected during in vivo studies.
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There are many different gene-delivering systems for animal study, and
intramuscular (IM) injection of “naked” DNA appears to be a simple and safe way to
achieve this purpose. IM injection was first reported to transfer genes into skeletal
muscle in vivo by direct injection of plasmid DNA without any delivery vehicle such as a
lipid shell (Wollf et al, 1990). Compared to virus vectors, direct gene transfer offers
several advantages (Levy et al, 1996; Davis et al, 1993). IM DNA injection does not
require dividing cells as the retrovirus do, and should have less possibility to create
immunological difficulties because plasmid DNA can be purified to homogeneity without
external protein. Despite evidence that the DNA remains in an unintegrated circular
form, expression has been shown to persist for up to 19 months (Wolf et al, 1992). The
epichromosomal structures also minimize the risk of genomic insertional mutagenesis.
Studies showed that in mouse skeletal muscle, plasmid DNA transfer holds better
efficiency than that of adenovirus and retrovirus.
IM DNA delivering method has been applied to deliver reporter genes into animal
model. Firefly luciferase (Wolff e/a/., 1990; Levy e/a/., 1996; Perez

a/., 1996;

Prigozy et al, 1993), chloramphenicol acetyltransferase (Wolff et al, 1990; Wells D. L,
1993; Prigozy et al, 1993), p-galactosidase (Wolff et al, 1990; Nishi et al, 1996;
Prigozy et al, 1993), and human placental alkaline phosphates (Perez et al, 1996) have
been reported to be directly transferred through IM injection. IM injection has also been
applied in DNA based immunization and DNA vaccination against Influenza A
(Montgomery et al, 1993; Yankauckas et al, 1993) and Hepatitis B virus (Mancini et al,
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1995; Michel et al, 1995; Davis et al, 1995; Gramzinski et al, 1998). Recent reports
showed that delivering plasmid DNA encoding cytokine (Nitta et al, 1998) through IM
injection could prevent type I diabetes in non-obese-diabetic mice.
In the work presented here, plasmid DNA encoding four reporter genes, SEAP,
Firefly luciferase, Renilla luciferase, and SRUC3, were delivered into BALB/c mice
through IM injection. Enzymatic analysis was conducted on blood and muscle samples.
Data showed that the signals of all four proteins were detected from muscle cells within
24 hours after injection and signals could last at least for 20 days. Activity of RUC and
SRUC3 in muscle cells were in similar range compared to that of Firefly luciferase and
SEAP, and it proved that RUC can be used as in vivo reporter protein in mice. However,
SRUC3 could not be detected from blood or serum. Due to its high background, the
conclusion of detection of SEAP from serum could not be made. Result from organ
culture showed that both SRCU3 and SEAP were secreted by muscle cells. SRUC3 has
to be further optimized before being applied as secreted markers for in vivo studies.

2. Materials and Method
2.1. Plasmid construction
pND2-Firefly: plasmid pND2-Firefly luciferase was kindly presented by
Dr. Malone from University of Maryland at Baltimore.
pND2-SEAP: plasmid pND2-SEAP was constructed by ligating the SEAP gene as
a 1708 bp Hindlll-Hpal DNA fragment from plasmid pSEAP2-Control (Clontech Inc.,
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Palo Alto, CA) into the Hindill-R^l sites of plasmid pBluescript II KS(+), and was
subcloned as a 1750 bp Sali-Notl DNA fragment into compatible sites of plasmid pND2
to generate plasmid pND2-SEAP.
pND2-RUC: plasmid pND2-RUC was constructed by ligating the Renilla
luciferase gene as a 980 bp SaR-Smal DNA fragment into the SaB-EcoRV site of plasmid
pND2, generating the plasmid pND2-RUC.
pND2-SRUC3: the construction of pND2-SRUC3 has been described elsewhere.

2.2. DNA preparation
Plasmid DNA constructions were isolated and purified by standard double-round
cesium chloride purification method. E.coli transformed with DNA constructs of interest
were grown in 2-liter culture medium overnight supplemented with antibiotics. Cells
were pelleted and DNA was extracted through standard alkaline-lysis method. DNA was
dissolved in double distilled water and CsCl was added at Ig/lml ratio. Solution was
warmed to 30°C to facilitate the dissolution of salt. Zero point eight ml of ethidium
bromide (lOmg/ml in water) were added for every 10ml DNA/CsCl salutation. The final
density of the solution should be 1.55g/ml, and the concentration of Ethidium bromide
should be approximately
740 pg/ml.
DNA/CsCl solution was added in to 15 ml high-speed centrifuge tubes and
centrifuged at 75,000 rpm for 16 hours at 20°C in XL-Ultracentrifuge (Beckman). Three
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layers were formed in the tube and DNA was contained in the clear, red one in the
middle. A 27-gauge needle was used to transfer the clear and red solution into another
15 ml high-speed centrifuge tube, and CsCl was added again and DNA-CsCl solution was
spun one more time. DNA band was removed and transferred into a 50ml plastic tube.
Aluminum foil was used during the procedure to protect the DNA degradation due to
visible light.
1-butanol saturated with water was used to remove the ethidium bromide from
DNA solution. Equal volume of 1-butanol was added into DNA solution, mixed well
with vertex, and upper layer of solution containing Ethidium bromide was removed. This
procedure was repeated at least 10 times until all the pink color disappears from both the
aqueous phase and the organic phase.
Dialysis tube from Pierce was used to remove CsCl from DNA solution. DNA
was dialysis twice in 2 liters TE buffer for 24 hours at 4°C, precipitated with
20% Ammonium Acetate and 3 volumes of ethanol for 5 hours at -20°C followed by
centrifugation at 10,000 x g for 30 minutes at 4°C, and was resuspended in double
distilled water at final concentration of 2 pg/pl.
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2.3 Intramuscular DNA injection
DNA (200 jag/leg) was injected into mice quadriceps muscle through a 27-gauge
needle under general anesthesia (Ketamine, 66 mg/Kg body weight, Phoenix
Pharmaceutical, Oxylazine, 7.5 mg/Kg body weight, LLOYD Laboratories, and
Acepromazine Maleate, 1.5 mg/Kg body weight, Fermenta). One hundred forty-four
7-week-old BALB/c mice (about 25 gm body weight) purchased from Jaskson Lab were
maintained in Loma Linda animal care facility during the experiment. Sixteen mice were
used as negative control with injection of pND2 vector only. The rest 128 mice were
evenly divided into four groups, and plasmid DNA pND2-Firefly, pND2-SEAP, pND2RUC, and pND2-SRUC3 were injected into each group. Four mice from each group
(two from control group) were killed on day 1, 3, 5, 7, 10, 12, 15 and 20 after injection
for enzymatic analysis.

2.4. Sample collection
All blood samples were collected through a cardiovascular puncture, stored at 4° C
degree overnight, centrifuged at 1200 x g for 10 minutes. Serums were harvested and
stored at -70° C. Quadriceps muscles (average 0.122 mg) were stored at -70° C after being
removed from mice.
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2.5. Enzymatic analysis
2.5.a. Firefly luciferase assay
Firefly luciferase assay system was purchased from Promega and was performed
as prescribed (Firefly luciferase system, Clontech, Palo Alto, CA). Muscle samples were
homogenized in 1 ml lx Cell Culture Lysis Reagent (CSLR) (25 mM Tris-phosphate,
pH7.8, 2 mM DTT, 2 mM l,2-diaminocyclohexane-N,N,N’,N’-tetraacetic acid,
10% glycerol, 1% Triton X-100) with OMNI 2000 homogenizer (Omni International Inc.,
VA, USA). 50 ul of homogenized tissue and 50 ul of serum samples were mixed
separately with 100 pi of room temperature Luciferase Assay Reagent. Samples were
vertexes 2 seconds and light production was measured in TURNER TD-20e luminometer.

2.5.b. secreted alkaline phosphatase assay
Great EscAPe SEAP Assay Kit was purchased from Clontech and performed as
described. 1 ml IX lysis buffer (10 mM Tris-HCl, pH 7.5, 0.5 mM MgCl2, and
0.1% Triton X-100) was used to homogenize muscle samples. Fifty pi homogenized
tissue and 50 pi serum samples were used in each assay. Tissue and serum samples were
mixed with 75 pi 1 x dilution buffer and incubated at 65°C for 30 minutes. Samples were
cooled to room temperature by being placed on ice for 2-3 minutes, and then being
equilibrated to room temperature. One hundred pi of assay buffer was added to each
sample and incubated for 5 minutes at room temperature. One hundred pi of 1.25 mM
chemiluminescent substrate CSPD (CSPD: chemiluminescent =1:19) was added to each

137
sample and incubates for 30 minutes at room temperature before light production being
measured in TURNER TD-20e luminometer.

2.5.C. RUC assay
Muscle samples were homogenized in 1ml RUC assay buffer (0.5 M NaCl, ImM
EDTA, lOOmM potassium phosphate, pH 7.4). Fifty microliters of homogenized samples
were assayed for bioluminescence in a luminometer (Turner TD-20e) after rapid injection
of 500 pi 1 pM coelenterazine (Molecular Probes Inc.). Two hundred microliters aliquots
of serum were assayed for bioluminescence as described above.

2.6. Organ culture of mouse quadriceps muscle
Twenty 7-week-old BALB/c mice (about 25 gm body weight) were purchased
from Jackson Lab and were maintained in Loma Linda animal care facility. Eight mice
were injected with plasmid pND2-SRUC3, six mice were injected with plasmid pND2RUC, and other six mice were injected with plasmid pND2-SEAP. To each case, 200 pg
DNA was injected into each leg of mice. Seven days after injection, mice were killed and
quadriceps muscles were removed, cut into 4 pieces, and directly incubated in 1 ml
DMEM medium with 10% Fetal Bovine Serum and 1% antibiotic-antimycotic
(lOOx, with 10,000 units penicillin, 10 mg streptomycin and 25 pg amphotericin B per ml
in 0.9% sodium chloride, Sigma-Aldrich Co. LTD., Irvine, KA) under normal cell culture
condition (37°C, 5% C02). Two hundred fifty microliters of medium (200 pi for RUC
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assay, 50 jal for SEAP assay) were taken at regular time interval and were used
immediately for functional assay. Two hundred fifty microliters of fresh medium were
added as replacement to each plate. SEAP assay and RUC assay were performed on all
samples serving as negative control to each other.

2.7. Whole body imaging of mice after intramuscular injection of luciferase genes
To check if it is possible to directly visualize the gene expression of reporter
genes after intramuscularly DNA injection, two 6-week-old mice were injected with
Firefly and Renilla luciferase, respectively. Two hundred pg of plasmid DNA were
injected into the right leg of the mouse, and 200 pg of DNA of PND2 vector were
injected into the left leg as negative control. Ninety six hours after injection, mice were
anaesthetized, stabilized on a piece of white paper, and substrate was injected into
quadriceps muscles and tail vein for whole body imaging (regular amount was used for
firefly luciferase, and 100 pi 50 pM coelenterazine for Renilla luciferase). Gene
expression of Firefly luciferase was monitored directly through mice body, but mouse
skin had to be pulled back to capture the signal of Renilla luciferase.
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3. Results and discussion
There is an increasing demand to develop new gene expression markers in the
past few years. Secreted bioluminescent marker proteins provide a rapid, sensitive, and
non-invasive assay to monitor gene activity. This becomes more important when
experiments are being conducted in animal model systems (Naffakh et al., 1996).
Renilla luciferase was engineered to be secreted by mammalian cells, and genetic
modification was conducted to improve its protein stability. To find out weather Renilla
luciferase can be used as an intracellular marker protein in comparison of Firefly
luciferase, and whether SRUC3 can be applied as secreted reporter protein in animal
studies, plasmid DNA encoding RUC, SRUC3, SEAP, and Firefly luciferase cDNAs
were transferred into B ALB/c through intramuscular injection. Expression of reporter
proteins was monitored by measuring photon from light-emission from muscle and
blood/serum samples.
Based on the data from muscle samples, the sensitive range of RUC assay are
comparable to that from Firefly luciferase and SEAP. RUC and SRUC3 displayed the
same trend of gene expression: the signal of luciferase can be detected 24 hours after
injection, peaks at seventh day, and starts to drop after that. Firefly luciferase displayed a
rather different expression pattern: signal did not reach peak until twelve days after
injection. Signal could still be detected at least for 20 days after injection for all three
markers. There is no significant background for both Firefly luciferase and Renilla
luciferase from muscle samples.
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Due to its unusually high background in muscle samples, no expression pattern
can be drawn regarding SEAP expression. Only data from day ten and day fifteen could
be considered statistically significant compared to background.
Bioluminescent assays were also performed on whole blood and serum. No signal
of Firefly luciferase and secreted Renilla luciferase was detected from either whole blood
or serum samples. Due to its wide-range high background from control samples, SEAP
signals were detected only in 7 out of 32 serum samples, and there is no gene expression
pattern could be drawn from these data. Because SEAP is supposed to be heat reliable at
65°C and resistant to Homoaragine, these two treatments have been used to eliminate the
background during in vitro studies. The high background from muscles and serum
samples may come from endogenous alkaline phosphate or unknown protein(s), which is
(are) capable of interacting with substrate for SEAP. For an unknown reason, heat and
Homoaragine were not able to eliminate the background caused by unidentified
protein(s). This unexpected high background could limit the application of SEAP as an
in vivo marker.
It is not clear why the secreted Renilla luciferase was not detected from blood or
serum, but there are several reasons will be discussed. Muscle cells may produce but not
secrete Renilla luciferase protein. The secretion efficiency may have been too low and
most of the proteins could be retained inside of the muscle cells. Renilla luciferase may
have been secreted into blood, but the gene expression level is not high enough to reach
the level of detection. Dilution of secreted protein by body fluid of mice may also reduce
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the chance of detection of Renilla luciferase. It is known that there are size and charge
requirements in kidney for proteins to be cleared out, Renilla luciferase may have been
cleared out through kidney after being secreted into blood because of its relative low
molecular weight. Protein may have been degraded by proteases in the blood or liver. It
may have been targeted to certain organ(s), or may not be stable enough in blood to
accumulate to a threshold level for being detected. Overall, several or none of these
reasons could explain the undetectable Renilla luciferase activity in the blood or serum.
To explore whether SRUC3 and SEAP protein were secreted by muscle cells or
not, in vitro organ culture experiments of isolated muscle tissues were conducted. Gene
expression and protein secretion were monitored up to 72 hours. Even though the activity
level of SRUC3 and SEAP in medium were fairly low compared to that from in vitro
studies, data from Renilla luciferase and SEAP assay on organ culture medium showed
that both SRUC3 and SEAP were secreted by muscle cells (Figure 3). The background
for SEAP from culture medium is noticeably lower than that from blood and muscle
samples. It is not clear why there is high in vivo background for SEAP, but it will limit
the application of SEAP as in vivo marker protein.
Whole body imaging experiments showed that Renilla luciferase could be used
with Firefly luciferase in a dual-marker system for in vivo study. Because of the relative
larger size of substrate for Renilla luciferase and subsequently poor penetration into
muscle cells, the signal of Renilla luciferase was weaker than that from Firefly luciferase.
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Consistent with the result from Renilla assay on blood samples, there was no signal for
secreted Renilla luciferase in mice.
If its sensitivity level can be improved, SRUC3 would be a better candidate as in
vivo marker protein compared to SEAP since it has no background in the mouse. The
following procedures can be conducted to improve Renilla luciferase assay system:
(1) Application of more efficient vector system with stronger promoter would
increase the odds for detection of secreted Renilla luciferase. Systemically delivering
system, such as T-cell-based-protein-secretion system, may also provide a better chance
to detect SRUC3.
(2) More studies on Renilla luciferase protein structure may reveal new direction
to improve protein stability, sensitivity, specific activity and secretion efficiency.
Modification could be conducted to change the codon usage in Renilla luciferase and
optimize it for mammalian cell expression. More knowledge about protein structure itself
may lead to find a better-match substrate with increase activity. It was reported that in
vitro secretion rate of SEAP was as high as 98%. Based on data obtained from in vitro
and in vivo studies, the secretion rate of Renilla luciferase was much lower than that.
Modification of SRUC3 needs to be done to achieve a higher secretion rate.
(3) Renilla luciferase fusion protein with increased molecular weight may elude
possible host clearance through kidney. Circulating proteins with lower molecular
weight may be cleared from kidney, although the exact cutoff size is not clear. Since
albumin (60 kDa) is retained in kidney, fusion of Renilla luciferase with another gene to
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generate a fusion protein with molecular weight higher than 60 kDa may prevent the
clearance of SRUC3. (4) The conduction of a more sensitive luminometer will also
increase the chance of picking up signals from blood/serum samples.
In summary, Renilla luciferase can be applied for in vivo studies as a sensitive
bioluminescent marker. We are currently modifying secreted Renilla luciferase and
optimizing detecting system for SRUC3 to be used as a secreted marker in animal
models.
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Figure 1. Partial structure of the plasmids used in this study. Ampicillin resistance gene
and bacterial origin of replication are not shown. (A) Plasmid pND2-/wc carries a cDNA
encoding the wild type Firefly luciferase protein. (B) Plasmid pND2-rwc carries a cDNA
encoding the wild type Renilla luciferase protein. (C) Plasmid ^HDl-seap carries a
cDNA encoding the secreted alkaline phosphatase. (D) Plasmid pND2-^rwci carries a
cDNA encoding the mutant form of secreted Renilla luciferase. CMV, cytomegalovirus
promoter; SEAP, secreted alkaline phosphatase; RUC, Renilla luciferase; SRUC3, mutant
form of secreted Renilla luciferase.
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Figure 2. Time-course of reporter gene activity appearance in muscle cells after DNA
injection. Plasmid DNA encoding RUC (A), SRUC3 (B), Firefly luciferase (C), and
SEAP (D), were injected into 5-week-old BALB/c mice. Muscle cells were isolated at
regular time interval, homogenized in assay buffer, and light emission was monitored by
luminometer. Relative light units (RLU) are shown as per second, per 50 ul
homogenized samples.
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Figure 3. Organ culture of muscle cells carrying plasmid DNA encoding SEAP, RUC,
and SRUC3. Seven days after injection, quadriceps muscle were isolated from BALB/c
mice, and incubated in DMEM + 10% FBS. Culture media were taken at 24, 48, and 72
hours after incubation, and SEAP assay (A) and RUC assay (B) were performed on all
samples. Medium from muscle carrying DNA encoding SEAP serve as negative control
in RUC assay, and medium from muscle carrying DNA encoding RUC/SRUC3 serve as
control in SEAP assay. Relative light units (RLU) are shown as per second, per 200 pi
cell culture medium.
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Figure 4. Whole body imaging of BALB/c mice intramuscularly injected with Firefly
and Renilla luciferase DNA. Five days after injection, mice were stabilized, and
substrate (100 jal of room temperature Luciferase Assay Reagent for Firefly luciferase,
and 100 pi 50 pM coelenterazine for Renilla luciferase) were directly injected into
quadriceps of mice. Imaging was taken immediately in NightOwl Image system.
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Summary
Our goal is to determine whether gene vaccination can be used for the treatment
of insulin-dependent diabetes mellitus (IDDM), an autoimmune disease. In this work,
weanling non-obese diabetic (NOD) mice, an animal model system for the study of
IDDM, received intramuscular injections of naked plasmid DNA encoding either
intracellular or secreted human glutamic acid decarboxylase (GAD), one of the major
autoantigens recognized during the onset of IDDM. Seven weeks later, each pancreas
was scored for insulitis, an inflammation indicative of the disease. Mice treated with
either type of gad gene-carrying plasmid showed a significant decrease in the severity of
insulitis when compared to controls. These results suggest that vaccination using
autoantigen-encoding genes may provide a means of treating IDDM.
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Introduction
Insulin dependent diabetes mellitus (IDDM), or type I diabetes, is a disease with
high morbidity and mortality that affects 1 in 300 persons in North America, with a
prevalence ever increasing in small children (for a review see Mandrup-Poulsen, 1998).
Although also called juvenile diabetes because it often affects young people, a similar
disease has been diagnosed in patients 50 years of age and older (Molbak et al, 1994).
IDDM is thought to be caused by both genetic and environmental factors, and is
associated with the autoimmune destruction of insulin-producing beta cells found in the
pancreatic islets of Langerhans. Loss of these insulin-secreting cells results in the
inability to metabolize glucose, leading to hyperglycemia and ketoacidosis, which in turn
cause a variety of debilitating and life-threatening ailments such as blindness, kidney
disease, heart attack, stroke, and neuropathy.

Although injection of the hormone insulin

can prolong life of IDDM patients, it does not provide a cure for the disease, likely due to
lack of proper regulation of insulin levels within the body. A cure for IDDM could be
achieved if the destruction of beta cells were averted.
IDDM has been characterized as an autoimmune disease based on the
observations that patients suffering from this illness have high levels of islet cell
autoantibodies in their sera (Bottazo et al, 1974), and chronic mononuclear cell
infiltration of their pancreatic islets (Gepts and Lecompte, 1981). Presence of
autoantibodies can be detected years before the onset of symptoms, and is considered to
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be diagnostic for IDDM (Maclaren, 1988), although it does not always imply occurrence
of the disease. In humans, the nature of these antibodies varies with age: autoantibodies
against insulin and tyrosine phosphatase IA-2 are associated with early childhood,
glutamic acid decarboxylase (GAD) and islet cell cytoplasmic protein autoantibodies with
late childhood and adolescence, while late onset can be associated with other typical
immune markers (Mandrup-Poulsen, 1998). Inflammatory infiltration of the islets
(insulitis) and beta cell destruction are due mostly to T lymphocytes, both CD4+ helper
and CD8+cytotoxic (Itoh et al, 1993; Peakman et al, 1994), and result in loss of islet cell
mass. When this cell mass drops below 10% of normal, hyperglycemia and ketosis
develop.
A large part of what is known about IDDM comes from studies of animal model
systems, in particular the non-obese diabetic (NOD) mouse. The NOD mouse possesses
most of the characteristics of human IDDM, such as genetic predisposition due to MHC
II linkage, development of insulitis with infiltration of T lymphocytes selectively toxic to
insulin-producing beta cells, and humoral reactivity to beta cells (for a review see
Bowman et al, 1994). However, unlike humans, NOD mice have a strong gender bias in
the appearance of the disease: 91% of females NOD/Lt mice manifest diabetes at
250 days of age, while only 21% of males show a similar symptom at that age (Baxter
et al, 1991).
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Studies of NOD mice (Kaufman et al, 1993; Tisch et al, 1993) and patients
(Baekkeskov et al, 1990) indicate that the GAD protein is a major autoantigen
recognized during the onset of IDDM. GAD is an enzyme found mostly in neurons
(Erlander et al, 1991) and pancreatic islet cells (Christgau et al, 1991), where it
catalyzes the synthesis of gamma-aminobutyric acid (GABA). GABA is an inhibitory
neurotransmitter in the central nervous system, and may be a paracrine signaling
molecule in the pancreas. Two forms of GAD are encoded by different genes in
mammals: a 65 kDa (previously called 64) and a 67 kDa (previously called 65) molecular
weight form. GAD65 is a membrane-anchored intracellular protein, while GAD67 is
found soluble in the cytosol (Christgau et al, 1991; Christgau et al, 1992). Both GAD65
and GAD67 are recognized by the immune system of IDDM patients (Baekkeskov et al,
1990; Honeyman et al, 1993). In addition, the first T cell response against beta cell
antigens in 4-week old NOD mice is against GAD65 (Kaufman et al, 1993;Tisch et al,
1993), and both CD8+ cytotoxic (Panina-Bordignon et al, 1995) and CD4+ T helperl
(Thl) (Tabata et al, 1998) lymphocytes specific for GAD65 can be found in patients
suffering from IDDM. Together with the finding that adoptive transfer of GAD-reactive
T cells can cause diabetes in NOD/SCID mice (Zekzer et al, 1998), these observations
strongly indicate that GAD65 plays an important role as an autoantigen during onset of
IDDM.
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The NOD mouse serves not only as a model to study IDDM, it is also an excellent
system for the development of new methods for preventive therapy of this form of
diabetes. Such therapies include immunosuppression, immunostimulation, tolerance
induction, manipulation of hormonal/dietary milieu, and anti-inflammatory agents
(Bowman et al, 1994). In this work, we have investigated whether gene vaccination
could be used to prevent insulitis in the NOD mouse. Specifically, we have used
intramuscular injection of “naked” plasmid DNA encoding human GAD65 and SGAD55,
an engineered secreted form of this protein. We report that injection of DNA encoding
these proteins resulted in significant decreases in insulitis, suggesting the possibility that
this form of gene therapy might be useful to prevent clinical manifestation of IDDM.

Results
Construction of a secretedform of human GAD65
Extracellular antigens can be used for tolerization or for suppression of MHC
class II restricted Thl inflammatory response, probably through a MHC class II restricted
CD4+ Th2 lymphocyte response, as Thl and Th2 responses appear to be mutually
exclusive (Mosmann and Sad, 1996). Therefore, two genes encoding GAD proteins that
had the potential of being secreted by mammalian cells were constructed.
The first construct consisted of the leader peptide from human interleukin-2 (IL-2)
protein fused to full-length human GAD65, generating a fusion protein encoded by the
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sgad65 gene. This leader sequence was previously shown to cause secretion by
mammalian cells of normally intracellular proteins (Okano et al, 1990; Liu et al, 1997).
However, because GAD65 is a membrane-anchored protein, the protein region
responsible for the anchoring could have interfered with secretion. The sequence
corresponding to approximately the first 100 amino acids (aa) of human GAD65 contains
a Golgi-targeting sequence (Solimena et al, 1994), as well as cysteine residues that are
palmitoylated and responsible for membrane anchoring (Christgau et al, 1992). In
addition, this sequence is not recognized by autoantibodies from IDDM patients (Richter
et al, 1993). The first 88 aa of the human GAD65 protein were therefore deleted, and the
remainder of the protein was fused to the IL-2 leader sequence, generating a fusion
protein (SGAD55) encoded by the sgad55 gene (Fig. 1 B).
Simian COS-7 cells were transiently transfected with the two gene constructs
coding for these proteins, and immunoblot analysis of intracellular GAD protein was
performed using a monoclonal human GAD65 antibody. Results confirmed the synthesis
of SGAD65 (Fig. 2 A, lane 3), and of the lower molecular weight SGAD55 (Fig. 2 A,
lane 4). To determine whether SGAD65 and SGAD55 were secreted by mammalian
cells, proteins from COS-7 cells transiently transfected with the different gene constructs
were labeled in vivo with 35S-methionine. Culture media from these cells were then used
for immunoprecipitation using the same antibody used for immunoblot analysis, and
immunoprecipitates were fractionated using sodium dodecyl sulfate polyacrylamide gel
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electrophoresis (SDS-PAGE). Results showed that SGAD55 protein was
immunoprecipitated from cell culture media (Fig. 2 B, lane 3). In contrast, no secreted
SGAD65 protein could be detected (Fig. 2 B, lane 4). The gene construct sgad55 was
therefore selected for further use in animal experiments.

Effects of intramuscular injection of GAD-encoding genes on insulitis and cytokine
profde
Each of four groups of three-week old female NOD mice received injections of
one of four plasmid DNAs, and injections were repeated after three days. Mice were
injected with either plasmid vector only, plasmid vector carrying gene sruc3 encoding a
stable mutant (JL and AE, unpublished data) of a secreted soft coral luciferase (Liu et al,
1997), the human gad65 gene, or the sgad55 gene encoding secreted GAD protein. The
sruc3 gene was used as control for possible non-specific effects of synthesis of a plasmidencoded antigen on insulitis. Another group of NOD mice was used as a non-injected
control (N.B. this group was kept in a different animal room at Loma Linda University,
and at a different time).
Mice were killed when 10 weeks old for histopathological analysis, insulitis
scoring, and immune assay. None of the mice had developed diabetes, as determined by
urine and blood glucose analysis (data not shown). Figure 3 shows representative islets
illustrating the levels of insulitis that were observed. Figure 4A shows that a significant
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reduction in the severity of insulitis was detected in mice receiving injections of plasmids
carrying the gad65 and sgad55 genes, when compared to the three control groups. In
addition, mice injected with these gad genes also had a higher percentage of insulitis-free
islets (Fig. 4B). Cytokine profiles of GAD65-stimulated spleen lymphocytes
(splenocytes) tended to support the histological findings. While the Thl-type cytokines
(IFNa and IL-2) were not different between groups (Fig. 5 A and B), IL-4 production
(Th2-type) was higher in the gene-vaccinated groups (Fig. 5 C, 3 and 4) than in the
controls (Fig. 5 C, 1 and 2), when challenged in vitro with recombinant human GAD65
protein.

Discussion
Gene vaccination consists of the introduction and expression of a gene into an
organism, with the purpose of generating an immune response against its encoded
product. The simplest way of achieving this purpose is to use the method of
intramuscular or subcutaneous “naked” DNA injection, originally presented as a means of
expressing plasmid-encoded genes after direct injection of DNA into mouse muscle
(Wolff et al, 1990). This method has since been used to generate immune responses to a
wide variety of antigens, such as human immunodefficiency virus 1 glycoproteins, and
malarial circumsporozoite protein (for a review see Tighe et al, 1998). Although the
majority of studies have focused on infectious diseases, “naked” DNA gene vaccination
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can also be applied to studies of alloimmunity (Geissler et al, 1994) and treatment of
cancer (Condon et al, 1996). Recently, gene vaccination was used to suppress the
symptoms of autoimmune encephalomyelitis in rats through synthesis of an autoantigenic
peptide (Lobell et al, 1998).
Glutamic acid decarboxylase (GAD) is thought to be a major autoantigen
contributing to the onset of insulin-dependent diabetes mellitus (IDDM), and injection of
GAD protein can delay the onset of the disease in NOD mice (Kaufman et al, 1993;
Tisch et al, 1993; Elliot et al, 1994; Petersen et al, 1994; Sai et al, 1996). In addition,
similar results are obtained with oral feeding of the protein (Ma et al, 1997; Ramiya
et al, 1997). In this work, we investigated whether expression of genes encoding two
forms of human GAD could cause reduction of insulitis in the NOD mouse, an
inflammation of pancreatic islets which is characteristic of IDDM in this model.
Two gad genes were used for expression in muscle tissue: a gad65 cDNA
encoding human GAD65 protein, and sgad55, a gene construct based on gad65, encoding
the interleukin-2 (IL-2) leader sequence fused to a GAD65 protein lacking its first
88 amino acids (SGAD55) (Fig. 1). The N-terminal region of GAD65 was removed in
the SGAD5 5 fusion protein because we suspected that it could interfere with its secretion,
since this region contains a Golgi-targeting and membrane-anchoring sequence. This was
confirmed by the finding that a fusion of the IL-2 leader sequence to full-length GAD65
could not be detected in the culture media of mammalian cells expressing its encoding
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gene (Figure 2B, lane 4). In contrast, SGAD55 protein was detected in culture media of
cells expressing the sgad55 gene (Fig. 2B, lane 3).
Intracellular and secreted forms of GAD65 were used in this study because of the
known differences in the type of immune response that intra- and extra-cellular antigens
can generate: intracellular antigens are presented by MHC class I molecules and generate
a CD8+ cytotoxic T lymphocyte response, while extracellular antigens are presented by
MHC class II molecules on the surface of antigen presenting cells, generating a CD4
helper T lymphocyte response (Tighe et al, 1998). Although secreted proteins are
synthesized within a cell, they appear to be less likely to be presented by MHC class I
molecules than cytosolic proteins (Yewdell et al, 1998).
Synthesis of intracellular GAD65 by muscle cells was not expected to affect
insulitis. Considering the small number of muscle cells able to express injected genes, the
levels of intracellular GAD65 protein found in injected and non-injected mice NOD
should not have differed greatly enough to generate an immune response influencing T
cell infiltration of islets. This supposition was corroborated by the finding that in NOD
mice transgenic for murine gad65, only those mice showing the highest levels of
transgene expression could exacerbate insulitis and diabetes (Geng et al, 1998). In
contrast, secretion of SGAD55 could have caused either reduced insulitis (through an
anti-inflammatory Th2 response) or increased insulitis (through an inflammatory Thl
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response), depending on the levels of extracellular antigens attained (Hosken et al,
1995).
Our results show that injections of gaddJ-carrying plasmids caused a reduction of
insulitis similar, if not greater, to that resulting from injections of sgadiJ-carrying
plasmid (Fig. 4). A variety of non-exclusive mechanisms are thought to lead to Thl and
Th2 immune responses after plasmid DNA injection, such as release of antigens from
intact cells expressing the plasmid-carried gene, or from lysed cells after a cytotoxic T
lymphocyte response, and direct transfection of antigen presenting cells (Davis et al,
1993; Xiang e? a/., 1994; Condon e/a/., 1996; Gregoriadis ^ a/., 1997). Our results
suggest that one (or both) of the latter two putative mechanisms was likely to be
responsible for the similar reduction of insulitis after intramuscular injection of gad65 or
sgad55 gene, since neither the intra- nor extra-cellular nature of the plasmid-encoded
GAD antigens appeared to affect the extent of insulitis differently.
To determine the nature of the immune response generated in plasmid-treated
NOD mice, cytokine secretion by splenocyte was measured after challenge with
recombinant human GAD65 protein. Splenocytes of all plasmid-injected mice secreted
similar levels of Thl-specific IFNa (Fig. 5A) and IL-2 (Fig. 5 B). However, cells from
mice receiving injections of gad65 or sgad55 genes maintained higher levels of Th2specific IL-4 than the controls when challenged with GAD65 autoantigen (Fig. 5 C).
No differences in splenic memory cell numbers (immunophenotyping) or blood levels of
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cytokines could be demonstrated between groups (data not shown). These results suggest
that the reduced levels of insulitis observed after injection of gad65 or sgad55 genes
could have been the result of a Th2-mediated response. This would be in accordance
with the observation that suppression of insulitis is associated with elevated synthesis of
IL-4 and IL-10 (for a review see Rabinovitch, 1998), and that suppression of the
diabetogenic response in NOD mice after injection of GAD65 protein is mediated by the
induction of GAD65-specific regulatory Th 2 cells (Tisch et al., 1998). Failure to detect
systemic changes in circulating cytokine levels (IFNa 75-1365 pg/mL) and splenic
phenotypes (13-15% CD62Lneg CD44pos T helper cells) was expected in light of the wellestablished organ-specificity of this disease. Further work on the cellular infiltrate should
reveal more relevant information.
Immunomodulatory gene therapy has been previously considered as a possible
approach for the prevention of IDDM. In one study, islet-specific Thl cells transduced
with engineered retroviruses carrying a gene encoding the anti-inflammatory cytokine
IL-10 was able to cause reduced insulitis and delayed onset of diabetes when injected into
NOD mice (Moritani et al, 1996). In contrast, intramuscular injection of plasmid DNA
encoding IL-10 did not cause reduced insulitis, but did result in delay of diabetes onset
(Nitta et al, 1998). In another study, intramuscular injection of DNA encoding TGF-pl
caused both reduced insulitis and delayed onset of diabetes (Piccirillo et al, 1998). Our
data suggest that intramuscular injection of DNA coding for an IDDM autoantigen could
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also be used for this purpose. Plasmid injection offers potentially both therapeutic and
economical advantages. Injection of plasmid DNA could permit the development of
plasmid “cocktails” encoding combinations of different autoantigens and
immunomodulating cytokines. When compared to injection of isolated proteins, the
availability, quality, and cost of these therapeutic proteins would not be a concern, since
their synthesis would occur within the host. Clearly, injection of plasmid DNA is a
promising approach for suppressing symptoms of IDDM or other autoimmune diseases in
the future.

Materials and Methods
Gene and plasmid construction
The sgad65 gene encodes a fusion of the leader peptide from human IL-2 to fulllength human GAD65 protein. This gene was constructed by ligating an 89 base pair (bp)
DNA fragment encoding the first 23 amino acids of IL-2 (isolated previously by PCR
from human cell line A293 as described by Liu et al., 1997) in frame with a 1.8 Kilobase
pair (Kb) Ncol-Xhol DNA fragment carrying a human GAD65 cDNA. The sgad55 gene
encodes a fusion of the leader peptide from human IL-2 to a truncated version of human
GAD65 with 88 aa deleted at its N-terminus. Two oligonucleotides were used to amplify
the 89 bp DNA fragment encoding the IL-2 leader peptide from gene sgad65, IL-01
(TTT TCT AGA ATG TAC AGG ATG CAA CTC CTG) and IL-03 (TTT ACG CGT
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AAG TAG GTG CAC TGT TTG TGA). IL-03 introduced a Mlu\ site which was used to
clone the PCR product in frame with the Mlul-Xhol 1.5 Kb DNA fragment encoding
GAD55, the truncated version of human GAD65. The identity of PCR products and
gene fusion junctions were confirmed using automated DNA sequencing.
For cell culture work, the gad65, sgad65, and sgad55 genes were cloned under
transcriptional control of the cytomegalovirus (CMV) promoter into plasmid vector
pLNCX (Miller and Rosman, 1989). For muscle injection, all genes were cloned under
transcriptional control of the CMV promoter in plasmid PND2, a vector known to
provide high gene expression in muscle tissues (Gary Rhodes and Robert Malone,
unpublished data).

Mammalian cell culture and transfection
Simian COS-7 cells were grown in 60 mm tissue culture dishes containing 3 ml
DMEM medium with 10% fetal bovine serum (FBS). Media were changed 3 hrs prior to
transfection when cells were 70% confluent. Cell transfection was performed using the
ProFection calcium phosphate system (Promega, Madison, WI) using 40 ug of plasmid
DNA per plate. Cells were incubated with the DNA-calcium phosphate complex for
6 hours, washed twice with phosphate-buffered saline (PBS), and 3 ml DMEM medium
+10% FBS was added into each plate. Culture plates were then incubated for 48 hours
before harvesting cells and media for analysis.
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Immunoblot analysis
Simian COS-7 cells were washed twice with cold PBS 48 hrs after transfection,
and harvested in 100 jil hot 2x gel-loading buffer (lOOmM Tric.HCl, 4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.01% bromophenol blue) using a rubber
policeman. Cells were lysed by sonication, boiled for 3 min, and lysates were centrifuged
at 1000 x g for 10 min to pellet cell debris. Twenty microliters from each sample was
loaded on a 12% SDS-polyacrylamide gel for fractionation. Proteins were then
transferred onto a nylon membrane by electroblotting, and a GAD65 monoclonal
antibody was used to detected GAD protein using a method previously described
(Lmetal, 1997).

Protein radiolabeling and immunoprecipitation
To detect secreted GAD proteins in cell culture media, 35S-methionine (specific
activity>1000 Ci/mmol, from DuPont NEN, Boston, MA) was used to label total cell
protein from COS-7 cells. Media were removed after incubation with the DNA-calcium
phosphate complex, and cells were rinsed twice with 1 x PBS and once with medium
without methionine and serum. Cells were then incubated in 3 mL DMEM medium
without methionine + 1% dialyzed FBS for 20 min to deplete intracellular pools of
endogenous methionine. One hundred microcuries of 35S-methionine was then added
directly into media for protein labeling. Cells were incubated for 24 hours before being
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harvested. Media were collected and concentrated using a Centricon spin column
(15 kDa molecular weight cut-off, from Amicon) to a final volume of 500 ul. 35S-labeled
GAD protein was immunoprecipitated from media using the Protein A
Immunoprecipitation Kit (Boehringer Mannheim, Indianapolis, IN) and a monoclonal
antibody raised against human GAD65. Immunoprecipitates were fractionated in a
12% SDS-polyacrylamide gel, and protein bands were detected by exposure to X-ray
film.

Isolation ofplasmid DNA for muscle injection
Plasmid DNA was amplified in Escherichia coli strain DH5a, using the alkalinelysis method, and isolated by standard double-round cesium chloride purification
(Maniatis et al, 1989). The quality and quantity of DNA was determined by UV
spectrophotometer (A260/A280 ratio greater than 1.8) and by agarose gel electrophoresis.
Plasmid DNA was dissolved under sterile conditions in double distilled water at a final
concentration of 2 ug/ul, and stored at -20°C.

Intramuscular DNA injection
Three-week old female NOD mice were purchased from Taconic Laboratories
(Germantown, NY) and kept at Loma Linda University animal facilities. Mice were
injected with DNA (200 pg/100 pl/leg) into each quadriceps muscle with a 27-gauge
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needle under general anaesthesia (Ketamine, 66 mg/Kg body weight, from Phoenix
Scientific, Sl Joseph, MO; Oxylazine, 7.5 mg/Kg body weight, from LLOYD
Laboratories, Shenandoa, 10; and Acepromazine Maleate, 1.5 mg/Kg body weight, from
Fermenta Animal Health Co., MO), and injections were repeated three days later. Urine
glucose levels were monitored weekly with Clinistix Reagent Strips for Urinalysis
(Bayer Corporation, Elkhart, IN). Mice were killed for insulitis scoring at the age of
10 weeks, and blood glucose levels were checked with ACC.-CHEK Advantage
(Boehringer Mannheim Corporation, Indianapolis, IN).

Histopathological analysis of insulitis
Pancreatic tissues were fixed with 10% buffered Formalin, stained with
hematoxylin, and counterstained with eosin, and an average of fifteen islets/mouse were
scored. A 7-level semi-quantitative scoring scale (Zhang et ah, 1991) was used for
insulitis scoring: 0, normal islet tissue without any detectable T cell infiltration; 1, focal
peri-islet T cell infiltration with less than one-third of the peri-islet area; 2, more
extensive peri-islet T cell infiltration with less than two-thirds of the peri-islet area;
3 peri-islet T cell infiltration with more than two-thirds of the peri-islet area; 4, intra-islet
T cell infiltration with less than one-third of the islet area; 5, intra-islet T cell infiltration
with less than two-thirds of the islet area; 6, severe intra-islet T cell infiltration with more
than two-thirds of the islet area. Scoring of 1-3 indicated peri-insulitis, and scoring of
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4-6 indicated intra-insulitis. Scoring was conducted using the double-blind method by
two different scorer.

In vitro challenge of splenocytes
Lymphocytes were flushed from splenic pulp and washed in complete media
(RPMI, 10% FBS, P/S, 2% L-Glutamine, and 4 x 10'5 M 2-mercaptoethanol). In a
24-well plate, 1x106 cells in 1 mL complete media (unstimulated control) or 1 mL
GAD65 (1.5 ug/ml) were cultured (37°C, 5% C02) for 72 hrs. Cell culture supernatants
and blood plasma (from terminal bleeds) were assayed by standard sandwich ELISA
(Endogen, Woburn, MA) for IFNa, IL-2 and IL-4.

Immunophenotyping ofsplenocytes
Since antigen-specific memory cells of the Thl-type T lymphocytes express
CD44 and lose expression of CD62 ligand (CD62L) (Mocci and Coffman, 1997; Bradley
et al, 1992), splenocytes were stained with three fluorochrome-conjugated monoclonal
antibodies (Becton Dickinson, Immunocytochemistry Systems, San Jose, CA) to CD4,
CD44 and CD62L. After red cells lysis, the phenotypes were analyzed by 3-color flow
cytometry. Phenotyping controls included untreated (autofluorescence) and isotype
antibody-treated cells (nonspecific staining). CD4 T cells (phycoerythrin) were backgated and these were analyzed for the expression of CD44 (PerCP) and CD62L (FITC).
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Statistical analysis
Comparison between groups was done using a ONE-WAY ANOVA and Duncans
post-hoc test for multiple comparisons.
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Figure 1. Partial gene constructs used for intramuscular DNA injection. Three genes
were placed under transcriptional control of the cytomegalovirus promoter (CMV) into an
expression plasmid: gad65, encoding a wild type intracellular human GAD65 protein (A),
sgad55, encoding a fusion of the IL-2 leader peptide (IL2-LP) to a truncated human
GAD65 protein (B), and sruc3, encoding a secreted Renilla luciferase (C).
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Figure 2. Detection of GAD proteins from lysates (A) and culture media (B) of
mammalian cells grown in vitro. A. Immunoblot analysis of simian COS-7 cells
transiently transfected with different gad genes. Cells were transfected with plasmid
vector only (lane 1), plasmid carrying genes gad65 (lane 2), sgad65 (lane 3), or sgad55
(lane 4). Lane 5 contains a truncated version of GAD65 isolated from Escherichia coli as
control. Total cells lysates were fractioned using SDS-PAGE, transferred onto a
membrane, and reacted with a mouse monoclonal antibody raised against wild-type
human GAD65, and subsequently to a secondary antibody bound to alkaline phosphatase
for chemiluminescent detection. B. Immunoprecipitation of 35S-Methionine-labeled
proteins from culture media. Culture media from COS-7 cells transiently transfected with
plasmid vector only (lane 1), plasmid carrying gene gad65 (lane 2), sgad55 (lane 3), or
sgad65 (lane 4) were used for immunoprecipitation using the same antibody used in A.
Immunoprecipitates were then fractionated using SDS-PAGE and exposed to X-ray film.
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Figure 3. Histopathological examination of pancreatic islets. Islets with score 0 (A), and
3 (B) from a GAD65-treated mouse are shown for comparison with islets with score 5
(C) and 6 (D) from a control animal. Arrows point to T cell infiltration.
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Figure 4. Insulitis scores of 10-week old female NOD mice. Severity of insulitis is
presented based on a 0-7 scoring scale (A), and as percentage of islets showing intra-,
peri-, or no insulitis (B). Insulitis was scored with untreated mice (group 1, n=5), mice
receiving injections of plasmid vector only (group 2, n=5), or vector carrying gene sruc3
(group 3, n= 6), gene gad65 (group 4, n=7), or gene sgad55 (group 5, n=7). Data are
presented as the mean score +- SEM. When individually compared to control groups 1
(*),2(* *), or 3 ( * * * ), group 4 or 5 showed statistically significant differences (P value
<0.05). No statistically significant differences were found among groups 1, 2, 3, or
groups 4 and 5.
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Figure 5. Cytokine profile of GAD65 protein-stimulated splenocytes. Splenocytes from
mice receiving injections with plasmid vector only (1), or plasmid carrying the sruc3 (2),
gad65 (3), or sgad55 (4) genes were stimulated with 1.5 ug/ml of isolated recombinant
human GAD65 protein. After 72 hours, culture supernates were assayed for IFNa (A),
IL-2 (B), and IL-4 (C).

CHAPTER EIGHT
CONCLUSION
In this work, proteins have been engineered for secretion to develop a non
destructive marker for monitoring gene activity in a biological system both in vitro and in
vivo, and to investigate whether DNA vaccination with plasmid DNA encoding a secreted
protein can be used to treat an autoimmune disease.
The development of reporter genes, especially those encoding light-catalyzing
proteins involved in chemiluminescence (CL) and bioluminescence (BL), has greatly
enhanced our ability to monitor the transcriptional activity of cloned promoter sequences
after their introduction into target cells or organs. Although the activity and amount of
reporter gene products are an indirect measurement of the transcriptional properties of the
test DNA, it is generally considered that reporter gene activity is directly proportional to
transcriptional activity (Alam and Cook, 1990).
Chemiluminescent marker proteins such as (3-galactosidase were among the first
reporter proteins to be utilized to monitor gene expression (Edlund et al, 1985).
However, bioluminescent reporter proteins have become the most commonly used ones
in recent years. Bioluminescent marker proteins are enzymes (luciferase) catalyzing the
light emission reaction, or light-emitting photoproteins (Kricka, 1991). The overall
quantum yield of a chemiluminescent reaction (the number of photons emitted vs number
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of molecules reacting) is generally in the range 1-10%, whereas for bioluminescent
reactions the yields are higher, typically in the range 10-30% (Kricka, 1991). Due to this
reason, bioluminescent reactions are considered more sensitive than chemiluminescent
reactions (Kricka, 1991).
Compared to traditional reporter proteins, bioluminescent reporter proteins
provide a more sensitive, rapid, and simple assay for analyzing regulation of gene
expression. However, the most commonly used bioluminescent reporter proteins are
intracellular proteins, and can only allow for a single assay with one sample. Secreted
bioluminescent reporter proteins could overcome this problem and permit continuous
assay on the same sample over a period of time without cell disruption. Several secreted
reporter proteins have been developed for this purpose, but each one has its own
shortcoming. For example, secreted alkaline phosphatase (SEAP) has high in vivo
background, the secreted GFP assay has low sensitivity, and the price for substrate for
naturally secreted Vargula luciferase is too high (about $2,000/mg vs $90/mg for Renilla
luciferase substrate as sold by Prolume Inc., Pittsburgh, PA). Because no reporter protein
can be universally applied to all conditions, it would be useful to develop a new secreted
bioluminescent reporter protein. Firefly luciferase, the most commonly used reporter
protein, is not functional after being fused with signal peptide from insulin for secretion
(Pouli et al., 1998). In addition, bacterial luciferase can not be secreted either (Alan
Escher, personal communication). Renilla luciferase, an intracellular enzyme catalyzing
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a light-emitting reaction in the sea pansy Renilla reniformis, has been previously used as
a gene expression marker (Lorenz et al., 1991; Srikantha et al., 1996; Lorenz et al.,
1996), and was selected in this project to be engineered for secretion.
A functional secreted Renilla luciferase (SRUC) was engineered after fusing with
human IL-2 leader sequence encoding a signal peptide (Figure L, Chapter Three). Data
from the Renilla luciferase assays showed that luciferase activity could only be detected
from the culture media of cells transfected with gene encoding SRUC, but not from the
cells transfected with gene encoding wild type Renilla luciferase. No morphology change
or increased cell death was observed on cultured cells after transfection, so it was unlikely
that the luciferase activity detected in culture medium was from cell lysis. The
immunoblot analysis following immunoprecipitation on culture medium directly revealed
the presence of secreted Renilla luciferase.
After generating a secreted form of Renilla luciferase, we went on to engineer
another secreted gene expression marker. This marker was a secreted Renilla luciferaseGFP (SRUC-GFP) fusion protein (Figure L, Chapter Four). It has been shown that
Renilla luciferase and GFP could work as a dual marker system (Wang et al., 1997). The
secreted Renilla luciferase-GFP fusion provides a unique way to monitor gene regulation:
GFP fluorescent signal can be used to visualize the in vivo protein trafficking, and Renilla
luciferase assay can be used to quantify this process. The SRUC-GFP also indicated that
Renilla luciferase not only can be secreted as a single protein, it can also be secreted as
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part of a chimeric protein. This finding is important for future use of SRUC as an in vivo
marker of extracellular protein translocation: SRUC could be fused to a protein of interest
to identify organs targeted by this protein within an animal.
During the development of secreted Renilla luciferase, the secreted luciferase
activity could not be detected from culture medium under undefined cell growth
conditions. Immunoblot analysis revealed that protein aggregation of secreted protein
caused the absence of secreted luciferase in the medium. This phenomenon led to the
hypothesis that the odd number of cysteine residues (there are three of them in native
Renilla luciferase) could have facilitated the formation of intermolecular disulfide bond,
and may have affected protein stability and rate of protein secretion. Using site-directed
mutagenesis to replace cysteine with alanine, four mutated SRUC genes were generated
(Figure 1, Chapter Five). Mutant SRUC3 showed dramatically increased protein signal
from both cell lysates and cell culture medium. Compared to the original SRUC, the
sensitivity of Renilla luciferase assay of SRUC3 in culture medium was increased up to
100 fold after 48 hours. Data showed that SRUC3 was more stable than the original
SRUC in culture medium (84 hours half-life for SURC3 compared to 14 hours for
SRUC). However, improved protein stability itself could not account for the 100-fold
increase of protein assay. Other changed properties, such as increased protein secretion
rate, or increased protein enzymatic activity, may also have contributed to the increase in
light emission.
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Compared to another commonly used secreted marker, SEAP, the sensitivity of
the SRUC assay is much lower (Liu et al., 1998). However, the Renilla luciferase assay
is much less time-consuming, and is sensitive enough to be used in many experiments
(Inouye and Shimonura, 1997).
Because our goal is to develop a secreted bioluminescent marker for animal
studies, we transferred genes encoding wild type Renilla luciferase and SRUC3 into
BALB/c mice using intramuscular plasmid injection to determine whether Renilla
luciferase could be used as an in situ marker. Two other commonly used reporter genes,
encoding firefly luciferase and SEAP, were also used in this experiment for comparison
with Renilla luciferase. Data showed that both intracellular and secreted Renilla
luciferase signals were easily detected in muscles tissues within 24 hours after injection,
and the sensitivity of Renilla luciferase assay was within the range of that from firefly
luciferase (intracellular protein) and SEAP (secreted protein). Unlike SEAP, Renilla
luciferase assay showed low in vivo background. However, a secreted Renilla luciferase
signal could not be detected either in whole blood or serum from mice. Data from in
vitro whole muscle tissues culture experiment showed that SRUC3 was expressed and
secreted by muscle cells at very low levels (Figure 4., Chapter Six). Therefore, more
modifications need to be made to further improve SRUC3 before it can be used as a
secreted gene expression marker in animals.
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The secreted Renilla luciferase assay could be improved in several ways.
Improving gene expression and/or protein production levels in muscle cells or other
possible target organs should increase the sensitivity of the Renilla assay. It was
reported that gene expression level of GFP could be increased by changing codon usage
(Zolotukhin et al, 1996), and we are currently conducting a similar approach to increase
the gene expression levels of Renilla luciferase. Beside intramuscular DNA injection,
other gene transfer techniques, such as cell encapsulation, may be an alternative way to
deliver srucS gene into animal model with higher levels of protein secretion.
Encapsulated cells expressing the sruc3 gene may provide higher gene expression and
protein production levels for a longer period of time, since cells encapsulated with an
immunoisolation shell may evade host immune system and avoid the destruction of cells
carrying the gene of interest (Josephs et al., 1999).
It was shown that replacing one amino acid (cysteine to alanine at amino acid
No. 152) could dramatically improve the stability of Renilla luciferase protein in cell
lysate and in cell culture medium (Chapter Five). If knowledge of the 3-D protein
structure of Renilla luciferase were available, we could further modify Renilla luciferase
to improve its enzymatic activity or protein secretion rate, and therefore increase the
sensitivity of the Renilla assay. Finding the optimal substrate for Renilla luciferase is
also important. It was reported that as many as 23 different coelenterazine analogues can
be used as substrate for the Renilla luciferase assay. The e-coelenterazine and u-
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coelenterazine are the most efficient substrate for Renilla luciferase (Inouye and
Shimonura, 1997), but highly unstable (Molecular Probe Inc., personal communication).
Developing more sensitive luminometer would be another means of improving the
secreted Renilla luciferase assay. In summary, a promising gene expression marker,
secreted Renilla luciferase, was developed in this work. With further modification, it
may be applied for future in vivo studies.
Another aspect of this project was to determine whether DNA vaccination using
plasmid DNA encoding an autoantigen could be used to treat an autoimmune disease.
Insulin-dependent diabetes mellitus (IDDM) was selected as a disease model in this work.
IDDM is caused by the progressive autoimmune destruction of insulin-producing
pancreatic (3 cells (Rabinovitch, 1994). Although the precise mechanism of development
of type I diabetes in human and NOD mice remains unclear, it is believed that the
presentation of p cell-specific antigens by macrophages and/or dendritic cells to CD4+ T
helper cells is the first step in the development of autoimmune IDDM. The activated
macrophages secrete IL-12, which stimulates the Thl cell subset. The activation of Thl
cells will induce cell-mediated immune response against pancreatic cells, and at the same
time downregulate the Th2 cell subset. Activated Thl cells secrete IL-2 and IFN-y,
which activate other resting macrophages to release cytokine and free radicals that are
toxic to p cells. During this process, IL-2 and other cytokines induce the migration of
CD8+ peripheral T cells to the inflamed islets by inducing the expression of a specific
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receptor. The infiltration of T helper cells, macrophages, and CTL into pancreatic islets
finally causes insulitis. The combination of macrophages, CD4+ T cells, and CD8+ T
cells destroys pancreatic p cells synergistically (Yoon et al., 1997).
Despite progresses made during the last decade, IDDM still remains a disease
without a cure. Diabetic patients need daily insulin injection to stay alive. The
implantation of pancreatic islet cells was thought to be able to cure type I diabetes, but
limited donor availability, host immune attack, and high cost make it difficult for it to be
widely applied to diabetic patients (Lacy, 1995; Efrat, 1998). Another potentially
attractive approach for patients who have already developed diabetes is p-cell
regeneration from islet cell precursors. However, this approach depends on the
identification of factors that induce P-cell neogenesis and replication as well as on the
development of ways to prevent recurring autoimmunity against the newly formed islets,
and is not considered to be clinically applicable any time soon (Efrat, 1998). Delivery of
recombinant insulin from encapsulated pancreatic islet should result in higher cell
survival rate and longer insulin production/secretion level (Peterson et al, 1998).
However, this approach is time-consuming and fairly expensive at this moment (Josephs
et al, 1999). Oral tolerance, defined as the delivery of specific autoantigens orally to
induce host immune tolerance, has been used to treat type I diabetes in animal model
(Hutchings and Cooke, 1998). The mechanisms of oral tolerance are not completely
understood. It appears that several outcomes can occur depending on the amount of
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antigen administered: with high-dose antigen treatment, T cells clonal deletion or anergy
occurs; with low-dose antigen treatment, active suppression happens (Seroogy and
Fathman, 1998). Since it is difficult to control gene expression levels after transferring
genes encoding antigens of interest in vivo, and therefore hard to control the amount of
antigen presented to host immune system, oral immune tolerance does not seem to be the
best approach for the treatment of autoimmune disease.
The best strategy to treat IDDM is to prevent the development of disease before
its onset. Recently, gene therapy strategies have been applied to the treatment of
autoimmune diseases, and organ-specific type I diabetes is a good disease model for gene
therapy approaches (Mathisen and Touhy, 1998). Because IDDM is a T-cell-mediated
autoimmune reaction, and the Thl/Th2 cell balance seems to be crucial during the
development of diabetes, most gene therapy approaches focus on activating Th2 cell and
suppressing Thl cells to reduce T-cell mediated immune attack on pancreatic islet cells
(Rabinovitch, 1994). Most of those approaches can be grouped into two categories:
cytokine gene therapy, and DNA vaccination (Efrat, 1998; Seroogy and Fathman, 1998;
Mathisen and Touhy, 1998).
Since cytokines are crucial during the development of IDDM, it is rational to
think that overexpression of anti-inflammatory cytokine should have protective effects on
IDDM. Genes encoding several cytokines have been delivered into animal model for
diabetes through somatic gene delivery or transgenic approach. However, the results
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were variable. Expression of anti-inflammatory cytokines such as TGF-pl and IL-4, have
been shown to prevent IDDM in NOD mice (Piccirillo et al, 1998; Ridgway et al.,
1994), and expression of IL-4, IL-10, IFN-p, and TGF-P were able to inhibit experimental
allergic encephalomyelitis, another autoimmune disease (Croxford, et al., 1998). On the
other hand, the transgene expression of IL-10, an anti-inflammatory cytokine, resulted in
an accelerated onset of clinical diabetes accompanies by severe pancreatic inflammation
in NOD mice (Lee et al, 1994; Wogensen et al, 1994). One major drawback of
cytokine gene therapy is that the production of cytokine is not antigen-specific, and with
the current understanding of the cytokine network, the appropriate levels of expression
for optimal efficacy are unknown and are difficult to be tightly regulated (Croxford et al.
1998). Thus, cytokine therapy approach may not be the best answer for IDDM.
The ideal approach to treat IDDM should be one that can provoke antigen-specific
host immune response and either induce immune tolerance or suppress autoimmune
attack on specific organs. Several autoantigens, such as insulin and GAD65, are the ideal
targets to generate specific immune response. Purified GAD65 protein has been injected
into NOD mice and showed protective effect on insulitis and diabetes (Tisch et al, 1993;
Kaufman et al, 1993). It is believed that active suppression after protein injection
leaded to this protective effect (Tisch et al, 1998). Transgenic expression of mouse
proinsulin II also prevented diabetes in NOD mice (French et al, 1996). However, a
transgenic approach is not applicable for clinical trial, and protein injection therapy of
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autoantigen has many drawbacks, such as contamination of endotoxin, limited
availability, and high cost. DNA vaccination would be an ideal approach to deliver
autoantigen into a host to provoke immune responses.
DNA vaccination is defined as direct administration of plasmid DNA encoding
antigen(s) specific to a particular pathogen into vaccine recipient (Cohen et al., 1998).
Compared with other vaccination methods, DNA vaccination can provoke host specific
immune responses with defined synthesis of antigen(s) and without virus or endotoxin
contamination. Both humoral and cell-mediated immune responses can be generated with
DNA vaccination, and it has been applied to treat a wide variety of genetic and infectious
diseases during recent years (Cohen et al., 1998). Recently, DNA vaccination was
applied to the treatment of an autoimmune disease, experimental autoimmune
encephalomyelitis (Youssef et al., 1997).
In this project, the use of DNA vaccination for preventing IDDM in NOD mice
was investigated. Plasmid DNA encoding a major autoimmune antigen, GAD65, was
directly injected into three-week-old NOD mice to induce Th2 cell subset mediated
humoral response to actively suppress the development of diabetes. However, it was
suspected that vaccination with plasmid DNA encoding the membrane-anchored GAD65
protein might not able to achieve this goal because DNA vaccination results in
endogenous antigen production, presumably through MHC Class I pathway, and
activation of CD8+ CTL cells (Condon et al., 1996). In contrast, secreted antigen might
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have been more likely to be taken by antigen-presenting cells (APC), processed and
presented through MHC Class II pathway to induce a host humoral response. A plasmid
encoding a secreted form of GAD antigen was therefore also constructed. DNA sequence
encoding human IL-2 signal peptide was fused to the 5 ’ end of GAD65 gene to facilitate
the secretion of GAD65 protein. However, this fusion gene did not encode a secreted
GAD65 protein, probably due to protein modification on the N-terminal region of GAD
protein (Christgau et al, 1992). Because there are no major epitopes found at the
N-terminal region of GAD65, and because the N-terminal region is responsible for
protein anchoring on cell membrane, the DNA sequence encoding the first 88 amino acid
of GAD65 protein was deleted and then fused with the signal sequence encoding the IL-2
signal peptide, to generate secreted GADS 5 (sgad55). Immunoprecipitation experiments
showed that both GAD65 and GADS5 proteins were detected with the predicated
molecular weights after transient gene expression, but that only sgad55 encoded a
secreted form of GAD protein (Figure 5, Chapter Seven).
Plasmid DNA encoding secreted GAD antigen was then directly injected into
quadriceps muscles of three-week-old NOD mice to activate Th2 cells and actively
suppress Thl cell subset. DNA encoding wild type GAD65 protein was injected into
another group of mice to compare the vaccination effect from intracellular or secreted
antigen. A reporter gene, sruc3, was also injected into NOD mice as negative control for
any biological effect induced by GAD proteins.
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Seven weeks after injection, mice were killed for insulitis score. Insulitis is a
major step in the progression of diabetes, and is defined as islet infiltration by
lymphocytes and macrophages (Andre et al., 1996). In the work presented here,
pancreatic tissues were isolated from NOD mice, and stained for histopathology analysis.
At least 15 islets from each mouse were scored under a double-blind .manner, and the raw
data were within normal distribution (personal communication with Dr. Grenith
Zimmerman, a professor of Biostatistics, Loma Linda University). Insulitis score showed
that injection of plasmid DNA encoding human GAD65 and SGAD55 could dramatically
reduced the development of insulitis in NOD mice, a specific effect since no such
protective effect was observed from control mice injected with sruc3. Several
immunoassays were conducted including cytokine assay and in vitro mitogen stimulation.
While there was no difference between control mice and GAD-treated mice in IFNy and
IL-2 levels when measured from either blood or in vitro culture, higher levels of Th2specific IL-4 from spleen cells from mice treated with gad65 or sgad55 genes suggested
that the protective effect could result from the induction of CD4+ Th2 cells, which
promote humoral immunity and inhibit Thl T-cell-mediated immunity.
Surprisingly, no meaningful statistical difference of insulitis score between mice
treated with GAD65 and SGAD55. A similar phenomenon was previously reported: in
vivo transfection of muscle cells with two plasmids encoding either secreted or
intracellular form of a malaria antigen generated comparable levels of antibody response
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(Haddad et al., 1997). Two hypotheses have been offered to explain this phenomenon.
One is that humoral responses may be provoked by release of antigens as a result of cell
lysis. Another possibility is that the actual process of genetic immunization directly
transfects professional APC, such as dendritic cells (Condon et al., 1996). At this
moment, there is no strong evidence supporting either of them.
It was reported recently that injection of plasmid DNA encoding rat GAD65
protein generated a strong humoral immune response in NOD mice, but the incidence of
diabetes in NOD mice were not reduced (Wiest-Ladenburger et al., 1998). Compared to
the experiment presented here, there are several differences in the protocol used by WiestLadenburger’s group which might explain our different results. Their group used small
amounts of DNA (100 pg/mice compared to 400 pg/mice in this research work), rat
GAD65 instead of human GAD65, and DNA injection was performed at the age of six
weeks old instead of three weeks. Since 6-week-old NOD mice have already started to
develop insulitis, it may be too late to start the treatment at this age and may lead to no
reduction effect on diabetes after DNA immunization with rat GAD65 (Andre et al..
1998).
Overall, the experimental data presented here demonstrated that DNA vaccination
could be used in the treatment of an autoimmune disease. However, more work needs to
be done to further reveal the molecular and immunology mechanism behind it and to
improve this approach.
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Future work should focus on two points: to determine if DNA vaccination with
plasmid DNA encoding autoantigen GAD has protective effect on diabetes in NOD mice,
and if there is a protective effect, to reveal the mechanism of it.
We have shown that DNA vaccination on three-week-old NOD mice can reduce
the development of insulitis. To fully evaluate the effect of DNA vaccination on
diabetes, we are monitoring the development of diabetes in NOD after the intramuscular
injection of plasmid DNA encoding GAD65 and SGAD55 in cyclophosphamide (CYP)induced diabetes. GYP is widely used clinically as an immunosuppressive agent,
particularly in autoimmune disease (Charlton et al, 1989). However, it is found that
administration of CYP actually accelerates the development of diabetes in NOD mice.
GYP has been used to compress the normal time course of diabetes in NOD mice
(Piccirillo et al, 1998; Charlton er a/., 1989).
However, even insulitis does not start to develop until 3-4 week of age, it is
believed that the autoimmune attack on pancreatic islets starts much earlier than that
(Andre et al, 1996). Although we have shown that plasmid mediated GAD treatment
could reduce the overall insulitis score, we may still improve this treatment by injecting
younger or even newborn NOD mice. We are planning to breed NOD in the Immunology
Research Center at Loma Linda University, and we will start DNA injection treatment as
early as in the first week after mice is bom. The result will be compared to that from
intramuscular DNA injection on 3-week-old mice.
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Despite of the fact that immunology has made tremendous progresses in recent
years, current attempts to optimize naked-DNA vaccination are proceeding without a
clear understanding of the mechanism of this form of immunization. One important
question is: what kind of cells are transfected after intramuscular DNA injection?
Although muscle cells are the main target for plasmid DNA injection, it is possible that
APC cells, such as dendritic cells and macrophage, may take in DNA and present antigen
directly to host immune system (Condon et ai, 1996). One way to determine what type
of cells take in and express injected DNA is to use promoter that only expresses in certain
type of cells, such as muscle-specific promoter (Miller et al., 1993; Huard et al., 1999;
Krempler and Brenig, 1999). Another possible method to answer this question is to inject
plasmid DNA encoding GFP marker protein. After encountering antigens, dendritic cells
will migrate to thymus or regional lymph nodes where they exhibit potent APC function
(Condon et al., 1996). GFP fluorescent signal will allow monitoring of dendritic cells
migration after intramuscular DNA injection.
In summary, DNA vaccination is an attractive approach for the induction of
immunity against viral infection, tumor, and for the treatment of autoimmune disease. It
offers several advantages over other gene transfer method. Among these is the potential
for rapid and inexpensive production of large-scale DNA preparation. Such vaccine
preparations can be prepared with relative purity and would be significantly more stable
than current protein-based vaccines. Furthermore, the use of “naked” DNA vaccines
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would be inherently safer than the use of viral mediated gene transfer. However, the
molecular mechanism behind DNA vaccination need to be further investigated, and
experimental data from studies in NOD mice must be carefully analysed for their
applicability to therapeutic intervention in human.
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